PURINERGIC TRANSMISSION IN MIGRAINE: ROLE OF P2Y RECEPTORS IN THE SPINAL-TRIGEMINAL SYSTEM IN VIVO AND IN VITRO by G. Villa
UNIVERSITÀ DEGLI STUDI DI MILANO 
 
Facoltà di Farmacia 
Dipartimento di Scienze Farmacologiche 
 
 
 
 
 
Corso di Dottorato di Ricerca in Scienze Farmacotossicologiche, 
Farmacognostiche e Biotecnologie Farmacologiche (XXIII CICLO) 
 
Graduate School in Pharmacological Sciences / Scuola di Dottorato in Scienze farmacologiche 
 
 
 
 
 
TESI DI DOTTORATO DI RICERCA 
 
PURINERGIC TRANSMISSION IN MIGRAINE: ROLE OF  
P2Y RECEPTORS IN THE SPINAL-TRIGEMINAL  
SYSTEM IN VIVO AND IN VITRO 
 
BIO/14 
 
 
 
 
 
 
Tesi di dottorato di: 
GIOVANNI VILLA 
MATRICOLA: R07517 
 
 
 
 
TUTOR: Chiar.ma Prof.ssa Maria Pia ABBRACCHIO 
 
CORRELATORE: Dr.ssa Stefania CERUTI 
 
COORDINATORE: Chiar.mo Prof. Guido FRANCESCHINI 
 
 
 
 
 
 
ANNO ACCADEMICO 2009/2010 
Index  
 
INDEX 
1.  INTRODUCTION _______________________________ 1 
1.1  PAIN AND NOCICEPTION 2 
1.1.1  Molecular basis of nociception 3 
1.1.2  The trigeminal nerve and the spinal-trigeminal system 4 
1.1.3  Role of non-neuronal cells in pain transmission 9 
1.2  MIGRAINE 12 
1.2.1  Description of the migraine attack 14 
1.2.2  How and where does the migraine attack originate? 15 
1.2.3  Familial hemiplegic migraine 21 
1.2.4  Current and future pharmacological treatment of migraine 24 
1.3  THE PURINERGIC SYSTEM 29 
1.3.1  Purinergic signalling 30 
1.3.2  P2X receptors  32 
1.3.3  P2Y receptors 33 
1.3.4  Pathophysiological roles of extracellular nucleotides in the nervous system 36 
1.4  PURINES AND PAIN 41 
1.4.1  Role of P2X receptors in pain transmission 42 
1.4.2  Role of P2Y receptors in pain transmission: sensory ganglia  46 
1.4.3  Role of P2Y receptors in pain transmission: CNS 48 
2.  AIM OF THE STUDY ____________________________ 51 
3.  METHODS  ____________________________________ 55 
3.1  CELL CULTURES 56 
3.2  PHARMACOLOGICAL TREATMENTS 58 
3.3  IMMUNOCYTOCHEMISTRY 58 
3.4  IMMUNOCYTOCHEMISTRY 59 
Index  
 
3.4.1  Tissue processing 59 
3.4.2  Immunostaining of tissues 59 
3.4.3  Quantification of results and data analysis 60 
3.5  INTRACELLULAR CALCIUM MEASUREMENTS 61 
3.6  TOTAL RNA ISOLATION AND RT-PCR ANALYSIS 62 
3.7  WESTERN-BLOTTING ANALYSIS  65 
3.8  ANALYSIS OF CGRP RELEASE BY ENZYME IMMUNO-ASSAY (EIA) 65 
3.9  IN VIVO EXPERIMENTS  66 
3.9.1  Animals 66 
3.9.2  Orofacial formalin test 66 
3.9.3  Synthesis of dsRNAs and their injection into the trigeminal ganglion 67 
3.9.4  Induction of TMJ inflammation 67 
3.9.5  Behavioral tests 68 
3.9.6  Measurement of Evans’ blue dye extravasation 68 
3.10  STATISTICAL ANALYSIS  69 
4.  RESULTS - Section I: in vitro studies ________________ 70 
4.1   SET UP OF PRIMARY MIXED TRIGEMINAL CULTURES AS AN IN VITRO 
MODEL FOR STUDYING CELL TO CELL COMMUNICATION IN THE 
TRIGEMINAL GANGLIA    71 
4.2   BOTH TRIGEMINAL NEURONS AND SATELLITE GLIAL CELLS BEAR 
FUNCTIONAL P2 RECEPTORS  74 
4.3.. CHRONIC APPLICATION OF THE PRO-INFLAMMATORY MEDIATOR 
BRADYKININ DIFFERENTIALLY AFFECTS NEURONAL P2X3 AND GLIAL 
P2Y RECEPTOR FUNCTIONALITY  79 
4.4   FOLLOWING BK APPLICATION, CGRP RELEASED FROM TG NEURONS IS 
RESPONSIBLE FOR P2Y RECEPTORS UPREGULATION IN SGCs    82 
4.5   CGRP, BUT NOT BK, RETAINS ITS ABILITY TO INDUCE P2Y RECEPTOR 
POTENTIATION IN PURIFIED SGCs CULTURES  84 
4.6.. THE ERK1/2 MAP KINASE PATHWAY HAS A PRIMARY ROLE IN CGRP-
INDUCED POTENTIATION OF GLIAL P2Y RECEPTORS  86 
4.7   CGRP RELEASE IS SIGNIFICANTLY ENHANCED IN TG CULTURES FROM 
CaV2.1 α1 R192Q MUTANT KNOCK-IN MICE  87 
4.8.. APPLICATION OF BK INCREASES THE NUMBER OF ADP- AND UTP-
RESPONDING SGCs IN TG CULTURES FROM CaV2.1 R192Q KI MICE  88 
Index  
 
4.  RESULTS - Section I: in vivo studies ________________ 91 
4.9   SET UP OF IN VIVO MODELS OF TRIGEMINAL PAIN FOR STUDYING 
ROLE OF THE PURINERGIC SYSTEM IN PAIN TRANSMISSION    92 
4.10   SGCs AND MACROPHAGES ARE SELECTIVELY ACTIVATED IN TG 
FOLLOWING TMJ INFLAMMATION  95 
4.11.. MICROGLIAL CELLS, BUT NOT ASTROCYTES, ARE ACTIVATED IN THE 
SPINAL TRIGEMINAL NUCLEUS FOLLOWING TMJ INFLAMMATION  98 
4.12   THE PURINERGIC P2Y12 RECEPTOR IS SELECTIVELY EXPRESSED BY 
MICROGLIAL CELLS IN THE CNS, BUT IT IS NOT UPREGULATED BY 
TMJ INFLAMMATION  101 
5.  DISCUSSION __________________________________ 103 
5.1   PRIMARY MIXED TG CULTURES AS AN IN VITRO MODEL FOR 
EVALUATING P2 RECEPTOR EXPRESSION AND FUNCTIONALITY    104 
5.2   EXPOSURE TO ALGOGENS EXERT A COMPLEX MODULATION OF P2 
RECEPTOR FUNCTIONALITY IN NEURONS AND GLIAL CELLS  107 
5.3.. THE GAIN-OF-FUNCTION MUTATION IN CaV2.1 CALCIUM CHANNELS 
AFFECTS P2Y RECEPTORS FUNCTIONALITY IN SGCs  108 
5.4.. SET UP OF IN VIVO MODELS OF TRIGEMINAL PAIN AS TOOLS FOR 
EVALUATING THE ROLE OF GLIAL P2Y RECEPTORS IN PAIN 
TRANSMISSION  110 
6.  REFERENCES _________________________________ 115 
7.  ABBREVIATIONS ______________________________ 132 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
2 
 
1.1 PAIN AND NOCICEPTION 
Pain can be defined as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such damage” 
(Merskey & Bogduk, 1994). It is a physical sensation arising from parts of the body, but 
it is also always unpleasant and therefore become an emotional experience. Experiences 
which resemble pain but are not unpleasant, e.g., pricking, should not be called pain 
(Merskey & Bogduk, 1994). Pain is a submodality of somatic sensation like touch and 
pressure, and serves as an important protective function by warning of injury that 
should be avoided or treated. However, unlike other somatic submodalities, and unlike 
vision, hearing, and smell, pain has an urgent and primitive quality, which is responsible 
for the affective and emotional aspects of pain perception (Basbaum & Jessell, 2000). 
The concept of pain is further complicated by the fact that its perception is always 
subjective. In fact, under similar conditions the same stimulus can produce different 
responses in different individuals (Merskey & Bogduk, 1994). Moreover, many people 
report pain in the absence of tissue damage or any likely pathophysiological cause; 
usually this happens for psychological reasons. The highly individual and subjective 
nature of pain makes difficult to treat it clinically. There are no “painful stimuli” that 
invariably elicit the perception of pain in all individuals. For example, many wounded 
soldiers do not feel pain until they are safely removed from battle. Similarly, athletes 
often do not detect their injuries until their game is over (Basbaum & Jessell, 2000).  
Pain can be subdivided in physiological pain and pathological or clinical pain. 
Physiological pain (also called acute pain, sometimes referred to as ‘‘good’’ pain) is 
adaptive, transient, and has a protective role that warns of potential tissue damage in 
response to a noxious stimulus. Pathological pain, or clinical pain (also called chronic, 
‘‘bad’’ pain) is usually maladaptive, persistent, and serves no meaningful defensive, or 
other helpful purpose (Cao & Zhang, 2008). This kind of pain is mainly subdivided into 
neuropathic pain, i.e. pain associated with damage or dysfunction of the peripheral 
nervous system (PNS) and central nervous system (CNS), and inflammatory pain, i.e. 
pain related to peripheral tissue damage/inflammation (e.g. arthritic pain). In addition, 
other types of pathological pain, such as cancer pain, and pain elicited by continuous 
infusion of morphine, share some features with inflammatory and neuropathic pain but 
also have their distinct characteristics (Brennan et al., 1996; Mantyh et al., 2002). 
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Pathological pain is typically characterized by hyperalgesia (increased responsiveness to 
noxious stimuli) and allodynia (painful responses to normally innocuous stimuli), as 
well as by spontaneous pain. Pain hypersensitivity is not only produced in the injured 
tissue or territory (innervated by the injured nerve), but also spread to the adjacent non-
injured regions or the extraterritory (extraterritorial pain) and to the contralateral body 
(mirror-image pain). This exaggerated pain is thought to result from peripheral 
sensitization (increase in sensitivity of nociceptive primary afferent neurons) and central 
sensitization (hyperexcitability of nociceptive neurons in the CNS (Cao & Zhang, 
2008). 
In the following paragraphs the basic principles of nociception, as well as the 
nociceptive neuronal pathways associated to the trigeminal perception of pain, will be 
discussed. Finally, the emerging role(s) of CNS and PNS glial cells in pain genesis and 
maintenance will be analyzed. 
 
 
1.1.1 Molecular basis of nociception 
Nociception is the process by which intense thermal, mechanical, or chemical 
stimuli are detected by a subpopulation of peripheral nerve fibers, called nociceptors 
(Basbaum et al., 2009). The cell bodies of nociceptors are located in the dorsal root 
ganglia (DRG) for the body, and the trigeminal ganglia (TG) for the head district, and 
have both a peripheral and central axonal branch that innervates their target organ and 
the spinal cord/brainstem, respectively (Lazarov, 2002). There are two major classes of 
nociceptors (Meyer at al., 2008). The first includes medium diameter myelinated (Aδ) 
afferents that mediate acute, well-localized “first” or fast pain (conducting signals at 
about 5-30 m/s). These myelinated afferents differ considerably from the larger 
diameter and rapidly conducting Aβ fibers that respond to innocuous mechanical 
stimulation (i.e., light touch). The second class of nociceptor includes small diameter 
unmyelinated “C” fibers that convey poorly localized, “second” or slow pain 
(conducting signals at a rate of less than 1.0 m/s). 
Neuroanatomical and molecular characterization of nociceptors has further 
demonstrated their heterogeneity, particularly for the C fibers (Basbaum et al., 2009). 
For example, the so-called “peptidergic” population of C nociceptors releases 
neuropeptides, substance P (SP), and calcitonin-gene related peptide (CGRP); they also 
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express the TrkA neurotrophin receptor, which responds to nerve growth factor (NGF). 
The nonpeptidergic population of C nociceptors expresses the c-Ret neurotrophin 
receptor that is targeted by glial-derived neurotrophic factor (GDNF), and a large 
percentage of the c-Ret-positive population also binds the IB4 isolectin and expresses 
the specific purinergic P2X3 receptor subtypes (see also Paragraph 1.4.3, Ruan & 
Burnstock, 2003; Basbaum et al., 2009). Nociceptors can also be distinguished 
according to their differential expression of channels that confer sensitivity to heat 
(TRPV1), cold (TRPM8), acidic milieu (ASICs), and chemical irritants (TRPA1; Julius 
& Basbaum, 2001). These functional and molecular heterogeneous classes of 
nociceptors are associated with specific functions. 
Primary nociceptive fibers have a unique morphology, called pseudo-unipolar, 
where both central and peripheral terminals emanate from a common axonal stalk. The 
majority of proteins synthesized by the DRG or TG neurons are distributed to both 
central and peripheral terminals (Basbaum et al., 2009). The biochemical equivalency of 
central and peripheral terminals means that the nociceptor can send and receive 
messages from either end. During neurogenic inflammation, in fact, a peripheral release 
of neuropeptides induces both local vasodilatation and extravasation of plasma proteins, 
and release of neurotransmitters in the CNS (see Paragraph 1.2.2).  
 
 
1.1.2 The trigeminal nerve and the spinal-trigeminal system 
The trigeminal nerve (the fifth cranial nerve) is the largest cranial nerve and 
functions as the great sensory nerve of the head and face districts, and the motor nerve 
for muscles involved in mastication (Gray, 2000).  The posterior scalp and the neck are 
instead innerved by spinal nerves between the C2 and C5. The trigeminal nerve emerges 
from the side of the pons, near to its upper border, by a small motor and a large sensory 
root (Figure 1.1; Gray, 2000). The fibers of the motor root arise from the brainstem (see 
also below), while fibers of the sensory root arise from the cells of the trigeminal 
ganglion, and provide the tactile, proprioceptive, and nociceptive afference of the face 
and mouth. At a distance of about 1-2 cm from the brainstem, the trigeminal nerve 
expands, to form the conspicuous trigeminal ganglion (see also below; Castano & 
Donato, 2001). Three major nerve branches emerge from the ganglion, namely the 
ophthalmic, the maxillary, and the mandibular nerve (Figure 1.1). The ophthalmic and 
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maxillary nerves have purely sensory functions, while the mandibular nerve has both 
sensory and motor functions (Castano & Donato, 2001). 
The Ophthalmic Nerve, or first (V1) division of the trigeminal nerve, supplies 
branches to the cornea, ciliary body, and iris; to the lacrimal gland and conjunctiva; to 
the part of the mucous membrane of the nasal cavity; and to the skin of the eyelids, 
eyebrow, forehead, nose and parts of the meninges (the dura and blood vessels). It is the 
smallest among the three divisions, and arises from the upper part of the trigeminal 
ganglion.  
The Maxillary Nerve, or second (V2) division of the trigeminal nerve is 
intermediate between the ophthalmic and mandibular, both in position and size. It 
begins at the middle of the semilunar ganglion, and supplies the upper lip, lateral 
portions of the nose, part of the oral cavity, mucosa of the nasal cavity, maxillary sinus, 
upper jaw and roof of the mouth, upper dental arch, ethmoid and sphenoid sinuses, and 
parts of the meninges (Gray, 2000). 
The Mandibular Nerve, or third (V3) division of the trigeminal nerve, supplies 
teeths and gums of the mandible, the skin of the temporal region, the auricula, the lower 
lip, the lower part of the face, and the muscles of mastication; it also supplies the 
mucous membrane of the anterior two-thirds of the tongue. It is the largest of the three 
divisions, and consists of two roots: a large, sensory root proceeding from the inferior 
angle of the semilunar ganglion, and a small motor root (the motor part of the trigeminal 
nerve), which passes beneath the ganglion, and unites with to the sensory root, just after 
its exit through the foramen ovale (Gray, 2000).  
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Figure 1.1 
Neuroanatomical organization of the spinal-trigeminal system.  
The trigeminal nerve consist of three major branches that emerge from the trigeminal ganglion (TG): the 
ophthalmic (V1), the maxillary (V2), and the mandibular nerve (V3). The trigeminal sensory fibers from 
the TG enter the pons and terminate in the trigeminal nuclear complex which is formed by three sensitive 
nuclei: the spinal trigeminal nucleus, the main trigeminal nucleus, and the mesencephalic trigeminal 
nucleus. The spinal trigeminal nucleus can be further subdivided from caudal to rostral in: subnucleus 
caudalis, subnucleus interpolaris and subnucleus oralis. Modified from Noback et al., 2005. 
 
 
 
The trigeminal ganglion 
The trigeminal ganglion (also called Semilunar or Gasserian ganglion) occupies a 
cavity (cavum Meckelii) in the dura mater covering the trigeminal impression near the 
apex of the petrous part of the temporal bone (Figure 1.1; Gray, 2000). It represents the 
cranial analog of DRGs in the PNS. In the ganglion parenchyma the somata of 
pseudounipolar neurons are contained, and a single neurite dividing into a central and a 
peripheral process, which convoy the sensory sensations from the head regions to the 
trigeminal nuclei of the brainstem, arises from each cell body (Castano & Donato, 
2001). On the basis of their morphology, the neuronal cells are traditionally divided into 
two classes: large light (A) and small dark (B) cells (Lazarov, 2002). It is known that 
thick myelinated (Aα/β) fibers originate from the large light A-cells and thin myelinated 
(type Aδ) and unmyelinated (type C) fibers derive from the small dark B-cells (Lazarov, 
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2002). According to the diameter of their somata, TG neurons can be also divided in 
three distinct groups: small (20-30 µm), medium-sized (30-50 µm), and large-sized cells 
(50-80 µm; Lazarov, 2002).  
The neuronal somata of sensory neurons are completely enveloped by a layer of 
small glial cells called satellite glial cells (SGCs; Hanani, 2005). In general, each 
sensory neuron has its own SGCs sheath (Figure 1.2), and the neuron and its 
surrounding SGCs form a distinct morphological and functional unit (Hanani, 2005). 
Originally it was believed that that SGCs provide a mere trophic support to the sensory 
neurons. However, starting from the observations that SGCs become reactive and 
increase considerably in number after peripheral nerve injury (Stephenson & Byers, 
1995; Hanani et al., 2002), it was suggested, and later demonstrated, that they actively 
participate in nociception. For this reason, a special discussion on the roles of SGCs in 
pain transmission will be provided in the next paragraph (Paragraph 1.1.3).  
 
 
Figure 1.2 
The neuron-SGCs morphological unit.  
A, An electron micrograph from the mouse dorsal root ganglion, showing the layer of SGCs (sc) around 
sensory neurons (N1-4). Neurons with their associated SGCs are separated by a connective tissue space 
(ct). Asterisks indicate non-myelinated axons surrounded by Schwann cells. Arrows indicate two SCG cell 
bodies. Calibration bar, 2 µm. B, Schematic drawing of the neuron-SGCs morphological unit. Modified 
from Hanani, 2005. 
 
* 
*
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The brainstem nuclei 
The central processes of TG neurons enter the pons via the sensory root of the 
trigeminal nerve, and terminate in the trigeminal nuclear complex which is formed by 
three sensitive nuclei: the spinal trigeminal nucleus, the main trigeminal nucleus, and 
the mesencephalic trigeminal nucleus (Figure 1.1; Capra & Dessem, 1992). The 
trigeminal nerve carries most of the sensory information from the face district, even if 
sensation from certain parts of the mouth, ear and meninges are carried by somatic 
fibers of the facial, the glossopharyngeal, and the vagus nerves. All sensory fibers from 
these nerves terminate in the trigeminal nuclear complex that contains a complete 
sensory map of the face and mouth. Near the main trigeminal nucleus the trigeminal 
motor nucleus of the fifth nerve is also located (Figure 1.1), where motor branches of 
the trigeminal nerve originate and are then distributed through the mandibular branch. 
The spinal trigeminal nucleus extends throughout the entire brainstem, from the 
midbrain to the medulla, and overlaps with the dorsal horn of the cervical spinal cord. 
Three major cytoarchitectonic subdivisions of this nucleus are generally recognized 
along its rostrocaudal axis. The most caudal is the subnucleus caudalis, which extends 
from C2 or C3 caudally to the obex rostrally; the subnucleus interpolaris extends from 
the obex caudally to the caudal pole of the facial motor nucleus; the subnucleus oralis 
extends from the caudal pole of the facial motor nucleus to the caudal end of the 
trigeminal motor nucleus (Figure 1.1; Castano & Donato, 2001). The caudal parts of the 
spinal trigeminal nucleus receive pain/temperature sensory sensations, while the rostral 
parts receive touch/position sensory information. Moreover, a specific dorso-ventral 
somatotopical organization of the spinal trigeminal nucleus can be distinguished: the 
trigeminal fibers innervating the ipsilateral mandibular division are most dorsally 
situated, the maxillary fibers are in the middle, and the ophthalmic fibers are in the most 
ventral part of the tract (Capra & Dessem, 1992).  
The main trigeminal nucleus receives touch/position sensory fibers from the face. 
It is located in the pons, close to the entry site of the fifth nerve. The main trigeminal 
nucleus contains a touch/position sensory map of the face and mouth, just as the spinal 
trigeminal nucleus contains a complete pain/temperature map. The main nucleus is 
analogous to the dorsal column nuclei (i.e. the gracile and cuneate nuclei) of the spinal 
cord, which contain a touch/position map of the rest of the body (Castano & Donato, 
2001). 
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The trigeminal mesencephalic nucleus (MTN) is the only known nucleus situated 
within the CNS that contains the cell bodies of primary afferent neurons. It could be 
considered a ganglion “embedded” in the brainstem. It is also unique in that its neurons 
constitute one distinct functional class of trigeminal sensory neurons, i.e. proprioceptive 
neurons. MTN neurons receive information, via the trigeminal nerve, from the 
masticatory muscle spindles, and from mechanoreceptors in the periodontal ligament. In 
turn, they transfer information to the muscles of mastication through their projections to 
trigeminal motoneurons and premotoneurons for controlling jaw movements, or to the 
cerebral cortex (via the thalamus) for transmission of sensory feedback (Lazarov, 2002). 
 
The thalamus/cortex nuclei 
From the trigeminal nuclear complex, the pain/temperature information from the 
face ascend in the trigeminal lemniscus to the ventral posteromedial nucleus (VPM) of 
the thalamus. From this nucleus, the pain/temperature information is projected to the 
primary and secondary sensory cortex. Other pain/temperature fibers are alternatively 
sent: (i) to the medial dorsal thalamic nucleus, which projects to the anterior cingulate 
cortex, (ii) to the ventromedial nucleus of the thalamus, which projects to the insular 
cortex, and (iii) to the intralaminar nuclei of the thalamus, which project diffusely to all 
parts of the cerebral cortex (Castano & Donato, 2001). Other impulses project to the 
ventrolateral area of the caudal periaqueductal gray region. This latter region is involved 
in the craniovascular pain not only through ascending projections to the thalamus, but 
also through descending modulation (mainly inhibitory) of nociceptive afferent 
information (Figure 1.3, see also below). 
 
 
1.1.3 Role of non-neuronal cells in pain transmission 
Despite great efforts in the last decades towards the understanding of its 
pathophysiology, and the development of new drugs, chronic pain is a difficult to 
manage and disabling condition. The reason for this failure may be partially due to the 
fact that most of the available drugs target neurons (Dworkin et al., 2010), whereas 
increasing evidence now indicates that glial cells in both sensory ganglia and CNS also 
play an important role in chronic pain genesis by participating to the development of 
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hyperalgesia and allodynia (Ren & Dubner, 2008; McMahon & Malcangio, 2009). As 
already mentioned in the previous paragraph, SGCs wrap around the cell bodies of 
primary neurons in sensory ganglia, forming a morphological and functional unit 
(Hanani, 2005). Like other glial cells (see also below), SGCs responds to nerve injury 
by upregulating glial fibrillary acidic protein (GFAP) expression and undergoing 
division  in response to chronic pain (Takeda et al., 2007). In addition, following nerve 
injury or inflammation, there is also an unregulated expression of gap junctions, and an 
increased coupling between SGCs (Ledda et al., 2009; Zhang et al., 2009). It has been 
speculated that these changes in SGCs coupling might be directly correlated to the 
generation or maintenance of neuropathic pain. Indeed, in a model of facial neuropathic 
pain the specific inhibition of Connexin 43 expression levels (one of the major gap 
junctions subunits expressed by glial cells; Vit et al., 2006) by RNA interference 
resulted in a strong reduction of pain behavior (Jasmin et al., 2010). 
A non-synaptic cross communication between neurons and SGCs is probably at 
the basis of SGCs activation following chronic pain (Takeda et al., 2009). Indeed, under 
physiopathological conditions, the somata of sensory neurons release in the extracellular 
space chemical mediators, such as CGRP, SP, and ATP, which in turn activate their 
receptors expressed by other neurons or by surrounding SGCs. Activated SGCs in turn 
release cytokines, such as Interleukin (IL)-1β and tumor necrosis factor α (TNFα), 
which may further potentiate neuronal excitability, leading to an auto-amplifying loop 
of neuronal sensitization (Takeda et al., 2009). Noteworthy, the purinergic system 
participate primarily to this bidirectional neuron-glial communication inside the sensory 
ganglia (Zhang et al., 2007; Suadicani et al., 2009), and in the Paragraph 1.4 more 
details on this subject will be provided. 
Since, differently from the CNS, in sensory ganglia there is no blood-brain 
barrier, immune cells are able to freely move in and out of the ganglion (Ohara et al., 
2009). In fact, each sensory ganglion harbors a large number of resident macrophages, 
representing the first immune cells to respond to nerve injury or viral infection; within 
days however, circulating macrophages and other immune cells invade the sensory 
ganglion (Gowrishankar et a., 2010). Inside the ganglion, activated macrophages divide 
and contribute to the persistence of chronic pain by responding to a mix of molecules 
including neurotransmitters, growth factors, and cytokines, most of which have been 
shown to cause increased pain behavior in animal models (Morin et al., 2007; Zhuang et 
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al., 2007). These data therefore indicate that also macrophages are directly involved in 
the regulation of chronic pain. 
In addition, also glial cells in the CNS (mainly astrocytes and microglia) 
participate in the development and maintenance of chronic pain, and may as well 
represent innovative targets for developing new pain killer molecules (McMahon & 
Malcangio, 2009). In fact, during chronic pain, both microglia and astrocytes become 
activated and undergo to cell proliferation (Ajami et al., 2007; McMahon & Malcangio, 
2009). Compared to resting microglial cells, activated microglia display shorter and 
thicker ramifications, functional changes (migration, phagocytosis and production/ 
release of pro-inflammatory substances), and upregulation of cell specific molecules, 
such as the complement receptor 3 (also known as CD11b), and the ionized calcium-
binding adapter molecule (Iba1; Smith, 2010; Vallejo et a., 2010). Astrocytes become 
activated to a lesser extent than microglia and at later time points after injury; they 
exhibit hypertrophic cell bodies with thick processes, upregulated GFAP levels, and 
increased production and release of a variety of pro-inflammatory substances 
(Raghavendra & Deleo, 2003). 
Similar to sensory ganglia, a bidirectional neuron-glia communication is 
responsible the neuronal sensitization in the CNS. Indeed, glia is first activated by 
neurotransmitters and other mediators released from primary afferent terminals involved 
in pain transmission (Ren & Dubner, 2008): these molecules include neurotransmitters, 
such as SP and CGRP (Guo et al., 2007), purinergic agents (Tsuda et al., 2010; see also 
Paragraph 1.4), glutamate (Kumar  et al., 2010), opioid peptides (Watkins  et al., 2007), 
and chemokines (Zhuang, 2007). Glial cells in turn release a variety of substances 
including inflammatory cytokines (White et al., 2007), prostaglandins (Zhao et al., 
2007), neurotrophic factors (Coull et al., 2005) and nucleotides (Tsuda et al., 2010), that 
modulate neuronal activity and facilitate pain transmission, eventually contributing to 
hyperalgesia and allodynia. To further sustain the hypothesis that glial cells are involved 
in chronic pain development and maintenance, it has been demonstrated that the 
pharmacological administration of glial cells inhibitors, like pentoxifylline, fluorocitrate 
and minocycline, effectively attenuates the development of both neuropathic (Mika, 
2008) and inflammatory pain (Clark et al., 2007).   
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1.2 MIGRAINE 
Migraine is an episodic neurovascular disorder, typically characterized by 
spontaneous and recurrent attacks of unilateral headache, with associated autonomic 
symptoms, like nausea, vomiting, and sensorial hypersensitivity. It belongs to the 
primary headaches family, which include also the tension-type headache, the cluster 
headache, trigeminal autonomic cephalalgias, and other headaches (Edvinsson & 
Uddman, 2005). Migraine is an highly disabling brain disorder that affects about the 
15% of the population, and its socio-economic implications are extensive with 
considerable impact on productivity and quality of life. It has been estimated to be the 
most costly neurological disorder in the European Community with €27 billion spent 
per year (Goadsby, 2007). Accordingly, it is now ranked at the 19th place among all 
world-wide diseases causing disability by the World Health Organization (Lipton et al., 
2004). 
Migraine can be classified into two major categories: the migraine without aura 
(MO) and the migraine with aura (MA). The first one, that occurs in about 80% of 
patients, is a clinical syndrome characterized by headache with specific features and 
associated symptoms. The second category, MA, is primarily characterized by focal 
neurological symptoms that usually precede or sometimes accompany the headache in 
the remaining 20% of migraineurs (Headache Classification Committee of the 
international Headache Society, 2004). The diagnostic criteria for these two categories 
are summarized in Table 1.1. 
One of the most important aspects of the pathophysiology of migraine is the 
inherited nature of the disorder. It is clear from clinical practice that many patients have 
first degree relatives who also suffer from migraine. However, only in few cases it has 
been possible to identify specific genes responsible for the inherited component. This is 
the case of the Familial Hemiplegic Migraine (FHM) which is caused by mutations of 
specific ion channels genes:  the α1 subunit of the Cav2.1 (P/Q) type voltage-gated Ca2+ 
channel (CACNA1A), causing the FHM type-I; the ATP1A2 gene, causing the FHM 
type-II; and the Na+ channel SCN1A, causing the FHM type III (see also below; 
Goadsby, 2007). 
Migraine is a complex neurological disorder, and despite recent advances in the 
comprehension of it pathophysiology, its pharmacological treatment still remains 
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unsuccessful in a significant number of patients. For this reason, new efforts in 
clarifying its mechanisms, in the discovery of innovative targets, and in the developing 
of new drugs are strongly needed. 
 
 
Table 1.1   Diagnostic criteria for migraine. 
Migraine without aura 
A. At least five attacks fulfilling criteria B-D. 
B. Headache attacks lasting 4 to 72 hours. 
C. Headache has at least two of the following characteristics: 
1. Unilateral location 
2. Pulsating quality 
3. Moderate or severe pain intensity 
4. Aggravation by or causing avoidance of routine physical activity  
D. During headache at least one of the following:  
1. Nausea and/or vomiting 
2. Photophobia and phonophobia 
E. Not attributed to another disorder. 
 
Migraine with aura 
A. At least two attacks fulfilling criteria B-D. 
B. Aura consisting of at least one of the following, but no motor weakness: 
1. Fully reversible visual symptoms including positive features (e.g, flickering lights, 
spots, or lines) and/or negative features (i.e, loss of vision) 
2. Fully reversible sensory symptoms including positive features (i.e, pins and 
needles) and/or negative features (i.e, numbness) 
3. Fully reversible dysphasic speech disturbance 
C. At least two of the following: 
1. Homonymous visual symptoms and/or unilateral sensory symptoms 
2. At least one aura symptom develops gradually over ≥ 5 minutes, and/or different 
aura symptoms occur in succession over ≥ 5 minutes 
3. Each symptom lasts ≥ 5 and ≤ 60 minutes 
D. Headache fulfilling criteria B-D for migraine without aura begins during the aura or 
follows aura within 60 minutes 
E. Not attributed to another disorder. 
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1.2.1 Description of the migraine attack 
The migraine attack can consist of four main phases: premonitory, aura, headache, 
and resolution.  
 
The premonitory phase 
Premonitory symptoms occur in 20-60% of patients with migraines, hours to days 
before headache onset. The most common symptoms are feeling tired or weary (72%), 
difficulty concentrating (51%), and a stiff neck (50%; Silberstein, 2004). Patients who 
reported premonitory symptoms usually predicted their incoming headaches. 
 
The aura phase 
Migraine aura consists of focal neurological symptoms that precede, accompany, 
or (rarely) follow an attack. Aura usually develops over 5-20 min, lasts for less than 60 
min, can be visual, sensory, or motor, and can involve language or brainstem 
disturbances (Table 1.1; Lipton et al., 2004). Headache usually follows within 60 min 
from the end of the aura phase. Patients can have multiple aura types: most patients with 
a sensory aura also have a visual aura. Auras vary in complexity; simple auras include 
scotomata, simple flashes (phosphenes), specks, geometric forms, and shimmering in 
the visual field. More complicated visual auras include teichopsia or fortification 
spectra (characteristic aura of migraine), metamorphopsia, micropsia, macropsia, zoom 
vision, and mosaic vision. Paraesthesias are often cheiro-aural, with numbness 
migrating from the hand up the arm and to the face (Silberstein, 2004). Apraxia, 
aphasia, and agnosia, states of altered consciousness associated with déjà vu, and 
elaborate dreamy, nightmarish, trance-like, or delirious states can occur (Silberstein, 
2004).  
 
The headache phase 
The median frequency of migraine attacks is 1-5 per month The typical headache 
is unilateral, of gradual onset, throbbing (85%), moderate to marked in severity, and 
aggravated by movements (Silberstein, 2004). Pain can be unilateral, bilateral, or start 
on one side and become generalized. It lasts 4-72 h in adults and 1-72 h in children 
(Lipton et al., 2004). Nausea occurs in almost 90% of patients, while vomiting occurs in 
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about one third (Lipton et al., 2004). Sensory hypersensitivity results in patients seeking 
for a dark, quiet room. Blurry vision, nasal stuffiness, anorexia, hunger, diarrhoea, 
abdominal cramps, polyuria, facial pallor, sensations of heat or cold, and sweating 
might occur. Depression, fatigue, anxiety, nervousness, irritability, and impairment of 
concentration are common (Silberstein, 2004).  
 
The resolution phase 
After the headache, the patient often feels tired, washed out, irritable, or listless, 
and can have impaired concentration, scalp tenderness, or mood changes. Some feel 
unusually refreshed or euphoric after an attack; others experience depression and 
malaise (Silberstein, 2004). 
 
 
1.2.2 How and where does the migraine attack originate? 
Despite the strong progresses made for a better understanding of migraine 
pathophysiology, a debate about its origin is still ongoing: some scientists argue for a 
central origin of the headache pain (for a review see Goadsby et al., 2009), whereas 
others believe that the headache is triggered by activation of peripheral nociceptors (for 
a review see Olesen et al., 2009). In the following paragraphs the older and newer 
theories raise to better explain this complex disorder will be discussed. 
For most of the last part of the 20th century, migraine pain was theorized to be 
due to dilatation of cranial vessels. According to this “vascular theory of migraine”, 
migraine aura would be caused by transient ischemia induced by vasoconstriction, and 
the headache would arise from rebound abnormal vasodilatation of intracranial arteries, 
and consequent mechanical activation of perivascular sensory fibers (Wolff, 1948; 
Pietrobon & Striessnig 2003). Two-thirds of migraineurs experience relief from pain 
after occlusion of the carotid artery ipsilateral to the side of headache, and distension of 
major cerebral vessels by balloon dilatation leads to pain referred to the ophthalmic 
division of the trigeminal nerve (Goadsby et al., 2009). However, more recent studies 
clearly indicate that vascular changes in the regional cerebral blood flow are totally 
unrelated to the phase of the attack; indeed, blood flow could be reduced or normal 
during the headache phase (Olesen et al., 1981; Olesen et al., 1990). Moreover, it was 
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shown that the vasoactive intestinal polypeptide (VIP), can induce vasodilatation 
without triggering migraine, and migraine can be induced without dilatation in the 
diameter of the middle cerebral artery, the principal artery of the dura mater (Kruuse et 
al., 2003). More recently, using high resolution 3T magnetic resonance angiography, it 
has been reported that migraine triggered by nitroglycerin occurs without any 
continuing change in intracranial or extracranial vessels (Schoonman et al., 2008). In 
conclusion, vasodilatation is neither necessary nor sufficient for migraine genesis.  
Within the skull, pain sensitivity is primarily restricted to the meningeal blood 
vessels, which are densely innervated by nociceptive sensory afferent fibers of the 
ophthalmic division of the trigeminal nerve (Pietrobon, 2005). It has been therefore 
hypothesized that migraine could arise from a primary dysfunction leading to activation 
and sensitization of the trigemino-vascular system. According to this view, the 
sensitization of meningeal nociceptors induced by inflammatory events may be an 
essential process in migraine. This idea was popular for nearly two decades in form of 
“the hypothesis of neurogenic inflammation” (Moskowitz, 1993). The key elements of 
neurogenic inflammation are: (i) vasodilatation, (ii) plasma extravasation and (iii) mast 
cell degranulation (which can experimentally be induced by stimulation of meningeal 
afferents) and the subsequent release of pro-inflammatory neuropeptides from these 
nerve fibers (Figure 1.3; Buzzi et al. 1995; Williamson & Hargreaves 2001). In fact, the 
neuropeptides SP and neurokinin-A are known to cause mainly plasma extravasation, 
while CGRP, VIP but also nitric oxide (NO) are powerful vasodilator of intracranial 
arteries in animals and humans (Pietrobon, 2005). CGRP also induces plasma 
extravasation and mast cell degranulation (Ottosson & Edvinsson, 1997). The 
importance of CGRP in migraine neurobiology is also supported by the fact that 
intravenous infusion of CGRP in migraineurs generates a delayed headache with most 
of the characteristics of migraine (Tepper & Stillman, 2008). Moreover, during an 
attack of migraine, plasma levels of CGRP, but not SP, have been found to be increased 
in the venous outflow from the head (Goadsby et al. 1990; Juhasz et al. 2005). 
Accordingly, relief of migraine corresponds to reduction of blood CGRP (Tepper & 
Stillman, 2008). For these reasons, CGRP receptor antagonists have been providing 
good results in clinical studies for migraine therapy (see below). Activation of the 
meningeal trigemino-vascular afferents finally leads to activation of the spinal 
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trigeminal nucleus, and impulses are then carried rostrally to brain structures involved 
in the perception of pain (see Paragraph 1.1.2 and Figure 1.3). 
 
 
Figure 1.3 
Neuronal pathways involved in trigeminovascular activation and pain processing. 
  
The development of 
migraine depends on the 
activation of nociceptive 
afferent fibers of trigeminal 
ganglion (TG) neurons 
innervating the blood 
vessels in the meninges and 
the subsequent activation of 
second-order dorsal  
horn neurons in the 
trigeminal nuclear complex 
(TNC) and neurons in 
structures involved in the 
processing and perception 
of pain, like the thalamus,   
the caudal periaqueductal 
gray region (PAG), and the 
cortex. The PAG is involved 
in craniovascular pain not 
only through ascending 
projections to the thalamus 
but also through descending 
modulation (mainly 
inhibitory) of nociceptive 
afferent information via 
projections to serotonergic 
neurons in the nucleus 
raphae magnus (MRN) 
 
IV, fourth ventricle; ACh, 
acetylcholine; CGRP, calcitonin 
gene-related peptide; LC, locus 
coeruleus; NKA, neurokinin A; NO, 
nitric oxide; SP, substance P; SPG, 
superior sphenopalatine ganglion; 
SSN, superior salivatory nucleus; 
VIP, vasoactive intestinal peptide. 
 
 
 
The crucial point of this theory is that neurogenic inflammation depends on a 
massive activation of meningeal afferents, and this alone would cause the headache. 
Even if there is no a satisfying idea of which spontaneous process causes the primary 
activation of meningeal afferents, a complex neurological event taking place in the 
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cortex during the aura phase, the so called Cortical Spreading Depression (CSD), has 
been proposed as good trigger candidate for neurogenic inflammation, and possibly for 
headache pain. CSD is a slow propagating (2-6 mm/min) wave of sustained strong 
neuronal depolarization that generates a transient intense spike activity in neurons as it 
progresses into the cortex, followed by a long-lasting neural suppression (Lauritzen, 
1994). It has been demonstrated that CSD and the aura phase that precede a migraine 
attack are strongly correlated events (Eikermann-Haerter & Ayata,  2010). Indeed, aura 
frequently consists in a visual scotoma (an area of lost vision) with a scintillating border 
that usually begins near the center of vision as twinkling stars and then develops into an 
expanding circle that slowly moves across the visual field toward the periphery (Figure 
1.4). By analyzing his own visual aura, in 1941 Lashley postulated that the scotoma 
resulted from a region of depressed neural activity in the visual cerebral cortex and that 
the scintillations resulted from a bordering region of intense cortical excitation 
(Lashley, 1941). A few years later, an electrophysiological correlate was reported in the 
rabbit cerebral cortex and was termed “Cortical Spreading Depression” (Leao & 
Morison, 1945). In animals, CSD can be triggered by focal (electrical, mechanical, or 
high K+) stimulation of the cerebral cortex, and its depolarization phase is associated 
with an increase in regional cerebral blood flow (rCBF), whereas the phase of reduced 
neural activity is associated with a reduction in rCBF (Lauritzen, 1994). The similarities 
between migraine visual aura and CSD led to the hypothesis that CSD was responsible 
for the migraine aura (Lauritzen, 1994). However, only in 2001 Hadjikhani and 
colleagues (2001) clearly correlated this two neurological events. In fact, by using blood 
oxygenation level-dependent functional magnetic resonance imaging (BOLD fMRI), it 
was demonstrated that several CSD-associated cerebrovascular changes happened in the 
cortex of migraineurs during a visual aura (Hadjikhani et al., 2001). A clear temporal 
correlation was established between the initial features of the aura percept (i.e., 
scintillations beginning in the paracentral left visual field) and the initial increase in the 
mean BOLD signal, reflecting cortical hyperemia (Figure 1.4). The subsequent decrease 
in mean BOLD level was temporally correlated with the scotoma following the 
scintillations. The BOLD signal changes developed first in the occipital cortex, 
contralateral to the visual changes. It then slowly migrated (3.5 mm/min) toward more 
anterior regions of the visual cortex, representing peripheral visual fields, in agreement 
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with the progressive movement of the scintillations and scotoma from the center of 
vision toward the periphery (Figure 1.4; Hadjikhani et al., 2001).  
 
 
 
BA
 
 
Figure 1.4 
Cortical spreading depression during migraine aura.   
A, Drawing illustrating the progression of a visual aura over time, consisting of a scotoma (an area of 
lost vision; in figure is represented within the dashed line), and scintillating borders. The cross indicates 
the fixation point. B, Cortical spreading depression that causes migraine aura consists of a wave of 
depolarization that spreads through the cerebral cortex at a rate of 2-6 mm per min (red area). The 
depolarization phase is associated with an increase in regional cerebral blood flow (rCBF). Shortly after 
this, repolarisation takes place and is accompanied by a prolonged decrease in rCBF (green area). A 
temporal correlation between the initial features of the aura (scintillations beginning in the paracentral 
visual field) and the rCBF is present. The subsequent decrease in rCBF is temporally correlated with the 
scotoma. Modified from Lauritzen, 2001. 
 
 
 
This observation was successfully confirmed by other neurological evidence 
(Bowyer et al., 2001), and therefore it can be concluded that visual aura arises from 
CSD. Besides causing the aura, CSD also has been proposed as a trigger of headache 
(Moskowitz, 1984). The CSD can activate the meningeal trigemino-vascular system and 
downstream pain pathways in rodents leading to meningeal inflammation and plasma 
extravasation (Moskowitz  et al., 1993; Bolay et al., 2002). Although the mechanism of 
activation remains unknown, it has been assumed that H+, K+, NO, and other agents 
released into the cortical extracellular space during the CSD, depolarize or activate 
adjacent perivascular trigeminal nerve endings surrounding local blood vessels. This 
evidence is further supported by data showing that migraine prophylactic drugs, which 
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are efficacious in preventing migraine attacks with or without a perceived aura, 
decreased CSD susceptibility (see Paragraph 1.2.4; Ayata et al., 2006).  
The facts that only about the 20% of migraineurs experience the aura phase (see 
above) conflicts with the idea of CSD as primary event in migraine pathogenesis. It 
could be hypothesized that in patients suffering of migraine without aura, CSD could 
occur in clinically silent area of the cortex, thus it would not give rise to aura symptoms 
(Woods et al., 1994). An alternative view considers migraine aura and headache as 
parallel processes and proposes that the primary cause of headache as an episodic 
dysfunction in brainstem nuclei involved in the central control of nociception. To 
support this idea two evidence can be considered. First, placement of electrodes in PAG 
for the treatment of chronic pain can produce migraine-like headaches in non-
migraineurs (Raskin et al., 1987). Second, rCBF increases in several areas of the dorsal 
rostral brainstem during migraine attacks (Bahra et al., 2001). Although the spatial 
resolution of the imaging techniques does not allow the distinction of most brainstem 
nuclei, the foci of maximum rCBF increase, as measured by Positron Emission 
Tomography (PET), coincided with the dorsal raphe nucleus and locus coeruleus in 
patients with MO, and with the red nucleus and substantia nigra in a patient with MA, 
during a spontaneous attack (Weiller et al., 1995). Animal studies indicate that these 
brainstem centers might be involved in the central control of nociception and, in 
particular, in descending mechanisms of pain inhibition. Compared to other hypothesis 
on migraine neurobiology, dysfunction of such brainstem structures and networks could 
not only account for the somatosensory component of migraine (headache) but also for 
the auditory, olfactory and visual components. Moreover, a locus coeruleus dysfunction 
could also explain the distractibility and anxiety which is often observed in migraineurs 
(Goadsby et al., 2009). On the other hand several criticisms can be pointed out to this 
brainstem generator theory (Pietrobon, 2005; Olesen et al., 2009), and unfortunately, we 
have to conclude that no clear answers to the crucial question of how and where the 
migraine pain arises are available so far. Migraine is a complex pathology, and different 
clinical manifestations can be observed among the migraineurs. It may be well that the 
primary dysfunction leading to headache could be different among patients, depending 
on either genotypical and/or phenotypical features. To provide an ultimate answer to 
this question, additional studies in this field are strongly needed. 
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1.2.3 Familial hemiplegic migraine 
As mentioned before, migraine has a strong genetic component, and an example 
of a monogenic subtype of migraine is familial hemiplegic migraine (FHM; Pietrobon, 
2007; de Vries et al., 2009). This form of migraine is a rare autosomal dominant 
subtype of MA, whose aura symptoms include motor weakness or paralysis (often, but 
not always, unilateral). Apart from the motor aura, typical FHM attacks resemble MA 
attacks. Usually at least three aura symptoms are present in FHM (typically in the 
temporal order: visual, sensory, motor, aphasic; see Table 1.1), and they last longer than 
in MA. Also the headache phase last longer in FHM than MA, while all other headache 
characteristics are similar (Pietrobon, 2007). In addition to typical FHM attacks, some 
FHM patients can experience atypical severe attacks with signs of diffuse 
encephalopathy, impairment of consciousness (coma) or confusion, prolonged 
hemiplegia lasting several days, and in a few cases seizures (Ducros et al., 2001). 
Moreover, about 20% of FHM families show permanent cerebellar symptoms consisting 
of progressive cerebellar ataxia with or without nystagmus. Emotional stress and minor 
head trauma are among the most common triggers of FHM attacks (Ducros et al., 2001). 
Three genes have been successively identified in FHM families, and, accordingly, three 
types of FHM are recognized.  
 
Familial hemiplegic migraine type 1 (FHM1)  
The first FHM gene identified is CACNA1A, which is located on chromosome 
19p13 and encodes for the α1 subunit of neuronal CaV2.1 (P/Q-type) voltage-gated 
calcium channel that is widely expressed throughout the CNS (de Vries et al., 2009). All 
the 21 FHM1 mutations known so far are missense mutations associated with a broad 
spectrum of clinical features besides hemiplegic migraine, including cerebellar ataxia 
and epilepsy (de Vries et al., 2009). The CaV2.1 channels are located in presynaptic 
terminals and somatodendritic membranes throughout the brain, where they control 
neurotransmitter release particularly at central excitatory synapses (Pietrobon, 2005). 
All the FHM1 mutants show an enhanced single channel Ca2+ influx in a wide range of 
mild depolarizations, reflecting an increased channel open probability, mainly due to a 
shift to lower voltages of channel activation (Tottene et al., 2002). In fact, the analysis 
of mutant channels in neurons from knock-in mice revealed that FHM1 mutations 
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produce gain of function of CaV2.1 channels. Mutant human CaV2.1 channels also open 
at lower voltages and more readily than WT channels, and Ca2+ influx through mutant 
channels can occur in response to small depolarizations insufficient to open WT 
channels. As a consequence, FHM1 mutations produce an increase of CaV2.1-dependent 
neurotransmitter release at synapses. Moreover, recent evidence indicates that FHM1 
knock-in mice are more susceptible to CSD than wild-type mice. Indeed, by using 
animal models of FHM1 (the R192Q and S218L knock-in mice) a lower threshold for 
CSD induction and an increased velocity of propagation of CSD induced by electrical 
stimulation of the visual cortex in vivo were demonstrated (van den Maagdenberg et al., 
2004). The CSD threshold is reached when the regulatory mechanisms that keep the 
local K+ ion concentrations in the physiological range are overwhelmed by the build-up 
of K+ via positive feedback loops. A lower increase of extracellular K+ can activate the 
hyper-functional CaV2.1 channels, leading to an abnormal release of glutamate which in 
turn initiate the positive feedback cycle leading to CSD. Thus, a relatively weak 
depolarizing stimulus, as a minor head trauma, which is without consequences in 
healthy individuals, may release enough glutamate to initiate the positive feedback 
cycle, therefore initiating the CSD (van den Maagdenberg et al., 2004; Pietrobon, 2007). 
Altogether, these findings support a key role of the CSD in the pathogenesis of FHM1. 
 
Familial hemiplegic migraine type 2 (FHM2)  
The second FHM gene was identified in 2003 in two Italian families (De Fusco et 
al. 2003). This gene, located on chromosome 1q23, encodes for the α2 subunit of the 
Na+,K+-ATPase pump that utilizes the energy of ATP to actively transport Na+ ions out 
of and K+ ions into the cell. Over 30 FHM2 mutations have been now recognized and, 
with a few exceptions, are all found in single families (De Fusco et al., 2003). The 
Na+,K+-ATPase pump generates the ion gradients that maintain resting membrane 
potential and cell volume, and provide the driving force for nutrient and 
neurotransmitter uptake. Glial and neuronal Na+,K+-ATPase pumps play an important 
role in the clearance of K+ from the extracellular space during neuronal activity and are 
also fundamental for the clearance of released glutamate from the synaptic cleft, 
because the active transport of glutamate into astrocytes and neurons is driven by both 
Na+ and K+ gradients (D’Ambrosio et al., 2002). Impaired clearance of K+ and 
glutamate by astrocytes during cortical neuronal activity, consequent to a decreased 
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number of functional Na+,K+-ATPase pumps, would depolarize neurons and enhance 
glutamate concentration in the synaptic cleft, thus impairing the recovery from neuronal 
excitation. On the basis of this mechanism, it could be predicted that also FHM2 
patients have enhanced susceptibility to CSD: a weak depolarizing stimulus, which 
would be without consequences in healthy individuals, may be able to produce a local 
buildup of K+ concentration above the critical value, leading to CSD in FHM2 patients 
(Pietrobon et al., 2007). 
 
Familial hemiplegic migraine type 3 (FHM3)  
The most recently identifed FHM gene is the SCN1A gene, which is located on 
chromosome 2q24, and was identified in 2005 in three German families (Dichgans et al. 
2005). SCN1A encodes for the α1 subunit of neuronal NaV1.1 voltage-gated sodium 
channels and represents an already well-known gene with over 100 truncating and 
missense mutations that are associated with several kind of epilepsy (de Vries et al., 
2009). Five FHM3 mutations have been identified so far (Castro et al. 2009; Vahedi et 
al. 2009), and for three of them their functional consequences have been investigated. 
When the FHM3 Q1489K and L1649Q mutations have been inserted in the cardiac 
NaV1.5 cDNAs, various gain-of-function effects were revealed (Vanmolkot et al. 2007). 
However, when these mutations were expressed in the more appropriate NaV1.1 protein, 
clear loss-of-function effects were detected (Kahlig et al. 2008). The third FHM3 
mutation, L263V, that causes FHM3, and in the majority of carriers also generalized 
tonic-clonic epilepsy, has essentially a gain-of-function effect (Kahlig et al. 2008). It 
was hypothesized that loss of sodium channel activity primarily disturbs the functioning 
of inhibitory neurons where the NaV1.1 are expressed normally, whereas gain-of-
activity has a predominant effect on excitatory neurons. The functional consequences of 
FHM3 mutations can be very complex; indeed, depending on the test paradigm the 
Q1489K mutation resulted in either hyperexcitability or hypoexcitability of cultured 
neurons (Cestele et al. 2008). The generation of FHM3 SCNA1a knock-in mice will 
allow to make the situation clearer, and to predict if the FHM3 mutation leads to 
enhanced susceptibility to CSD, similarly to the other FHM types. 
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1.2.4 Current and future pharmacological treatment of migraine 
Migraine pharmacotherapy begins with a correct diagnosis, and the choice of 
treatment depends on the severity and frequency of the attack, associated symptoms, 
coexistent disorders, as well as previous treatment responses, drugs’ efficacy, and 
adverse events (Bartleson & Cutrer, 2010). Pharmacological treatment can be acute 
(abortive) or preventive (prophylactic), and patients might need both approaches. Acute 
treatment attempts to reverse or stop the headache progressing once it has started. 
Preventive treatment is designed to reduce the frequency and severity of the attack. 
Acute treatment is appropriate for most attacks and should be restricted to 2-3 days a 
week; it can be specific (with ergotamine derivatives or triptans), or non-specific (with 
nonsteroidal anti-inflammatory drugs, NSAIDs, or opioids). Nonspecific drugs control 
migraine pain or other pain disorders, whereas specific drugs are effective in migraine 
headache attacks, but are not useful for non-headache pain disorders (Silberstein et al., 
2004). Analgesics are used for mild to moderate headaches while triptans or ergotamine 
derivates are first-line drugs for severe attacks and for less severe attacks not responding 
to analgesics (Goadsby & Sprenger, 2010). A list of the common used drugs is listed in 
Table 1.2.  
Ergot alkaloids and triptans are potent 5-HT1B/1D agonists and in some cases 5-
HT1F receptor agonists. Ergots alkaloids have much greater receptor affinity at 5-
HT1A, 5-HT2, adrenergic, and dopaminergic receptors than triptans, leading to more 
adverse events. Contraindications include documented or suspected ischaemic heart 
disease, Prinzmetal’s angina, uncontrolled hypertension, basilar or hemiplegic migraine, 
and pregnancy (Silberstein et al., 2004).  
Triptans, whose progenitor is sumatriptan, are more effective than ergotamine 
derivates. They are safe (for patients without cardiovascular risk factors), effective, and 
appropriate first-line treatment for patients who have a moderate to severe migraine 
headache or for whom analgesics have failed to provide adequate relief. Subcutaneous 
sumatriptan is the fastest and most effective. Sumatriptan or zolmitriptan nasal spray 
sometimes provide a faster onset of action than oral triptans. Triptans were originally 
thought to provide relief from migraine by causing cranial vasoconstriction, through 
their action at postsynaptic 5-HT1B receptors on the smooth-muscle cells of blood 
vessels. It is now theorized that triptans also block the release of vasoactive peptides 
from the perivascular trigeminal neurons through their action at presynaptic 5-HT1D 
Introduction 
25 
 
receptors on the nerve terminals. In addition, triptans are thought to have a central 
activity by blocking the release of neurotransmitters that activate second-order neurons 
ascending to the thalamus, and facilitating descending pain inhibitory systems (Loder, 
2010). All triptans have the same contraindications and safety concerns. None is safer 
than another; however, the response to triptans is often idiosyncratic. One triptan might 
work for one patient and cause no adverse events, and a different triptan might work for 
another patient. The triptan of choice is the one that restores the patient’s ability to 
function by swiftly and consistently relieving pain and associated symptoms with 
minimum adverse events and without recurrence of symptoms. Triptans also relieve 
from nausea and vomiting (Loder, 2010). Before deciding that a drug is ineffective, at 
least two attacks should be treated. It might be necessary to change the dose, 
formulation or route of administration or add an adjuvant. When the response is 
inadequate, the headache recurs, or adverse events are bothersome, changing the drug 
might be needed. If all treatments fail, rescue drugs (opioids, neuroleptics, and 
corticosteroids) are needed. They provide relief, but they have important adverse effects 
(Silberstein et al., 2004) 
Preventive drugs reduce attack frequency, duration, or severity. Indications for 
preventive treatment include: migraine that substantially interferes with the patient’s 
daily routine despite acute treatment; failure of, contraindication to, or troublesome 
adverse events from acute drugs; very frequent headaches with risk of drug overuse; 
special circumstances, such as hemiplegic migraine or attacks with a risk of permanent 
neurologic injury. Preventive drugs include β-adrenergic blockers, antidepressants, 
calcium-channel antagonists, serotonin antagonists, anticonvulsants, and non-steroidal 
anti-inflammatory drugs (Table 1.2). The choice is based on effectiveness, adverse 
events, and coexistent and comorbid conditions (Goadsby & Sprenger, 2010). If 
headache is well controlled, treatment can be lessened and discontinued, in order to 
provide a better risk-to-benefit ratio. Behavioral and psychological interventions can be 
also used for prevention, and they include relaxation training, thermal biofeedback 
combined with relaxation training, electromyography biofeedback, and cognitive-
behavioral treatment (Silberstein et al., 2004). 
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Recent and future pharmacological options 
Although triptans remain the most effective option for acute attack therapy, not all 
patients respond to treatment, and of those who do respond, about one out of three 
experience headache recurrences within 24 hours. Moreover, despite their relative 
safety, the fact that triptans constrict cranial and coronary blood vessels is an important 
issue for patients with cardiovascular diseases (Loder, 2010). For this reason, 
substantial efforts for discovering more effective, and safer, treatments are strongly 
needed. Possible future candidates for migraine treatment include CGRP receptor 
antagonists, nitric-oxide synthase inhibitors, vanilloid receptor antagonists, glutamate 
(AMPA, kainate) receptor antagonists, and 5-HT1F receptor agonists (Goadsby & 
Sprenger, 2010). The purinergic P2 receptors have been proven as important mediators 
in acute and chronic pain (Burnstock et al., 2009b; Jarvis, 2010; Villa et al., 2010), and 
Table 1.2   Current pharmacological treatments for migraine. 
Acute treatments 
Specific drugs 
- NSAIDS: aspirin, ibuprofen, tolfenamic acid, naproxen sodium and 
acetaminophen 
- Neuroleptics and antiemetics: prochlorperazine and droperidol 
- Corticosteroids: hydrocortisone, methylprednisolone, and dexamethasone 
- Opioids 
Non-specific drugs 
- Ergotamine and dihydroergotamine 
- Triptans: sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, 
frovatriptan, and eletriptan.  
 
Preventive treatments 
- β-blockers: propranolol, nadolol, atenolol, metoprolol, and timolol 
- Antidepressants: amitriptyline, fluoxetine and venlafaxine 
- Calcium-channel blockers: flunarizine 
- Anticonvulsant drugs: valproate, gabapentin and topiramate 
- Serotonin antagonists: methysergide 
- Nutraceuticals: riboflavin, coenzyme Q, butterbur (Petasites hybridus) and 
feverfew (Tanacetum parthenium) 
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we strongly believe that this receptor family has a role also in migraine. Indeed, as 
discussed in Chapter 2, our research is based on the study of this field, in order to find 
new molecular targets for migraine therapy. In the meantime, some prominent 
pharmacological approaches are currently studied in clinical trials; in the next section 
they will be briefly discussed. 
CGRP receptor antagonists: CGRP is one of the most important molecules 
involved in migraine neurobiology (see Paragraph 1.2.2). CGRP receptor antagonists 
are the most advanced class in clinical for migraine therapy. The intravenous antagonist 
olcegepant and the orally available antagonist telcagepant have shown clear effects in 
phase 1 and 2 studies. Telcagepant has recently undergone two phase 3 studies without 
cardiovascular liability. A phase 2 trial for another CGRP receptor antagonist, BI44370, 
has been completed and results are awaited. CGRP receptor antagonists have shown 
some positive effects in terms of reduced headache recurrence. The clinical tolerability 
of these drugs in terms of CNS and vascular side-effects seems to be more favorable 
than for triptans. However, concerns about possible liver toxicity remain (Tepper & 
Stillman, 2008). The development program of one compound, MK3207, which was 
undergoing phase 2 evaluation, has been discontinued because of delayed liver test 
abnormalities. Moreover, in a migraine prevention study of daily telcagepant over 3 
months, increases in transaminases were observed in a few patients. FDA filing for 
telcagepant has thus been delayed to allow a review of additional safety data (Goadsby 
& Sprenger, 2010). 
Serotonin receptor agonists: The announcement of the success of a phase 2 study 
with the 5-HT1F receptor agonist COL-144 offers another prospect for acute anti-
migraine therapy. Unlike triptans, COL-144 does not act at 5-HT1B/D receptors and 
therefore does not cause vasoconstriction. In clinical studies it was shown than the drug 
was well tolerated and did not produce triptan-like chest symptoms. At the effective 
doses of COL-144, a higher proportion of patients showed a headache response at 2 h 
than those on placebo. An orally bioavailable formulation of COL-144 is now in phase 
2 testing (Neeb et al., 2010). 
CSD inhibitors: Similarly to the already available preventive agents, tonabersat, a 
novel potential preventive agent that has recently been investigated in three phase 2 
studies, is a specific CSD inhibitor. During clinical studies investigators found a 
significant reduction of the number of aura attacks in tonabersat-treated patients, 
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although the number of migraine headache days was unaffected. This result is in 
agreement with the view that CSD is the experimental equivalent of aura, and 
substances effective in reducing CSD are also effective in preventing aura symptoms. 
Unfortunately, three different clinical studies were negative in terms of prevention of 
migraine without aura (Hauge et al., 2009). Together, these results suggest that, 
although tonabersat is unlikely to be a major step forward for the treatment of patients 
with migraine without aura, it could be a valid option for the management of patients 
with aura.  
Botulinum toxin type A: Botulinum toxin type A (onabotulinum toxin A; BTA) is 
a reversible inhibitor of presynaptic acetylcholine release at motor nerve terminals. 
Open-label experience from its cosmetic use suggested its potential benefits in headache 
after injection into glabellar, frontalis, and temporalis muscles. Its effectiveness in pain 
disorders is probably due to inhibition of the release of neurotransmitters, such as SP 
and CGRP, and effects on muscle spasm and nerve transmission. Despite positive open-
label studies and case reports, BTX has not proven to be effective for many patients 
with chronic tension-type headache or episodic migraine based on double-blind 
placebo-controlled trials. There is increasing evidence, however, that BTX is effective 
in the treatment of chronic migraine and chronic daily headache. More recently, a large 
multicenter randomized, double-blind, placebo-controlled trial of more than 1300 
patients with chronic migraine demonstrated significant reductions in headache 
symptoms, frequency, disability and triptan utilization along with improvements in 
measures of health-related quality of life. Compared with other preventive treatments, 
BTX has a rapid onset of action (less than 2 weeks) with few serious adverse events and 
does not require daily medication use or titration (Goadsby & Sprenger, 2010).  
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1.3 THE PURINERGIC SYSTEM 
ATP has long been recognized only as an intracellular energy molecule, and its 
acceptance as an extracellular signaling molecule has taken a considerably long period 
of time. The potent effects of ATP on the heart and blood vessels were first described in 
1929 (Drury & Szent-Györgyi, 1929), while in 1972 Burnstock proposed new roles for 
adenosine-5'-triphosphate (ATP) as neurotransmitter in non-adrenergic, non-cholinergic 
nerves in the gut and bladder (Burnstock, 1972). In the following years ATP 
metabolites, like the nucleotide adenosine-5'-diphosphate (ADP) and the nucleoside 
adenosine (Ado), obtained by its enzymatic hydrolysis, as well as other extracellular 
nucleotides like the uridine-5'-triphosphate (UTP), uridine-5'-diphosphate (UDP), and 
sugar nucleotides, were progressively proposed as transmitters not only in sensory 
nerves, but also in motor nerves and CNS neurons (Fields & Burnstock, 2006; Inoue et 
al., 2007). The actions of these molecules in the extracellular environment implicated 
the existence of post-junctional receptors. Accordingly, numerous subtypes of these 
receptors were progressively cloned, and scientists gradually coined and accepted the 
term “purinergic system” for describing the system composed by extracellular 
nucleotides/nucleosides and their receptors. The first classification of purinergic 
receptors family dates back to 1978, when Burnstock proposed some criteria for 
differentiating these receptors in two families: the P1 receptors activated by Ado and 
antagonized by methylxantinic compounds, and the P2 receptors, responding to ATP 
and ADP.  
Nowadays, P2 purinoceptors are divided into two families: the ionotropic 
receptors P2X and the metabotropic P2Y receptors (Burnstock & Knight, 2004). P2X 
receptors are ligand-activated cationic channels, specifically activated by ATP 
(Burnstock & Knight, 2004), while P2Y receptors are activated by purine or pyrimidine 
nucleotides, or by sugar-nucleotides, and couple to intracellular second-messenger 
systems through heteromeric G proteins (Abbracchio et al., 2006). In 1994, the 
IUPHAR Subcommittee for Purinoceptor Nomenclature and Classification has 
approved the new classification and has proposed to substitute the term “P2 
purinoceptors” with “P2 receptors”, in order to take into account the observation that 
some P2 receptors are preferentially activated by uridine nucleotides (Fredholm et al., 
1997). To date, at least seven P2X subtypes (P2X1-7) and eight P2Y members 
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(P2Y1,2,4,6,11,12,13,14) have been cloned from different animal species (Abbracchio et al., 
2006). The missing numbers in the P2Y series correspond to receptors cloned from 
vertebrates different from mammals and for which no mammalian orthologs have been 
identified so far, or to receptors that have not been functionally characterized yet. 
The concept that ATP is an extracellular signalling molecule has been established 
not only in the rapid signalling involved in neurotransmission, but also in a wide range 
of other biological processes, including release of cytokines, neurotransmitters and 
hormones, cell proliferation, differentiation and apoptosis in tissues as diverse as the 
skin, skeletal muscle, bone, nervous and immune system (Fields & Burnstock, 2006; 
Inoue et al., 2007). Thus, alterations in purinergic signalling may contribute to the 
development of disorders of the immune system, inflammation, neurodegeneration, 
osteoporosis and cancer. On this basis, a better understanding of the roles of purinergic 
signalling may help identifying novel therapeutic targets for several human diseases. 
 
 
1.3.1 Purinergic signalling 
The first clues on the role of extracellular nucleotides in signal transduction came 
from the observation that neurons and neuroendocrine cells released ATP copackaged 
with other neurotransmitters (Burnstock, 1972). Moreover, it has been demonstrated 
that, following mechanical stress, also non secretory tissues can release nucleotides 
(Lazarowski et al., 2000) which may signal to the same secretory cell (autocrine 
stimulation) as well as to adjacent cells (paracrine stimulation). Following injury or 
inflammation, nucleotides can also be released as a consequence of cell lysis. There is 
ongoing debate, however, about the transport mechanisms involved in nucleotide 
release. There are hints for exocytotic release from endothelial and urothelial cells, 
osteoblasts, astrocytes, and mast and chromaffin cells, but other transport mechanisms 
have been proposed, including ATP binding cassette transporters, connexin 
hemichannels and plasmalemmal voltage-dependent anion channels (Fields & 
Burnstock, 2006). More recently, pyrimidine nucleotides release has been described 
(Lazarowski et al., 2003).  
Once released in the extracellular environment, nucleotides are rapidly degraded 
by ubiquitous ecto-nucleotidases (Zimmermann, 2000), a family of phosphatases 
expressed on the cell surface that are able to dephosphorylate different nucleotides. ATP 
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hydrolysis sequentially produces ADP, AMP and adenosine, whether UTP is degraded 
to UDP, UMP and uridine; many of these metabolites can act as extracellular signalling 
molecules The local response to a specific nucleotide is thus the result of the effects of 
the nucleotide itself and of its degradation products. Distinct classes of ecto-
nucleotidases with different properties and different substrate specificities have been 
identified so far (Yegutkin, 2008). Some are membrane proteins with an extracellular 
catalytic domain, but soluble forms released in the extracellular space have also been 
described. Ecto-nucleotidases can be also released with ATP from sympathetic nerve 
terminals, representing one of the mechanisms to turn off neurotransmitter signalling 
(Todorov et al., 1997). A general scheme of nucleotide-hydrolyzing enzymes include: 
(i) the ectonucleoside triphosphate diphosphohydrolase (E-NTPDase) family, (ii) the 
ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) family, (iii) ecto-5'-
nucleotidase, and (iv) alkaline phosphatases (AP; Yegutkin, 2008). This various 
enzymatic family demonstrates that ATP and other nucleotides can be considered 
classical neurotransmitters whose signal can be regulated by enzymatic degradation. 
Nucleotides released or leaked from both glial cells and neurons play a role in 
cell-to-cell communication under physiological and pathophysiological conditions 
(Burnstock & Knight, 2004). Accordingly, in CNS both neuronal cells and the major 
classes of glia (i.e. astrocytes, microglia and oligodendrocytes), express a broad range 
of purinergic receptors (Fields & Burnstock, 2006). For instance, astrocytes release 
ATP in response to various stimuli or even spontaneously, and communicate with 
neurons, microglial cells, and even vascular cells at capillaries (Inoue et al., 2007). Also 
microglial cells respond to a wide range of ATP receptor agonists, through increases in 
intracellular calcium, secretion of cytokines, and rapid changes in their morphology and 
migration (Inoue, 2008). Extracellular nucleotides represent therefore a class of 
signalling molecules that functionally “unite” glia and neurons together. Not by chance 
neuron-glia or glia-glia communications participate in the control of several 
pathophysiological mechanisms, including regulation of synaptic transmission 
(Wieraszko & Ehrlich, 1994), neuroimmune interactions (Inoue et al., 2007), processing 
of information through the retina (Newman, 2006), Schwann cell proliferation and 
myelination (Fields, 2006; Stevens, 2006), cell proliferation (Neary et al., 2006), 
inflammation (Di Virgilio et al., 2009), and pain (Burnsock, 2009a,b; see also 
Paragraph 1.4) 
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1.3.2 P2X receptors 
P2X receptors are membrane ion channels that open in response to the binding of 
extracellular ATP. ATP can elicit rapid responses (<10ms) via these ion channels, 
resulting in selective permeability to Na+, K+, and Ca2+ cations (North, 2002). In 
vertebrates, seven genes encode P2X receptor subunits, which are 40-50% identical in 
their aminoacidic sequence. Each subunit has two transmembrane domains, separated 
by an extracellular domain (~280 aminoacids). Channels function as trimers of several 
subunits (Figure 1.5). As of today, seven homomeric channels (P2X1-7) have been 
identified, but functional expression studies have also highlighted the existence of 
heteromeric P2X1/5, P2X2/3, P2X2/6, P2X4/6, P2X4/7 and P2X5 receptors which assemble 
with any others, except P2X7 (North, 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The lengths of P2X subunit differ from 384 (P2X4) to 595 (P2X7) aminoacids. 
Each subunit has two hydrophobic regions of sufficient length to cross the plasma 
membrane, placing most of the protein extracellularly. These hydrophobic regions are 
Table 1.4  Pharmacological properties of rodent P2X receptors. 
Receptor n° of amminoacids Agonist potency Antagonists 
P2X1 399 
BzATP >> 2MeSATP > 
ATP > ,αβmeATP 
TNP-ATP, 
Suramin, 
PPADS, 
MRS2159 
P2X2 472 2MeSATP > ATP  PPADS 
P2X3 397 
BzATP >> 2MeSATP  > 
ATP = α,βmeATP TNP-ATP 
P2X4 388 
ATP > 2MeSATP >> 
α,βmeATP TNP-ATP 
P2X5 455 ATP > 2MeSATP > ADP - 
P2X6 379 ATP > 2MeSATP > ADP PPADS  
P2X7 595 BzATP >> ATP4- 
KN-62,  
PPADS,  
oATP 
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separated by the bulk of the polypeptide. The NH2 and COOH terminals are both 
cytoplasmic (North, 2002). The extracellular loop contains the ATP binding site as well 
as sites for antagonists and modulators (Khakh et al., 2001). The aminoacidic identity 
between P2X receptor subunits is distributed throughout the extracellular domain, a 
striking feature of which is the conservation of 10 cysteine residues among all known 
receptors which form disulfide bonds to give the correct conformation to the receptor 
(Vial et al., 2004). All the P2X receptor subunits have consensus sequences for N-
linked glycosylation (Asn-X-Ser/Thr), and some glycosylations are essential for 
trafficking to the cell surface. The extracellular domain carries few conserved glycine 
(G) and proline (P) residues which are involved in conformational changes subsequent 
to ligand-receptor binding. Extracellular protons, bivalent cations and some metals are 
P2X receptors allosteric modulators. In addition, P2X receptors can be modulated via 
phosphorylation of serine (S) and threonine (T) residues. A list of the main nucleotide 
analogues acting as agonists or antagonists at the P2X receptors is summarized in Table 
1.3. 
 
 
1.3.3 P2Y receptors 
P2Y receptors belong to the superfamily of G protein-coupled receptors (GPCR). 
GPCR are a family of membrane receptors responding to a wide variety of ligands such 
as nucleotides, biogenic amines, peptides and other small molecules (Marchese et al., 
1999). The binding of the GPCR to its specific ligand results in the activation of the 
associated heterotrimeric G protein (α, β and γ subunits) that mediate a number of 
intracellular responses. In particular, ligand binding to its receptor results in a decreased 
affinity of the α subunit of the G protein for GDP, that is thus exchanged for GTP. This 
binding causes a conformational modification in the G protein and the dissociation of 
the α subunit from the βγ complex. Both α and βγ subunits can then activate signal 
transduction pathways (Rebois et al., 1997). 
From a phylogenetical point of view, the eight human P2Y receptors can be 
subdivided into two distinct subgroups characterized by a relatively high level of 
sequence divergence. The first subgroup encompasses P2Y1, P2Y2, P2Y4, P2Y6 and 
P2Y11, whereas the second subgroup encompasses P2Y12, P2Y13 and P2Y14 (Abbracchio 
et al., 2006). Site-directed mutagenesis of P2Y1 and P2Y2 receptors has shown that some 
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positively charged residues in transmembrane domains 3, 6 and 7 are crucial for 
receptor activation by nucleotides (Abbracchio et al., 2006). They probably interact 
with the negative charges of the phosphate groups of nucleotides.  
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Figure 1.5 
Organization of P2X and P2Y receptors 
A, Schematic representation of a typical P2X receptor, and a P2Y receptor. B, Representation of P2X and 
P2Y receptor organization in the plasma membrane, and of their intracellular signalling pathways. While 
activation of P2X receptors lead to increase in permeability to Na+, K+, and Ca2+, nucleotides acting at 
P2Y receptors cause activation of specific G proteins:  Gq/G11 for the P2Y1,2,4,6,11, leading to the 
recruitment of the PLC pathway with increases in intracellular calcium;  GS for P2Y11, leading to 
increases in cAMP levels; Gi/o for P2Y12,13,14, leading to decrease in cAMP levels. 
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The eight P2Y receptors identified so far have a H-x-x-R/K motif in TM6 that 
might be important for agonist activity. Receptors in the first subgroup also share a YQ/ 
K-x-x-R motif in TM7 (proposed to participate in ligand binding), whereas in receptors 
of the second subgroup, another motif (K-E-x-x-L) which might affect ligand binding 
characteristics, is observed (Abbracchio et al., 2006). These two P2Y receptor 
subgroups also differ in their primary coupling to transductional G proteins. In 
particular, all receptors in the first subgroup (i.e., P2Y1,2,4,6,11) couple to Gq/G11 to 
activate PLC/IP3 pathway and release intracellular calcium, whereas receptors in the 
second subgroup (i.e., P2Y12,13,14) almost exclusively use the Gi/o class of G proteins to 
lower cAMP levels. Secondary couplings have been also reported, especially for 
receptors of the first subgroup in heterologous expression systems (Abbracchio et al., 
2006). Among receptors of the second group, P2Y13 has been also reported to couple to 
Gα16 and to stimulate PLC in recombinant systems overexpressing this G protein 
(Fumagalli et al., 2004). Such “promiscuity” of G protein coupling may depend on the 
indirect activation of additional G protein subtypes within protein complexes containing 
the P2Y receptor. 
From a pharmacological point of view, P2Y receptors can be broadly subdivided in four 
groups based on their responsivity to nucleotides: i) adenine nucleotide-preferring 
receptors, mainly responding to ADP and ATP. This group includes human and rodent 
P2Y1, P2Y12, and P2Y13, and human P2Y11; ii) uracil nucleotide-preferring receptors, 
including the human P2Y4 and P2Y6 responding to either UTP or UDP; iii) receptors of 
mixed selectivity, the human and rodent P2Y2, the rodent P2Y4 and, possibly, P2Y11; 
and iv) the P2Y14 receptor, responding to both UDP and sugar nucleotides (mainly 
UDP-glucose and UDP-galactose; Abbracchio et al., 2006; Carter et al., 2009). In this 
latter group it could be possibly included a receptor phylogenetically and structurally 
related to already known P2Y receptors, named GPR17, which has been recently 
reported to respond to both cysteinyl-leukotrienes and uracil nucleotides (Ciana et al., 
2006). A list of the main nucleotide analogues, which can act both as agonists, 
antagonists or partial agonists at the P2Y receptor subtypes, is summarized in Table 1.4. 
Unfortunately, although important progress in exploring structure-activity relationships 
has been achieved, most of the P2Y receptor subtypes are still lacking potent and 
selective synthetic agonists and antagonists (Abbracchio et al., 2006).  
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Table 1.4  Pharmacological properties of rodent P2Y receptors. 
Receptor n° of amminoacids 
G-protein 
coupling Agonist potency Antagonists 
P2Y1 373 Gq/G11 
2MeSADP > MRS2365 > 
ADP  > ATP 
MRS2500, 
MRS2179 
P2Y2 377 Gq/G11 UTP = ATP = MRS2698 
Suramin, 
PSB-716 
AR-C126313 
P2Y4 365 Gq UTP > ATP PPADS 
P2Y6 328 Gq/G11 
PSB-0474 > 5-iodo-UTP > 
UDP >  UTP 
MRS2567, 
MRS2578, 
MRS2575 
P2Y11 374 
Gq/G11 
and Gs 
NF546 > ATP > 2 MeSATP  
Suramin,  
Reactive blue 2, 
NF340 
P2Y12 342 Gi 
2MeSADP = 2MeSATP > 
ADP >ATP > UTP 
Cangrelor, 
PSB-0739 
AZD6140 
P2Y13 333 Gi ADP = 2MeSADP 
Cangrelor 
MRS2211 
P2Y14 338 Gi/Go 
UDPglucose > UDPgalactose 
> UDP - 
 
 
1.3.4 Pathophysiological roles of extracellular nucleotides in the nervous system 
The hypothesis that ATP plays a central role in modulating cerebral functions 
rises from the broad distribution of P2 receptors in the CNS (Abbracchio et al., 2006). 
ATP is released from nerve terminals and has rapid and direct actions, generally 
associated to activation, whether Ado has inhibitory effects with a negative feed-back 
action on the effects of ATP and of other neurotransmitters released at the synapse. The 
first evidence suggesting a role of ATP as a neurotransmitter in the brain was obtained 
in 1992, with the demonstration that its stable analog, α,β-meATP, provokes a current 
of excitation in rat neurons which is antagonized by P2 antagonists (Edwards et al., 
1992). In some brain areas, ATP regulates neurotransmission through the modulation of 
glutamate release from nerve endings. This effect is mediated by P2 receptors located 
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on the presynaptic as well as on the post-synaptic element (Motin & Bennett, 1995). In 
particular, it has been suggested that ATP can amplify glutamate post-synaptic action 
following interaction with a P2Y receptor, or by activating an ecto-kinase responsible 
for the phosphorylation of membrane proteins associated to glutamate receptors (Chen 
et al., 1996). These observations have led to the hypothesis that ATP, and maybe also 
UTP, might participate in long-term synaptic potentiation, memory, and learning 
processes (Price et al., 2003, Fujii, 2004). According to this hypothesis there is the 
experimental evidence indicating colocalization of ATP with neurotransmitters and 
neuropeptides in secretory vesicles of most synapses. Noradrenaline (NA) and ATP are 
released from sympathetic nervous system endings in variable ratios according to the 
tissue and to the animal species considered (Burnstock & Verkhratsky, 2010). ATP co-
transmission has been also observed in isolated blood vessels as well as in skeletal 
muscle, kidney and intestine vasculature (Burnstock, 2009a). Despite the demonstration 
that ATP is stored in the nerve endings together with NA, prejunctional 
neuromodulation studies demonstrate that ATP and NA are released independently 
following different stimuli (Starke et al., 1996). It can thus be hypothesized that 
different nerve populations containing different ratios of NA and ATP exist in the 
sympathetic nervous system. Finally, indirect evidence demonstrates that ATP and 
acetylcholine co-localize in central and peripheral cholinergic terminals and that a co-
transmission with peptides such as SP, CGRP, neuropeptide Y and somatostatin also 
exists (Burnstock, 1997; Zimmermann, 2008).  
Recent studies also highlighted a direct involvement of extracellular nucleotides 
in neurogenesis and gliogenesis. In the nervous system ATP has been identified as a 
mitogen for v-myc immortalized neural progenitor cells (Ryu et al., 2003), and ATP-
mediated purinergic signalling through the P2Y1 receptor has been associated with 
developmental neurogenesis (Weissman et al., 2004). Moreover, neurospheres cultured 
from the adult SVZ express functional nucleotide receptors as well as enzymes for their 
degradation (Milosevic et al., 2006; Mishra et al., 2006). Interestingly ATP release and 
purinergic signalling may be required not only for the developmental expansion of 
progenitor cell and neurogenesis, but also to control the proliferative and differentiative 
potential of the progenitor cells in the adult brain. The colocalization of both P2Y 
receptors and ecto-nucleotidases activity to regions of active mitotic progenitor cell 
expansion and neurogenesis in the adult brain (Braun et al., 2003; Shukla et al., 2005) is 
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particularly significant in this regard, given the apparent necessity of purinergic 
signalling to neural progenitor cell expansion in vitro (Mishra et al., 2006). 
Following pathological/traumatic events a massive release of purines and 
pyrimidines at the site of injury is observed and they seem to have a dualistic effect: on 
one hand, they contribute to lesion worsening, but on the other side they are involved in 
tissue regeneration and repair. In the next sections the main roles of these molecules 
during pathological events will be briefly discussed, whereas a detailed dissertation of 
their role in pain transmission will be provided in the following paragraphs. 
 
Brain ischemia and spinal cord injury 
During ischemia or hypoxia in the CNS a massive release of nucleotides is 
observed (Neary et al., 1996; Melani et al., 2005). ATP participate to cell death 
induction immediately (minutes to hours) following tissue injury, probably as a 
consequence of a diffuse dysregulation of the release mechanisms and of a pathologic 
activation of P2 receptors. For instance, it has been demonstrated that ATP has a 
cytotoxic effect on cerebellar neurons (Amadio et al., 2002) and potentiates 
hypoglycemia-induced tissue injury (Cavaliere et al., 2002). In the weeks following 
ischemic injury, when homeostatic control is re-established in the injured area, ATP 
seems to contribute to differentiation and to promote the long-term functional repair of 
the damaged area (Abbracchio & Ceruti, 2006; Abbracchio & Verderio, 2006). During 
ischemic and hypoxic events, high extracellular concentrations of adenosine are also 
reached, in part as a consequence of ATP degradation. It has been demonstrated that 
adenosine has a protective role in cerebral ischemia in several experimental models. 
Accordingly, both adenosine administration as well as inhibition of its degradation 
reduces injury associated to cerebral or cardiac ischemia and protects from organ loss of 
function (Phillis & O'Regan, 1996; Mentzer et al., 1996; Fredholm, 2010). 
Extracellular nucleotides can also induce cell death, through the formation of 
P2X7 receptor-associated pore (Di Virgilio et al., 1996; Ferrari et al., 1997). This 
mechanism could influence neuronal remodeling through the elimination of critically 
injured cells, in particular during acute brain ischemic events, thus limiting the area of 
damaged tissue (Neary et al., 1996). Brain damage caused by a transient MCAo results 
in a sustained pathologically high ATP outflow; while in the infarct region the release 
of ATP is low because of disturbed cellular synthesis, in the peri-infarct area its 
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concentration is increased, due both to the deregulation of its enzymatic degradation, 
and to the concomitantly enhanced outflow of the nucleotide from damaged cells 
(Melani et al., 2005). 
An abnormal purinergic signaling has been also observed following spinal cord 
injury (SCI). In the peritraumatic spinal cord regions, ATP is released at high levels and 
causes neuronal cell death through P2X7 receptors. In this respect, P2X7 receptor 
blockade is associated to improved functional recovery and diminished cell death in the 
peritraumatic zone (Wang et al., 2004). Analysis of P2X4 receptor expression following 
SCI also demonstrated a significant accumulation of P2X4-positive 
microglia/macrophages as early as 24 h after SCI, peaking on day 7 (Schwab et al., 
2005). Taken together, these observations confirm the role of the purinergic system in 
the traumatic degeneration, and possibly in tissue remodeling. 
 
P2 receptors in reactive astrogliosis 
Astrocytes respond to traumatic and inflammatory CNS insults through major and 
rapid modifications of their morphology and cell structure and with an increased 
proliferation, a process known as “reactive astrogliosis” (Eddleston & Mucke, 1993). 
Reactive astrogliosis occurs in several pathologies, including ischemia and chronic pain, 
and is characterized by hypertrophy and proliferation of astrocytes around the injured 
region (Marchetti & Abbracchio, 2005). Reactive astrocytes produce and release 
inflammatory mediators such as cytokines and chemokines, as well as various growth 
factors. In addition, reactive astrocytes upregulate the expression of nestin, GFAP, and 
vimentin markers (Clarke et al., 1994). The functional role of reactive astrogliosis has 
not been clearly delineated yet; some studies suggest a protective role of the glial scar 
that protects nervous tissue and limits damage progression, whereas others indicate that 
it could interfere with axonal growth and regeneration (Sofroniew & Vinters, 2010). 
Despite these discordant experimental evidence, there is agreement on the fact that an 
excessive and long-lasting reactive gliosis can be deleterious for functional repair of the 
damaged area. Probably this mechanism is initially activated as a protective response to 
tissue injury, but a prolonged activation can result in a pathological event and contribute 
to neurodegeneration. Importantly, astroglial cell activation has been correlated to P2 
activation (Neary et al., 2006). It has been demonstrated that ATP induces pro-
inflammatory enzymes and arachidonic acid release (Bolego et al., 1997; Brambilla et 
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al., 1999), therefore worsening the neurodegenerative damage through the formation of 
radical oxygen species, prostaglandins, leukotrienes and the blockade of glutamate 
reuptake (Volterra et al., 1994). These data suggest that in pathological conditions, P2 
receptor activation on both neurons and astrocytes can contribute to neurodegenerative 
damage, and thus P2 antagonists might represent an interesting approach to 
neuroprotection in acute cerebral damage. 
 
Chronic neurodegenerative diseases 
P2 receptor ligands have been proposed as potential neuroprotective agents 
following neuronal death associated with neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral 
sclerosis and multiple sclerosis (Burnstock, 2008). For instance, different P2 receptor 
subtypes are involved the development and growth of dopaminegic neurons in CNS 
(Heine et al., 2007), and P2X7 receptors are involved in ATP-mediated necrotic volume 
increase in substantia nigra, which has been implicated in the pathogenesis of 
Parkinson’s disease (Jun & Kim, 2004). P2X7 receptors have been also found 
upregulated in the brain of patients with Alzheimer’s disease (McLarnon et al., 2006), 
and ATP released during neuronal excitation or injury enhances the inflammatory 
effects of cytokines and prostaglandin E2 in astrocytes, thus contributing to the chronic 
inflammation seen in Alzheimer’s disease (Xu, et al., 2003). P2X7 receptor antagonism 
therefore represents a therapeutic strategy for blocking inflammatory responses 
associated to neurodegenerative disorders.  
In the brain, stress or damage causes the release of nucleotides and activation of 
P2Y2 receptors, leading to pro-inflammatory responses including the stimulation and 
recruitment of glial cells, which can protect neurons from injury (Peterson et al., 2010). 
Indeed, P2Y2 receptor expression is increased in glial cells by stimulation with IL1β, a 
pro-inflammatory cytokine whose levels are elevated in Alzheimer’s disease, and this 
effect has been proposed to be neuroprotective, since it increases the non-
amyloidogenic cleavage of the amyloid precursor protein (Camden et al., 2005). Thus, 
activation of P2Y2 receptors in glial cells can promote neuroprotective responses, 
therefore indicating this receptor subunit as a novel pharmacological target for the 
treatment of neurodegenerative diseases.  
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1.4 PURINES AND PAIN  
The first hints about the involvement of ATP in pain transmission came from the 
observation that its injection into the human skin elicited pain (Bleehen and Keele, 
1977; Krishtal et al., 1983). A significant breakthrough in this field was made in 1995, 
when the P2X3 receptor channel was cloned from rat DRG, and it was shown to be 
expressed on small nociceptive sensory neurons together with P2X2/3 heteromultimer 
receptors (Chen et al., 1995; Lewis et al., 1995). The next year Burnstock proposed a 
unified hypothesis on the role of ATP in pain, suggesting that: (i) ATP released as a 
cotransmitter with noradrenaline and neuropeptide Y from sympathetic nerve terminal 
varicosities is involved in sympathetic pain; (ii) ATP released from vascular endothelial 
cells of microvessels during reactive hyperaemia is associated with pain in migraine, 
angina and ischemia; (iii) ATP released from tumor or damaged cells activates P2X3 
receptors on nociceptive sensory nerves (Burnstock, 1996). This hypothesis has been 
followed by an increasing number of papers that confirmed and expanded this concept 
(see also below). 
Although ATP is one of the key mediators in nociception, emerging evidence 
indicates that also other extracellular nucleotides (namely ADP, UTP and UDP), and 
nucleosides (adenosine) participate in the modulation of pain transmission (Liu & 
Salter, 2005; Burnstock, 2009a; Jarvis, 2010). Indeed, several P1 and P2 receptors have 
been found to be expressed by both neurons and glial cells involved in nociceptive 
transmission (Donnelly-Roberts et al., 2008; Burnstock, 2009a), and the effects of 
extracellular nucleotides on nociception are extremely complex and related to the 
specific receptor subtypes and/or their cellular localization. For instance, both P2X 
(e.g., P2X4) and P2Y (e.g., P2Y6,12) purinergic receptors are upregulated in activated 
microglia following nerve injury, and their pharmacological or biotechnological 
inhibition has been demonstrated to critically modulate the development and 
maintenance of neuropathic pain (Inoue, 2008; Tsuda et al., 2010). Another interesting 
pharmacological target involved in pain pathophysiology is the P2X7 channel, 
specifically expressed by SGCs in sensory ganglia. The purinergic P2 receptors 
therefore represent interesting targets in nociception, and the development of clinically 
administrable drugs will be of primary importance for successfully treating chronic pain 
diseases like migraine. 
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1.4.1 Role of P2X receptors in pain transmission 
Since the publication of early works demonstrating ATP involvement in pain (see 
above), the expression and function of P2X receptors in sensory neurons have been 
characterized. To date the most important P2X receptors subtypes implied in pain 
transmission are the P2X3 and P2X2/3 receptors subtypes, expressed by sensory neurons; 
the P2X4 receptor, expressed by CNS microglia; and the P2X7 receptor, expressed in 
sensory ganglia by SGCs (Burnstock, 2009b).  
 
P2X3 and P2X2/3 receptors  
The P2X3 receptor was originally cloned from the rat DRG, and was shown to be 
expressed by about the 40% of small to medium-sized nociceptive sensory neurons, 
together with P2X2/3 heteromultimer receptors. P2X3 receptors are expressed by IB4-
positive sensory neurons, colocalize with the vanilloid receptor subtype 1 (VR1), and 
only partially with the neuropeptide CGRP (Bradbury et al., 1998; Guo et al., 1999). 
P2X3 receptor subunits are synthesized in the cell bodies of sensory neurons and then 
transported both peripherally and centrally: peripheral expression contribute to ATP 
nociceptive sensory transmission, while the central projections of P2X3-positive 
neurons terminate in inner lamina II of the spinal cord (Vulchanova et al., 1998).  
Expression level and functional properties of P2X3 and P2X2/3 are dynamically 
modulated in different pain models. For instance, chronic inflammation induced by 
complete Freund's adjuvant (CFA) results in the upregulation of P2X3 or P2X2/3 
receptor expression and functionality in both in DRG and TG neurons (Xu & Huang, 
2002; Shinoda et al., 2005). Moreover, injury produced by the chronic constriction of 
the sciatic nerve produces a general increase of P2X3 receptor-positive DRG cells, in 
both small- and medium-sized neurons (Novakovic et al., 1999). By using an 
experimental model of trigeminal neuropathic pain, produced by the partial ligation of 
the infra orbital nerve, it was shown that the number of P2X3-immunoreactive neurons 
was significantly increased ipsillaterally, and the heat-related hyperalgesia development 
was inhibited by the peripheral injection of P2 receptors antagonists pyridoxal-
phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) and 2',3'-O-(2,4,6-trinitrophenyl) 
adenosine 5'-triphosphate (TNP-ATP; Shinoda et al., 2007). This evidence, together 
with others indicating a strong expression of P2X3 receptors in deep craniofacial nerve 
Introduction 
43 
 
terminals (Ambalavanar & Dessem, 2009), indicates this receptor as a potential target 
for developing novel therapies for trigeminal neuropathic pain, and possibly for 
migraine.  
The subcutaneous or intrathecal injection of the highly selective, stable and 
competitive P2X3/P2X2/3 antagonist, A-317491, effectively attenuated both formalin-
induced acute pain, and thermal hyperalgesia induced by intra-plantar CFA injection. 
Spinal delivery of A-317491 also reduces chronic neuropathic pain induced by the 
chronic constriction of the sciatic nerve, or by the L5/L6 spinal nerve ligation (Jarvis et 
al., 2002; McGaraughty et al., 2003). The selective knock down of P2X3 receptors 
expression by using antisense oligonucleotides (ASO) or RNA interference 
demonstrated a significant role for P2X3 receptor in both inflammatory and neuropathic 
pain. Indeed, the nociceptive behaviors observed after injection of formalin or α,β-
methylene-ATP (α,β-meATP) into the rat hind paw, the mechanical and thermal 
hyperalgesia induced by CFA, as well as the mechanical hyperalgesia and allodynia 
induced by nerve injury were significantly reduced by acute P2X3 gene knock down 
(Honore et al., 2002; Barclay et al., 2002; Dorn et al., 2004).  Finally, the physiological 
role of P2X3 receptor subunits in sensory transmission has been also studied using P2X3 
null mutant mice (Cockayne et al., 2000; Souslova et al., 2000). These animals respond 
normally to acute noxious thermal and mechanical stimuli, but display attenuated 
responses to non-noxious warm stimulation. Formalin-induced nociceptive behavior is 
attenuated in P2X3 null mice, thus providing a genetic evidence for the requirement of 
this receptor in acute inflammatory pain. However, in chronic inflammation induced by 
CFA, there is a paradoxical enhancement of thermal hyperalgesia in P2X3 null mice, 
which may be due to some unknown developmental compensatory changes (Souslova et 
al., 2000). Moreover, ATP-induced hyperalgesia is reduced but not eliminated in P2X3 
null mice, thus indicating that other P2 receptors are probably involved in these 
mechanisms (Cockayne et al., 2000; Souslova et al., 2000). 
A role for the P2X3 receptor during migraine has been also proposed. In fact 
application of migraine mediators, like NGF and the neuropeptide CGRP, enhanced 
P2X3 receptor conductance in cultured trigeminal sensory neurons (Fabbretti et al., 
2006; Giniatullin et al., 2008). Moreover, by using a mouse genetic model of FHM1 
(knockin for the R192Q mutation of the CACAN1A gene, see Paragraph 1.2.3), a 
significant increase in P2X3 receptor activity was found (Nair et al., 2010). The 
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molecular analysis of this mechanism revealed that P2X3 potentiation in these animals 
is due to increased calcium/calmodulin kinase II (CaMKII)-dependent activation of the 
phosphatase Calcineurin, and subsequent impairment of the phosphorylation state of the 
receptor. Although these studies require further investigations, it has been proposed that 
a strong P2X3 receptor activation might facilitate ATP-dependent migraine and sensitize 
trigeminal nociceptors (Nair et al., 2010). 
 
P2X4 receptors 
An initial clue indicating a role for P2X4 receptors in pain came from 
pharmacological investigations of pain behavior after nerve injury. Indeed, the 
pharmacological blockade of spinal P2X4 receptors reversed tactile allodynia caused by 
peripheral nerve injury, without affecting acute pain behaviors (Tsuda et al., 2003). 
Following nerve injury, the expression of P2X4 receptors increased specifically in spinal 
cord microglia, indicating that a tonic activation of this receptor is necessary for 
sustaining allodynia (Tsuda et al., 2003). Moreover, intraspinal administration of P2X4-
specific ASO decreased the induction of receptor expression, and suppressed tactile 
allodynia. Conversely, intraspinal administration of microglia in which P2X4 receptors 
had been induced and stimulated, produced tactile allodynia in naive rats. Therefore, 
P2X4 receptor activation in microglia is not only necessary but also sufficient to cause 
tactile allodynia (Tsuda et al., 2003). This hypothesis is substantially supported by 
recent findings showing that both mice treated spinally with a P2X4 ASO and mice 
lacking P2X4 show attenuated tactile allodynia after nerve injury (Tsuda et al., 2010).  
The mechanisms by which microglia are crucial for producing neuropathic pain 
involve signaling pathways from activated microglia to dorsal horn neurons. In this 
respect, studies on rats spinal cord slices revealed that spinal microglia stimulated by 
P2X4 receptors agonists cause neuropathic pain through a rise in intracellular [Cl-] in 
spinal lamina I neurons (Coull et al., 2005). This effect was shown to be mediated by 
activation of P2X4 receptors on microglial cells and the subsequent release of brain 
derived neurotrophic factor (BDNF; Trang et al., 2009). Accordingly, interference of 
signaling between BDNF and its receptor (TrkB) prevented tactile allodynia caused by 
peripheral nerve injury or by intrathecal administration of P2X4-stimulated microglia. 
Thus, these results indicate that P2X4-stimulated microglia release BDNF as a crucial 
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factor to signal to dorsal horn neurons, causing a collapse of their transmembrane anion 
gradient with a subsequent neuronal hyperexcitability (Trang et al., 2009).  
The above evidence indicates that the P2X4 subtype might be a potential 
therapeutic target to treat neuropathic pain. However, there are currently no antagonists 
to potently and selectively inhibit P2X4 receptors. It has been proposed that some 
antidepressants and anticonvulsants clinically used in patients with neuropathic pain 
have inhibitory effects on ATP-evoked Ca2+ response in cells expressing recombinant 
P2X4 receptors and primary cultured microglial cells (Nagata et al., 2009). Among the 
drugs used, paroxetine and fluvoxamine, but not citalopram, produced an anti-allodynic 
effect in an animal model of neuropathic pain, and this effect correlated with the 
potency of inhibition of rat P2X4 receptors. Interestingly, the anti-allodynic action of 
paroxetine is insensitive to 5-HT receptor antagonists, suggesting that this effect could 
be independent from the spinal 5-HT system, and could be mediated through a direct 
inhibition of P2X4 receptors (Nagata et al., 2009). It remains to be tested whether novel 
selective P2X4 antagonists will elicit analgesic effects in neuropathic and inflammatory 
pain states. 
 
P2X7 receptors 
In sensory ganglia, the P2X7 subunit has been demonstrated to be selectively 
expressed by SGCs (Kobayashi et al., 2005; Zhang et al., 2005; Chessell et al., 2005; 
Chen, et al., 2008). In non-neuronal cells from DRG, the pharmacological 
characterization of cell responses showed a rank order of potency for known P2X 
receptor agonists as follows: BzATP > ATP > α,β-meATP, and the inhibition of 100µM 
BzATP-evoked currents by pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate 
(PPADS) and Mg2+ (Zhang et al., 2005). This pharmacological profile was consistent 
with the involvement of P2X7 receptors (Bianchi et al., 1999).  
In 2005, Chessell and coll. have shown that the P2X7 knock out mouse did not 
develop either mechanical allodynia or thermal hyperalgesia after inflammatory and 
neuropathic injury, while normal nociceptive processing was preserved (Chessell et al., 
2005). Interestingly, this receptor was found upregulated in DRGs and injured nerves 
from chronic neuropathic pain patients (Chessell et al., 2005). Given that P2X7 
stimulation is known to induce IL-1β release from macrophages/microglia and reactive 
astrocytes (Bianco et al., 2005; Sanz et al., 2009) and IL-1β levels were also strongly 
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upregulated in the inflamed paws following CFA intraplantar injection (Chessel et al., 
2005), it has been suggested that the P2X7 receptor subtype might play a pivotal role in 
the molecular cascade of events leading to inflammatory and neuropathic pain. In this 
context, growing evidence supports a role for P2X7 receptors as a "sensor of danger" 
that, by monitoring ATP extracellular levels, may participate to the modulation of IL-1β 
processing and release (Bianco et al., 2005; Ferrari et al., 2006). To further confirm this 
issue, systemic administration of selective P2X7 receptor antagonists, such as A-740003 
(Honore et al., 2006), and A-438079 (McGaraughty et al., 2007), was associated with a 
significant dose-dependent reduction of both allodynia and hyperalgesia in several 
animal models of neuropathic and inflammatory pain. The antinociceptive actions of A-
438079 were correlated to its ability to reduce both the evoked and the spontaneous 
firing of different classes of spinal neurons in neuropathic animals, and to inhibit the 
release of IL-1β (McGaraughty et al., 2007). Thus, these results would suggest a 
specific role for glial P2X7 receptors in neuron to glial cell interaction associated with 
ongoing pain (Zhang et al., 2005; Jarvis, 2010).  
 
 
1.4.2 Role of P2Y receptors in pain transmission: sensory ganglia  
In contrast to the abundance of data on the roles of P2X receptors in pain, only 
little and controversial information about the involvement of P2Y receptors in 
nociceptive transmission is known. However, these receptors are widely expressed in 
both neurons and glial cells of the PNS and CNS and therefore the comprehension of 
their nociceptive functions is of paramount importance for discovering new potential 
targets for pain therapy.  
In sensory ganglion neurons, P2Y receptors are located not only at the cell body, 
but also at the peripheral and central terminals (Gerevich & Illes, 2004; Burnstock, 
2009a). Here, their activity is integrated within the complex molecular network 
associated to the transmission of nociceptive signals to the CNS. For example, the 
preferential P2Y1 agonist ADP was found to inhibit the N-type voltage-activated 
calcium channels in rat DRG neurons. The outcome of this channels inhibition could be 
a decrease of sensory transmitters release from DRG terminals in the spinal cord, 
therefore diminishing the spinal pain transmission (Gerevich et al., 2004). P2Y receptor 
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expression on sensory terminals could also control ATP actions on P2X subtypes. In 
fact, P2Y1 and P2X3 receptors are often coexpressed in the same neuron (Ruan & 
Burnstock, 2003), and functional studies in DRG showed that P2Y1 receptor activation 
leads to P2X3 receptor inhibition (Gerevich et al., 2005; Chen et al., 2008). P2Y 
receptors can also modulate neuropeptide release; indeed, the P2Y2-4 preferential 
agonist UTP was found to induce release of CGRP from the rat DRG neurons (Sanada 
et al., 2002). Others studies failed to demonstrate a direct release of CGRP by UTP, but 
rather an enhancement of acid buffer solutions and capsaicin evoked neuropeptide 
release (Zimmerman et al., 2002; Huang et al., 2003). 
In sensory ganglia, P2Y receptors undergo significant changes on their expression 
levels after neuropathic or inflammatory conditions. It has been shown that after 
peripheral axotomy of the sciatic nerve in rat, P2Y1 mRNA is upregulated in DRGs 
(Xiao et al., 2002). Additionally, P2Y2 mRNA levels were strong upregulated after CFA 
injection in the hindpaw, while P2Y2-4-6 RNAs were downregulated (Malin et al., 2008). 
After CFA-induced inflammation, only WT mice showed hyperensivity to noxious heat, 
while P2Y2-/- mice failed to develop thermal hyperalgesia. On the contrary, there were 
no differences in the extent of mechanical allodynia between WT and P2Y2-/- mice 
(Malin et al., 2008). These results demonstrate that neuronal P2Y2 receptor subtype is 
specifically involved in thermal nociceptive transmission. It has been also demonstrated 
that receptor subtypes that are expressed but not functional upon basal conditions (e.g., 
P2Y14), are upregulated under specific chronic pathological painful situations (Vega-
Avelaira et al., 2009). These receptors could therefore represent innovative drug targets 
with an ideal therapeutic profile, since their pharmacological manipulation should not 
interfere with physiological transmission. 
Very few data are available on the role of the P2Y receptor family in SGCs. In 
DRG, in situ hybridization histochemistry (ISHH) studies detected mRNA expression 
only for the P2Y12 and P2Y14 receptor subtypes on these cells (Kobayashi et al., 2006). 
However, immunofluorecence studies showed staining for P2Y1 on both neurons and 
SGCs (Chen et al., 2008). Immunofluorescence staining also indicated the selective 
expression of P2Y4 on SGCs from both mouse and rat TG (Weick et al., 2003; Vit et al., 
2006). Unfortunately no functional studies, which could help clarifying this issue, are 
available for DRG-derived SGCs. Calcium imaging experiments on intact trigeminal 
ganglia revealed that application of ATP and UTP caused functional raises in [Ca2+]i in 
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almost all SGCs (Weick et al., 2003). This effect persisted in nominally Ca2+-free 
extracellular solution, but was blocked by cyclopiazonic acid, an inhibitor of 
intracellular Ca2+ release from the endoplasmic reticulum. These experiments confirmed 
that ATP/UTP responses on SGCs were due to functional P2Y receptors, likely the 
P2Y2/P2Y4 receptor subtypes (Weick et al., 2003). Moreover, [Ca2+]i increases were 
observed in SGCs after application of adenosine 5'-[β-thio]-diphosphate (ADPβS) and 
2-methylthio adenosine 5'-diphosphate (2MeSADP), two P2Y1 receptor selective 
agonists (Abbracchio et al., 2006), therefore suggesting that P2Y1 receptors are also 
expressed and functional in these cells (Weick et al., 2003). In conclusion, also SGCs 
from TG bear a wide panel of functional P2Y receptors, thus suggesting a primary role 
for nucleotides in modulating cell-to-cell communication in sensory ganglia.  
As already mentioned in Paragraph 1.1.3, SGCs form a morphological and 
functional unit together with sensory neurons (Hanani, 2005). Recent evidence suggests 
that, within this functional unit, a non-synaptic cross communication between neurons 
and SGCs can increase the excitability of both primary afferents and centrally 
projecting neurons, leading to the development of hyperalgesia and allodynia (Takeda et 
al., 2009). The P2 purinergic receptors expressed by SGCs participate primarily to this 
bidirectional neuron-glial communication inside the sensory ganglia. Indeed, a seminal 
work by Zhang and coll. (Zhang et al., 2007) reported that the electrical stimulation of 
DRG neurons elicited robust vesicular ATP release from their somata. The rate of ATP 
release was dependent on the frequency of nerve stimulation, and on the entry of 
external Ca2+ into the neuron. In addition, released ATP could activate P2X7 receptors 
on SGCs, leading to the release of TNFα, which in turn potentiated P2X3-mediated 
ATP currents in neurons (Zhang et al., 2007). The purinergic signaling pathways 
activated in SGCs might therefore represent interesting pharmacological targets to be 
exploited for the development of new analgesic strategies. 
 
1.4.3 Role of P2Y receptors in pain transmission: CNS  
There are only few and relatively controversial data on the presence and functions 
of P2Y receptors in spinal cord (Jarvis, 2009; Tsuda et al., 2009). For instance, 
intrathecal administration of UTP and UDP elevated the mechanical nociceptive 
threshold and prolonged the thermal nociceptive latency in uninjured rats. Moreover, 
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following partial ligation of the sciatic nerve UTP and UDP produced significant anti-
allodynic effects, thus suggesting an antinociceptive role for the P2Y2, P2Y4 and P2Y6 
receptor subtypes (Okada et al., 2002). Surprisingly, this study contrasts with a more 
recent data showing that the intrathecal delivery of suramin (a non-selective P2Y2 and 
P2Y4 receptor antagonist) blocks microglia activation and long-term hyperalgesia 
induced by formalin injection, therefore suggesting that a block, rather than an 
activation,  of P2Y receptors con provide pain relief following inflammatory conditions 
(Wu et al., 2004).  
Contrasting data notwithstanding, it seems clear that purinergic receptors 
expressed by microglial cells critically participate to the genesis and maintenance of 
neuropathic pain. Several purinoceptors are expressed by microglial cells, including the 
P2X4, P2X7, P2Y6, and P2Y12 receptor subtypes (Inoue & Tsuda, 2009). Besides the 
prominent roles of the P2X4 subtype (see previous paragraph), recent studies have 
revealed that the P2Y12 receptor is also crucial for neuropathic pain. Both the expression 
of P2Y12 receptor mRNA and protein are markedly enhanced in microglial cells of the 
ipsilateral spinal cord following nerve injury (Tozaki-Saitoh et al., 2008) or partial 
ligation of the sciatic nerve (Kobayashi et al., 2008). Interestingly, administration of 
P2Y12 receptor antagonists, such as Cangrelor (intrathecally) or Clopidogrel (orally), as 
well as antisense oligonucleotide for P2Y12 receptors, significantly suppressed the 
development of neuropathic pain after spinal nerve injury (Tozaki-Saitoh et al., 2008) 
and partial sciatic nerve injury (Kobayashi et al., 2008). Furthermore, mice lacking 
P2Y12 receptors displayed impaired tactile allodynia after nerve injury without any 
change in basal mechanical sensitivity (Tozaki-Saitoh et al., 2008). The P2Y12 and P2X4 
receptor subtypes have been identified as primary sensors for ATP-mediated 
chemotaxis in microglia (Inoue & Tsuda, 2009), and P2Y12 receptors are also 
implicated in the motility of microglial cells (Haynes et al., 2006). The strategic 
importance in P2Y12 receptor targeting is due to its restricted expression in the CNS. In 
fact, this receptor is specifically localized to brain and spinal cord resident microglia, 
but not in peripheral macrophages (Haynes et al., 2006). Therefore, the P2Y12 receptor 
subtype could be considered as a molecular switch to specifically inhibit microglial cell 
activation, and possibly, chronic pain.  
Microglial cells also express P2Y6 receptors, and their expression markedly 
increases in the spinal cord after peripheral nerve injury (Koizumi et al., 2007). It has 
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been also found that UDP, an agonist for P2Y6 receptors, facilitated phagocytosis in 
primary cultured microglial cells. The P2Y6 receptor can be thus considered a sensor for 
microglial cell phagocytosis by sensing diffusible UDP signals (Koizumi et al., 2007); 
unfortunately its role under neuropathic pain conditions still remains unknown. 
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Migraine is a highly disabling neurovascular disorder, affecting about 15% of 
adults in the Western World, which is characterized by spontaneous and recurrent 
attacks of unilateral headache with associated autonomic symptoms. Its socio-economic 
implications have a considerable impact on both productivity and quality of life, and it 
has been estimated to be the most costly neurological disorder in the European 
Community (Goadsby, 2007). Accordingly, it is now ranked at the 19th place among all 
worldwide diseases causing disability by the World Health Organization (Lipton et al., 
2004). Despite the strong progresses made in recent years, there is still ongoing debate 
about the mechanisms leading to the generation of migraine pain. Consistently, the 
pharmacological treatment of migraine still remains unsuccessful for a significant 
number of patients. For this reason, new efforts in the study of its pathophysiological 
mechanisms, in the discovery of innovative pharmacological targets, and in the 
developing of new effective drugs are strongly needed. 
As mentioned in Paragraph 1.1.2, the trigeminal ganglia (TG) are the location of 
primary afferent neurons for sensing and relaying nociceptive sensations associated 
with painful conditions, such as dental pain, trigeminal neuralgia, and 
temporomandibular disorders (Fried et al., 2001). Importantly, the peripheral 
sensitization of sensory neurons in the TG and the concomitant increased release of 
neurovascular mediators, like the Calcitonin Gene-Related Peptide (CGRP), are also 
thought to play an important role in migraine (Messlinger, 2009). Sensory neurons in 
the TG act in strict synergy with non-neuronal satellite glial cells (SGCs), which 
envelop neuronal bodies to constitute a functional unit within the ganglion (Hanani, 
2005). Recent evidence suggests that, within this functional unit, a non-synaptic cross 
communication between neurons and SGCs can increase the excitability of both primary 
and CNS neurons, leading to the development of hyperalgesia and allodynia (Takeda et 
al., 2009). Although various pro-inflammatory mediators are released in the TG 
(Takeda et al., 2009), the whole molecular network at the basis of this neuron-to-SGCs 
interplay, and its involvement in migraine pain mechanisms, is still largely unknown. 
Therefore, the identification of the signalling molecules controlling neuron-to-glia 
communication could help finding new potential strategies to modulate pain 
transmission and, possibly, to yield new pharmacological targets to prevent or abort 
migraine attacks. 
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Starting from the first observations that ATP injection into the human skin elicited 
pain (Bleehen and Keele, 1977; Krishtal et al., 1983), several studies progressively 
indicated that the purinergic system plays a crucial role in the transmission and 
integration of pain sensation. Besides ATP, emerging evidence indicates that also other 
extracellular nucleotides (ADP, UTP and UDP), and nucleosides (adenosine) participate 
in the modulation of pain transmission (Liu & Salter, 2005; Burnstock, 2009a; Jarvis, 
2010). The most studied and characterized receptors involved in nociception are the 
P2X3 and the P2X2/3 receptor channels, which are expressed by neurons in sensory 
ganglia, and play a fundamental role in transducing ATP-mediated painful signals 
(Burnstock, 2009a). However, a role for G protein-coupled P2Y receptor subtypes in 
nociception is also emerging (Jarvis, 2010). These receptors are widely expressed by 
both neurons and glial cells of the PNS and CNS, and undergo significant changes in 
their expression levels after neuropathic or inflammatory conditions (Jarvis, 2010). 
However, most of the currently available information on P2Y receptors in nociception is 
based on results obtained from dorsal root ganglia (Burnstock, 2009b), or from the 
spinal cord (Tsuda et al., 2010). Therefore, deciphering the nociceptive functions of 
P2Y receptors in TG is of paramount importance for discovering new potential targets 
for migraine therapy.  
On this basis, the first objectives of my study have been aimed at setting up an in 
vitro model of primary mixed neuron-glia cultures from mouse TG, and at evaluating 
the presence and functionality of P2 receptors in both neurons and SGCs. To evaluate 
the presence of the specific P2 receptor subtypes, I have utilized RT-PCR analysis and 
single cell calcium imaging by applying subtype-selective P2 ligands. Since very few 
data are available on the role of the P2Y receptor family in SGCs (Villa et al., 2010), 
peculiar attention has been given to the characterization of P2Y receptors in this cell 
population. I have also evaluated changes in P2Y receptors calcium transients in vitro 
after acute or long-term treatments with Bradykinin and CGRP, two mediators involved 
in migraine neurobiology (See Paragraph 1.2.2; Pietrobon, 2005).  
One of the most important features of the pathophysiology of migraine is its 
inherited nature. However, only few specific genes have been correlated with migraine. 
This is the case of the Familial Hemiplegic Migraine (FHM) which is caused by 
mutations of specific genes: the α1 subunit of the Cav2.1 (P/Q) type voltage-gated Ca2+ 
channel (CACNA1A), causing the FHM type-I; the ATP1A2 gene, causing the FHM 
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type-II; and the Na+ channel SCN1A, causing the FHM type III (Goadsby, 2007). We 
have taken advantage of a genetic mouse model of FHM1, carrying the R192Q 
missense mutation in the α1 subunit of CaV2.1 calcium channels (van den Maagdenberg 
et al., 2004), and we have looked for possible alterations in purinergic signaling in TG 
cultures that could have implications for migraine pathophysiology. 
The last part of my PhD project has been aimed at setting up in vivo models of 
pain, as tools for evaluating the roles of specific P2Y receptors expressed by glial cells. 
I have initially set up a model of acute pain, based on the injection of formalin into the 
upper lip of mice, and I have looked for changes in pain behavior after double-stranded 
RNAs mediated silencing of the P2Y4 receptor subtype, which is selectively expressed 
by SGCs in the TG.  
As for migraine pain, chronic pain is still a difficult to manage and disabling 
condition, despite great efforts in the last decades towards the understanding of its 
pathophysiology, and the development of new drugs. The reason for this failure may be 
partially due to the fact that most of the available drugs target neurons (Dworkin et al., 
2010), whereas increasing evidence now indicates that glial cells in both sensory 
ganglia and CNS also play an important role in chronic pain genesis (McMahon & 
Malcangio, 2009). A well-established model of inflammatory pain, which shares several 
characteristics with migraine-associated TG sensitization (Ballegaard et al., 2008; Taub 
et al., 2008), is based on the injection of pro-inflammatory mediators (e.g., the 
Complete Freund’s Adjuvant, CFA) in the temporomandibular joint (TMJ). TMJ 
inflammation potentiates the excitability of both primary and secondary neurons, and 
leads to increased neuron-to-SGC communication within the TG (Iwata et al., 1999; 
Thalakoti et al., 2007). However, no studies have explored the reaction of glial cells in 
the whole spinal-trigeminal system following induction of TMJ inflammation so far. 
Therefore, we have characterized the reaction of PNS and CNS glial cells to the 
injection of CFA into the rat TMJ and, finally, we have evaluated expression changes 
for the P2Y12 receptor subtype, which is selectively expressed by CNS microglia, and 
participates actively in chronic pain development (see Paragraph 1.4.3). This model of 
sub-chronic inflammation will allow us to evaluate the role of specific P2Y receptor 
subtypes, expressed by glial cells, in the development and maintenance of chronic 
trigeminal pain and migraine-associated pain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. METHODS 
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3.1 CELL CULTURES  
Primary mixed neuron-satellite glial cells (SGCs) cultures were prepared from 
trigeminal ganglia (TG) of wild type C57Bl/6J mice (Charles River lab, Calco, Italy) or 
of transgenic CaV2.1 α1 R192Q mutant KI mice at postnatal day 11 (P11; van den 
Maagdenberg et al., 2004), as previously described (Ceruti et al., 2008) (see Figure 
3.1A for a schematic protocol). Briefly, after decapitation TG were rapidly excised and 
dissociated in 0.25 mg/ml trypsin, 1 mg/ml collagenase and 0.2 mg/ml DNAse (Sigma-
Aldrich, Milan, Italy) in F12 medium (Invitrogen, Gibco, Italy) at 37oC. Enzymes were 
then inactivated by adding 10% fetal calf serum and 0.125 mg/ml trypsin inhibitor 
(Sigma-Aldrich). Cells were centrifuged at 1,000 rpm for 5 min, resuspended in F12 
medium +10% fetal calf serum and plated onto poly-L-lysine-coated 24 mm-diameter 
glass coverslips. Experiments involving primary mixed neuron-SGCs cultures were 
performed 48 h after plating. A representative field of primary mixed neuron-SGCs 
cultures is shown in Figure 3.1B.  
SGCs purified cultures were prepared from mixed cultures at day 6 in culture, 
after replacing culture medium at days 1 and 3 (Figure 3.1A). At day 6, cells were 
detached from the Petri dish by a 5-min treatment with 0.5%-trypsin/0.2%-EDTA 
(Sigma-Aldrich, Milan, Italy) at 37°C, resuspended in fresh culture medium, and 
replated onto uncoated wells or 24 mm diameter coverslips. This procedure completely 
removed all neurons without affecting SGCs adhesion and growth (England et al., 2001; 
Capuano et al., 2009). The culture medium was replaced 24 hours later, and 
experiments were performed after additional 24 hours. A representative field of purified 
SGCs cultures is shown in Figure 3.1C. 
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Figure 3.1 
Schematic experimental protocol for trigeminal cultures preparation.  
A, Primary mixed neuron-SGCs cultures were prepared from trigeminal ganglia of P11 wild type 
C57Bl/6 mice or of transgenic CaV2.1 α1 R192Q mutant KI mice (see text for more details). B, 
Representative picture showing primary mixed neuron-glia trigeminal cultures 48h after plating. NeuN-
positive neurons are shown in green. C, Representative picture showing purified SGCs cultures 8 days 
after plating. Using our purification protocol (see text for more details), neurons were completely 
removed, as demonstrated by the lack of NeuN staining. In all pictures, nuclei were stained with the 
Hoechst 33258 dye. Scale bars: 50 μm. 
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3.2 PHARMACOLOGICAL TREATMENTS 
Both primary mixed and purified SGCs cultures were exposed to 100 nM BK 
(Sigma-Aldrich), or 1 µM CGRP (Tocris Bioscience, Bristol, UK) for the indicated time 
periods (see Results and Figures). In selected experiments, the CGRP receptor 
antagonist, CGRP8-37 (2 µM; Tocris Bioscience), or the ERK1/2 inhibitor PD98059 (50 
µM; Sigma-Aldrich), were added to the culture medium 30 min before CGRP or BK 
application. Parallel control cells were treated with vehicle (Ham’s F-12) alone. 
For single cell calcium measurements, the following pharmacological agents were 
tested: αβ-methylene-ATP (αβ-meATP; 100 μM), ADP (10 and 100 μM), UTP (10 and 
100 μM), UDP (100 µM), UDP-glucose (100 μM), N6-methyl-2-deoxyadenosine 3',5'-
bisphosphate (MRS2179; 100 μM), Cangrelor (10 μM), Reactive-blue-2 (RB-2, 100 
μM), Suramin (100 μM). All reagents were obtained from Sigma-Aldrich, except for 
Cangrelor that was a kind gift of The Medicines Company, Parsippany, NJ, USA.  
 
 
3.3 IMMUNOCYTOCHEMISTRY 
Cell cultures were fixed at room temperature for 25 min with 4% 
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS; Euroclone, Milan, Italy) 
containing 0.12 M sucrose. Cells were subsequently incubated for 20 min at room 
temperature with Goat Serum Dilution Buffer (GSDB; 450 mM sodium chloride and 20 
mM sodium phosphate buffer, pH 7.4, 15% goat serum, and 0.3% Triton X-100), before 
exposure to the primary antibodies diluted in GSDB. The following primary antibodies 
were utilized: rabbit anti-CGRP (1:800; Enzo Life Sciences AG, Lausen, Switzerland), 
mouse anti-β-Tubulin-III (β-TubIII; 1:500; Promega, Milan, Italy), mouse anti-
glutamine synthetase (GS, 1:100; Millipore, Vimodrone, Italy), mouse anti-vesicle 
associated membrane protein 2 (VAMP2; 1:300; Synaptic Systems, Göttingen, 
Germany), rabbit anti-P2X3 (1:250 o/n at 4°C; Alomone Labs, Jerusalem, Israel), mouse 
anti-2'3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase, 1:100, 1 hour room 
temperature; Chemicon). Bandeireae simplicifolia isolectin B4 directly conjugated to 
fluorescein isothiocyanate (FITC-IB4, 1:100; Sigma-Aldrich) was also utilized. After an 
overnight incubation at 4°C, cells were rinsed three times for 10 min in a high salt 
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buffer solution (500 mM sodium chloride and 20 mM sodium phosphate buffer, pH 
7.4), and then incubated (1 hour, room temperature) with secondary goat anti-rabbit and 
goat anti-mouse antibodies conjugated to AlexaFluor®488 or AlexaFluor®555 (1:600 in 
GSDB; Molecular Probes, Invitrogen, Milan, Italy). Subsequently, nuclei were labeled 
with the fluorescent dye Hoechst-33258 (1:10,000 in PBS, Molecular Probes, 
Invitrogen). Cells were rinsed three times in high salt buffer, once in PBS, and finally 
once in 5 mM sodium phosphate buffer, pH 7.4. Coverslips were mounted with 
Fluorescent Mounting Medium (Dako, Milan, Italy), and analyzed using an inverted 
fluorescence microscope (200M; Zeiss, Milan, Italy) connected to a PC computer 
equipped with the Axiovision software (Zeiss). The same software also enabled us to 
measure neuron diameters. Non-specific staining was evaluated on coverlips where the 
primary antibodies were omitted from the staining procedure.  
 
 
3.4 IMMUNOHISTOCHEMISTRY  
3.4.1 Tissue processing 
Naïve mice or rats injected with saline or CFA (see Paragraph 3.9) were 
anesthetized with intraperitoneal injection of 400 mg/kg chloral hydrate and 
transcardially perfused with 4% formalin fixative. Intact brains and TGs were excised, 
postfixed in 4% formalin for 60-90 min, and cryoprotected in 30% sucrose for at least 
48 hours. The left and right TG from each animal were embedded together in mounting 
medium (OCT; Tissue Tek, Sakura Finetek, Zoeterwoude, The Netherlands), and cut 
longitudinally on a cryostat at 15 μm thickness. Brainstems were separate from the rest 
of the brain, and marked ventrally on the contralateral side to subsequently identify 
tissue orientation. Transverse 40 μm thick free-floating sections were then cut on a 
cryostat. 
 
3.4.2 Immunostaining of tissues 
Free-floating brainstem sections or on-slide TG sections were incubated for 45 
min at room temperature in PBS containing 10% normal goat serum (Sigma-Aldrich, 
Milan, Italy) and 0.1% Triton X-100 (Sigma-Aldrich), and then overnight at room 
temperature with the primary antibodies listed in Paragraph 3.3 with the addition of: 
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rabbit anti-glial fibrillary acidic protein (GFAP, 1:600; Dako, Milan, Italy), mouse anti-
NeuN (1:500; Millipore, Vimodrone, Italy), rabbit anti-ionized calcium binding adaptor 
molecule 1 (Iba1, 1:800; Biocare Medical, Space Import-Export, Milan, Italy), rabbit 
anti-P2Y12 receptor polyclonal antiserum (1:1,500; a generous gift by Prof. David 
Julius, University of California San Francisco, CA, USA), and mouse anti-ED1 (1:200; 
Serotec, Space Import-Export).  
For fluorescence analysis, sections were then rinsed three times with PBS, and 
incubated for 1 h at room temperature with goat anti-rabbit and goat anti-mouse 
secondary antibodies conjugated to AlexaFluor®488 or AlexaFluor®555 fluorochromes 
(1:600; Molecular Probes, Invitrogen, Milan, Italy). Nuclei were subsequently labeled 
with the fluorescent dye Hoechst 33258 (1:10,000 in PBS; Molecular Probes). Slides 
were finally washed, mounted with Fluorescent Mounting Medium (Dako), and 
examined with a laser scanning confocal microscope (LSM 510; Zeiss, Jena, Germany). 
Images were acquired and analyzed using the LSM Image Browser software (Zeiss). 
For light microscopy, sections were incubated for 1h at room temperature with an 
anti-rabbit biotinylated secondary antibody (1:500; PerkinElmer, Monza, Italy), and 
then with horseradish peroxidase (HRP)-conjugated streptavidin (1:400, 45 min at room 
temperature; PerkinElmer). To visualize the antibody-antigen complex, the nickel- 3,3'-
diaminobenzidine (Sigma-Aldrich) protocol was used. Sections were mounted with the 
DPX mountant for histology (Sigma-Aldrich), and analyzed with an inverted 
microscope (Axiovert 200; Zeiss) equipped with a color CCD camera (AxioCam HRc; 
Zeiss), connected to a PC computer equipped with the software Axiovision (Zeiss).  
All antibodies were diluted in PBS containing 0.1% Triton X-100 and 1% normal 
goat serum. 
 
3.4.3 Quantification of results and data analysis 
Quantitative analysis of the number of Iba1+ macrophages in TGs was performed 
by using the NIH Image-J software on digital images of immunolabeled sections, 
captured at 10x magnification. A stack of all acquired images was created, and the 
threshold was set to a level that included all Iba1 immunopositive pixels but not the 
lighter background pixels. Both the number and the size of Iba1+ cells, distributed in the 
V1, V2 and V3 divisions, were then automatically measured. The number of positive 
cells has been normalized to the area of measurement.  
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ED1-immunoreactivity in the TG, and GFAP-, Iba1- and P2Y12 receptor-
immunoreactivity in the brainstem was assessed by densitometric analysis. A digital 
image of the immunolabeled sections was acquired at 20x or 10x magnification for TG 
or brainstem, respectively, and the threshold for the positive staining was set as 
described above. The number of immunostained pixels was then automatically counted 
by using the NIH Image-J software. For GFAP, Iba1 and P2Y12 receptor 
immunostaining, the mean pixel intensity values were expressed as fold increase 
compared to the contralateral side of saline injected animals set to 1.0.  
Two sections for each TG or brainstem and for each antibody were analyzed. To 
avoid variability in the staining procedure, all the sections to be compared were 
immunostained together, and images were acquired under the same exposure 
conditions. The anatomical structures in the brainstem and spinal cord were identified 
with reference to a rat brain atlas (Paxinos & Watson, 1986). 
 
 
3.5 INTRACELLULAR CALCIUM MEASUREMENTS 
Cultures were loaded for 45 min at 37°C with 2 μM Fura-2 pentacetoxy 
methylester in Krebs-Ringer solution buffered with HEPES (KRH; 125 mM NaCl, 5 
mM KCl, 1.2 mM MgS04, 2 mM CaC12, 10 mM glucose, and 25 mM HEPES/NaOH, 
pH 7.4), as previously described (Ceruti et al., 2008), and transferred to the recording 
chamber of an inverted microscope (Axiovert 100TV; Zeiss) equipped with a calcium 
imaging unit. Polychrome IV (TILL Photonics, Germany) was used as light source. 
Fura-2 fluorescence images were collected with a CCD camera Imago-QE (Till 
Photonics), and analyzed with the Tillvision 4.0.1 software.  
Fura-2 is a ratiometric fluorescent dye which binds to free intracellular calcium. 
The Fura-2-Ca2+ complex adsorbs the light at 340nm, while the free form of Fura-2 
adsorbs at 380nm. Application of stimuli increasing the intracellular calcium 
concentration ([Ca2+]i), evoke an increase in light absorption at 340nm and a decrease at 
380nm. Calcium concentrations are estimated by measuring the emitted light after 
excitation at 340 and 380 nm wavelengths, and by calculating the F340/380 
fluorescence ratio. A representative calcium imaging experiment, showing the [Ca2+]i 
increase after application of 100µM ATP or 50mM KCl, is shown in Figure 3.2. In our 
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settings, recordings were usually made at 1 ratio/s, and were increased up to 8 ratios/s 
upon stimulation with αβ-meATP. Neurons were identified by their peculiar 
responsiveness to 50 mM KCl. The total number of cells analyzed for any given 
condition is indicated as “n”.  
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Figure 3.2 
Representative series of pictures from a Calcium imaging experiment.  
A-C, representative series of pseudocolor images of Fura-2-loaded cells under basal conditions (basal, 
A), and after application of 100µM ATP (B) or 50mM KCl (C). The latter is utilized as a depolarizing 
agent to identify neurons. Graded colors from blue to green and yellow indicate the increase in F340/380 
ratio. Scale bar: 15 µm. D, representative temporal plot of [Ca2+]i changes recorded from the  two cells 
circled in A-C, and stimulated with 100 µM ATP followed by 50mM (blue circle: neuron, indicated by the 
blue trace, and responding to KCl; red circle: SGC, indicated by the red trace). 
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3.6 TOTAL RNA ISOLATION AND RT-PCR ANALYSIS 
Total RNA was extracted using the TRIZOL® reagent (Invitrogen) according to the 
manufacturer's instructions. Total RNA was then pre-treated with RQ1 DNase 
(Promega) for eliminating genomic DNA contamination. Retrotranscription of 1μg 
RNA was performed with Superscript II RNaseH Reverse Transcriptase (200U per 
sample; Invitrogen) using 100 pmoles of random hexamers or OligodT (Applied 
Biosystems) as primers. Aliquots of total cDNA (1-2μl) were amplified in each PCR 
assay with Platinum Taq DNA polymerase (1.25U per sample; Invitrogen) in a 25μl 
reaction mixture containing 20 pmoles of primer pair, in a standard PCR buffer (50mM 
KCl, 1.5mM MgCl2, 20mM Tris–HCl, pH 8.4). For cDNA, control samples which did 
not undergo reverse transcription (indicated as -RT) were processed in parallel with the 
same experimental protocol to check for contamination of RNA with genomic DNA. 
Amplifications were performed in a GeneAmp 9700 thermal cycler (Applied 
Biosystems, Milan, Italy) for 35 cycles (typically 94 °C/45 sec; 45 sec at an the optimal 
annealing temperature for each primer pair, see Table 3.1; 72 °C/45 sec), after an initial 
denaturation at 94 °C for 2 min. The primer pairs used for detecting the RNAs of 
interest via PCR amplification, and designed with the software Oligo 4.0, are reported 
in Table 3.1. Amplified products were size-separated by electrophoresis on a 1.5% 
agarose gel with ethidium bromide, and visualized under an UV light. 
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Table 3.1: Primer sequences, annealing temperatures and expected molecular weight 
of the detected PCR products.  
Gene Primers Ta (°C) 
cDNA 
(bp) 
Accession 
number 
(Gene Bank) 
β-Actin S   5’-TGACGGGGTCACCCACACTGTGCCCATCTAC-3’ A   5’-CTAGAAGCATTGCGGTGGACGATGGAGGG-3’ 55.0 661 NM_007393 
β-TubIII S   5’-CTTCCAGCTGACACACTCAC-3’ A   5’-AGACACAAGGTGGTTGAGGT-3’ 56.5 295 NM_023279 
B1 S   5’- TCCTGTCCTTCTTCCTTTTG -3’ A   5’- CCATTGTCTTGCTGTCCTTG -3’ 57.4 600 NM_007539.2 
B2 S   5’- TTCACCAACGTGCTGCTGAAC -3’ A   5’- ACTGTTTCTTCCCTGCCCAGTC -3’ 60.0 508 NM_009747.2 
RAMP1 S   5’- GACGCTATGGTGTGACT -3’ A   5’- AGTGCAGTCATGAGCAG -3’ 57,4 249 NM_007588.2 
CLR S   5’- TGCTGGAATGACGTTGCAGC -3’ A   5’- GCCTTCACAGAGCATCCAGA -3’ 54,1 483 NM_016894.3 
P2X1 
S   5’-GTTTGGGATTCGCTTTGA-3’ 
A   5’-TCAGGAAGGGAAGTGTGG -3’ 55.8 452 NM_008771 
P2X2 
S   5’-GGTGGAGGATGGGACTTC-3’ 
A   5’-ATGGTGGGAATGAGACTG-3’ 53.1 498 
AB094664 
AB094663 
P2X3 
S   5’-ACTTTGTGGGGTGGGTTT-3’ 
A   5’-GCTGCCATTCTCCATCTT-3’ 55.6 767 NM_145526 
P2Y1 
S   5’-CCTGCGAAGTTATTTCATCTA-3’ 
A   5’-GTTGAGACTTGCTAGACCTCT-3’ 51.6 319 NM_008772 
P2Y2 
S   5’-GCAGCATCCTCTTCCTCACCT-3’ 
A   5’-CATGTTGATGGCGTTGAGGGT-3’ 60.2 503 NM_008773 
P2Y4 
S  5’- CTTTGGCTTTCCCTTCTTGA -3’ 
A  5’- GTCCGCCCACCTGCTGATGC -3’ 57.2 492 NM_020621 
P2Y6 
S   5’-CGCTTCCTCTTCTATGCCAA-3’ 
A   5’-GTAGGCTGTCTTGGTGATGTG-3’ 59.6 480 AF298899 
P2Y12 
S   5’-CCGCTACCTGAAGACCACCA-3’ 
A   5’-GTTCGCCACCTTCTTGTCCTT-3’ 55.1 641 NM_027571 
P2Y13 
S   5’-CAGGGACACTCGGATGACA-3’ 
A   5’-CACCGCATAAAACAGAAGC-3’ 55.4 577 NM_028808 
P2Y14 
S   5’-GTCTCTGCCGTCATCTTCT-3’ 
A   5’-GGGTCCAGACACACATTG-3’ 54.3 591 NM_133200 
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3.7 WESTERN-BLOTTING ANALYSIS 
Whole-cell lysates were prepared and analyzed by Western blotting as previously 
described (Bianco et al., 2005). Briefly, approximately 30 μg aliquots from each protein 
sample were loaded on 11% sodium-dodecylsulphate polyacrylamide gels, and blotted 
onto nitrocellulose membranes (Bio-Rad Laboratories, Milan, Italy). Filters were then 
saturated with 10% non-fat dry milk in Tris-buffered saline (TBS; 1 mM Tris-HCl, 15 
mM NaCl, pH 8) for 1 h at RT, and incubated overnight at 4°C with mouse anti-
phospho-ERK1/2 (p-ERK1/2) and rabbit anti-ERK1/2 primary antibodies (1:500 and 
1:1,000 in 5% non-fat dry milk in TBS respectively; Cell Signaling, Danvers, MA, 
USA). Filters were then washed in TBS-T (TBS plus 0.1% Tween20®), incubated for 1 
h with goat anti-rabbit or anti-mouse secondary antibodies conjugated to horseradish 
peroxidase (1:4,000 or 1:2,000 in 5% non-fat dry milk in TBS respectively; Sigma-
Aldrich). Detection of proteins was performed by enhanced chemiluminescence (ECL, 
Amersham Biosciences, Milan, Italy) and autoradiography. Non-specific reactions were 
evaluated by in the presence of the secondary antibodies alone. 
 
 
3.8 ANALYSIS OF CGRP RELEASE BY ENZYME IMMUNO-ASSAY   
Basal and stimulated extracellular CGRP concentrations were evaluated in 
primary mixed cultures after 48 h in vitro. For each sample, basal CGRP levels were 
measured after a 15-min incubation with fresh culture medium (see above), which was 
then removed, stored for subsequent analysis, and replaced with culture media alone 
(CTR), or containing 100 nM BK. After 1 hour at 37°C, culture medium was collected, 
samples were centrifuged at 1,200 rpm for 5 min, and the supernatants processed for 
CGRP evaluation. Maximal CGRP released was evaluated by a 15 min incubation with 
50 mM KCl. A commercial Enzyme Immunometric Assay (EIA) kit for rat CGRP 
(SPIbio, Montigny-le-Bretonneux, France) was utilized, following manufacturer’s 
instructions. We validated the use of this EIA kit for the measurements of mouse CGRP 
by verifying the homology between the mouse and rat mature α-CGRP peptide 
sequences (UniProtKB database; www.uniprot.org), which was found to be 100%. 
Samples were analyzed at a 415 nm wavelength with a microplate reader (iMarkTM, 
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Bio-Rad Laboratories). CGRP concentrations in pg/ml were extrapolated from a best-fit 
line calculated from serial dilutions of a CGRP sample standard. 
 
 
3.9 IN VIVO EXPERIMENTS 
3.9.1 Animals 
Experiments were performed on adult male Sprague-Dawley rats (200 - 250 g) or adult 
C57Bl/6J mice (30 g; Charles River Lab, Calco, Milan, Italy). Animals were housed 
under controlled conditions (temperature 22 ± 2 °C; relative humidity 50 ± 10%; 
artificial light 12 h light/dark cycle, lights on at 7 A.M.). All animals had access to both 
distilled water and standard diet ad libitum. The study has been approved by the Council 
of the Department of Pharmacological Sciences of the Università degli Studi di Milano, 
Milan, Italy, and was carried out in accordance with National and European regulations 
regarding the protection of animals used for experimental and other scientific purposes 
(D.M. 116192; 86/609/EEC), as well as following the ethical guidelines of the 
International Association for the Study of Pain (IASP; Zimmermann, 1983). 
 
 
3.9.2 Orofacial formalin test  
A 29-gauge needle was used to inject subcutaneously 10µL of 4% formalin or 
saline (0.9% NaCl), into the center of the right vibrissae pad of adult mice. Injections 
were performed as quickly as possible, with minimal animal restraint. Following the 
injection, animals were placed in a test box, and video recorded for 30 min. The total 
recording time was divided into 6 blocks of 5 min, and the nociceptive behaviour was 
determined for each block by measuring the number of seconds that the animals spent 
grooming the injected area with the ipsilateral fore- or hindpaw. Movements of the 
ipsilateral forepaw were accompanied by movements of the contralateral forepaw. 
Analysis of the behaviour was made by an investigator who was blinded to the animal’s 
group assignment.  
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3.9.3 Synthesis of dsRNAs and their injection into the trigeminal ganglion 
To reduce P2Y4 receptor expression, long double-stranded RNAs (dsRNAs) sequences 
that have been shown to produce robust, specific, and reversible gene silencing were 
used (Bhargava et al., 2004). A BLAST (basic local alignment search tool) search of the 
non-redundant mouse database identified a 564 bp sequence that was not homologous to 
any other sequences, and therefore targeting only P2Y4 receptor. cDNA of P2Y4 was 
produced by reverse transcription of total RNA followed by a 30-cycle PCR using 
specific primers. These cDNAs were then cloned into a pTOPO vector (Invitrogen). The 
specific forward and reverse primer sequences used to make the dsRNAs corresponded 
to nucleotides 481-500 and 1114-1145, respectively (GenBank accession number 
NM_020621). MalE sequences were used as nonspecific dsRNA control as previously 
described (Bhargava et al., 2004). Sense and antisense RNAs were synthesized from 
cDNA inserts by using MegaScript RNA kit (Ambion, Monza, Italy) according to the 
manufacturer’s specifications. Before the injection in the trigeminal ganglion, 11 µg of 
dsRNAs of either P2Y4 or MalE dsRNA were mixed with 1µL lipofectamine 
(Invitrogen) in a final volume of 5µl, and let stand at room temperature for 30 min. 
Injections were performed under xylazine-ketamine anesthesia by placing the 
mice in a stereotaxic instrument. The skull was exposed, and a burr hole was drilled 
above the location of the trigeminal nerve of the right trigeminal ganglion, at 1.6 mm 
posterior to the bregma, and 1.6 mm lateral to the midline. A pulled pipette, filled with 
dsRNAs, was then inserted through the hole, at 6.6 mm below the cortical surface. The 
pipette was connected to a Hamilton syringe attached to a microinjection pump, set to 
deliver the 5µL dsRNAs over a 2 min period. 
 
 
3.9.4 Induction of TMJ inflammation  
The sub-chronic TMJ inflammation was induced by injecting 50 µl of CFA 
(Sigma, Milan, Italy) oil/saline (1:1) emulsion into the left TMJ capsule, under 
isoflurane anesthesia. Control rats were injected with saline (0.9% NaCl). The TMJ 
capsule was identified by palpating the zygomatic arch and condyle, and the injection 
was delivered by advancing a 27-gauge needle medioanteriorly through the skin 
immediately below to the posteroinferior border of the zygomatic arch until it entered 
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into the joint capsule (Bereiter et al., 2005). Then, CFA or saline was injected slowly 
over 2 minutes. 
 
 
3.9.5 Behavioral tests 
Mechanical allodynia was measured by a previously described protocol with some 
minor modifications (Ren et al. 1999). Unrestrained rats were trained to stay in position 
and to be probed with von Frey filaments (North Coast Medical, Morgan Hill, CA, 
USA) at least one week before the injection of CFA. The left and right orofacial skin 
regions were tested, near the center of the vibrissa pad. An ascending series of von Frey 
filaments was used. The starting filaments corresponded to log unit 4.31 (force: 2 
grams) and 3.22 (force: 0.16 grams) for control and inflamed animals, respectively. 
Each filament was tested five times with an interval of a few seconds. The response 
threshold was defined as the lowest force required eliciting at least three head 
withdrawal responses out of five tests. The elapsed time between the applications of a 
new filament was 2 minutes. All experiments were carried out in a quiet room between 
the 8.30 AM and 1.00 PM, in order to avoid diurnal variations. 
 
 
3.9.6 Measurement of Evans’ blue dye extravasation  
Evans’ blue dye (5 mg/kg, 0.3% solution) was injected into the tail vein (Zhou et 
al., 1999), 10 minutes before animal perfusion with PFA (see Paragraph 3.4) . Ipsi- and 
contra-lateral (with respect to the side of CFA injection) TMJs were then dissected, cut 
into small blocks and incubated overnight at room temperature in a 7:3 (vol/vol) 
mixture of acetone and 35.2 mM sodium sulphate on a shaking table. Samples were 
then centrifuged, the supernatant separated, and dye absorbance determined in a 
spectrophotometer at 620 nm. Evans’ blue dye concentrations, in μg/ml, were 
extrapolated from a best-fit line calculated from a standard curve, prepared from a series 
of supernatants extracted from the TMJs of naïve animals, and mixed with serial 
dilutions of the Evans’ blue dye. 
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3.10 STATISTICAL ANALYSIS 
All results are expressed as mean±s.e.m. of at least three independent 
experiments. Statistical significance between groups was derived from one-way 
ANOVA followed by Scheffe’s analysis, performed with the SPSS software. Three 
degrees of significance were considered: P < 0.05 (*), P < 0.01 (**), P < 0.001 (***). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS 
Section I: in vitro studies 
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4.1. SET UP OF PRIMARY MIXED TRIGEMINAL CULTURES AS AN IN VITRO 
MODEL FOR STUDYING CELL TO CELL COMMUNICATION IN THE 
TRIGEMINAL GANGLIA 
As mentioned in Chapter 2, the first part of my PhD experimental work has been 
aimed at evaluating the presence and function of P2 receptors in an in vitro model of 
primary mixed cultures from mouse trigeminal ganglia (TG). This culture model was 
previously set up and validated as a reliable experimental model to study the purinergic 
regulation of trigeminal functions (Fabbretti et., 2006; Simonetti et al., 2006). However, 
these studies were focussed on studying only the neuronal P2X3 receptor subtype, while 
no evidence on the role of other purinergic receptors, or on the contribution of glial cells 
to purinergic signalling, was provided.  
As a first step, we have characterized our primary TG cultures, 48h after their 
preparation, in terms of the presence and organization of the different cell populations. 
As discussed in Paragraph 1.1.2, the cellular organization of the intact TG consists of 
neuronal cell bodies surrounded by satellite glial cells (SGCs; Hanani, 2005). These 
cells can be identified by the expression of the marker Glutamine Synthetase (GS), as 
shown by immunohistochemistry on sections from intact undissociated ganglia (Figure 
4.1A). Since SGCs share some common characteristics with oligodendrocytes, a 
subpopulation of SGCs was also stained with an antibody against 2',3'-cyclic nucleotide 
3'-phosphodiesterase (CNPase; Figure 4.1B). Panels D and E of Figure 4.1, show the 
typical appearance of primary mixed TG cultures 48 hours after plating, consisting of 
neurons, identified by staining with the neuronal marker β-tubulin-III (β-tubIII; Figure 
4.1D-F), surrounded by GS- (Figure 4.1D) and CNPase-positive (Figure 4.1E) glial-like 
cells. Interestingly, several neurons sat on and were wrapped by glial cells, likely 
belonging to the SGCs population (Figure 4.1D,E). Cultured neurons displayed the 
typical pseudo-unipolar morphology of sensory neurons (Figure 4.1D) and accounted 
for the 11.1±0.97% of total cell population (n=8340; 12 coverslips from 8 independent 
experiments). As shown in Figure 4.1H and in line with previous data (Fabbretti et., 
2006; Simonetti et al., 2006), the 41.5±5.8% of total neuronal cells were small neurons 
with a diameter of the soma lower than 15 μm, the 53.4±4.1% were medium neurons 
with a diameter between 15 and 25 μm and only the 5.1±0.7% were large neurons with 
a diameter greater than 25 μm.  
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We also characterized the molecular phenotype of the cultured sensory neurons. 
Most of the nociceptive neurons that have unmyelinated C-fibre axons can be 
subdivided into two overlapping groups, on both anatomical and functional c (see 
Paragraph 1.1.2; Ruan & Burnstock, 2003): the first group contains peptidergic 
neuropeptides, such as the Calcitonin gene-related peptide (CGRP), the other can be 
distinguished by the binding of the Isolectin B4 (IB4). By immunofluorescence analysis 
we showed that in intact ganglia CGRP was expressed by 34.2±0.80% of β-tubIII- 
positive neurons (n=3251; Figure 4.1C). Interestingly, primary mixed TG cultures 
retained the neuronal location of CGRP observed in the intact tissue (35.0±1.85%, 
n=588; Figure 4.1F). Moreover, in our cultures the 37.3±1.5% of the total β-tubIII-
positive neurons were also positive for IB4 (Figure 4.1G,G’). These cells were 
exclusively small- to medium-sized, as shown in Figure  4.1H. 
In conclusion, in our primary mixed TG cultures the presence of neurons 
surrounded by SGCs resembles the morphological and probably functional unit 
observed in the intact ganglia. Moreover, cultured sensory neurons retain most of the 
phenotypical characteristics observed in vivo. Taken together, these data validate the use 
of dissociated primary cultures as an adequate model to study the nociceptive functions 
of the various TG cell populations and the associated cross talk between neurons and 
SGCs.  
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Figure 4.1 
Primary mixed neuron-SGCs trigeminal cultures partially maintain the cellular and 
anatomical organization of the trigeminal ganglia in vivo.  
A, B, C, Representative confocal microscopy pictures from intact trigeminal ganglia after double 
immunofluorescence staining for the neuronal marker β-tubIII (red) together with glutamine synthetase 
(A), CNPase (B) and CGRP (C) expression (green). D, E, F, Double immunostainings, with the same 
antibodies as above, of primary mixed trigeminal cultures after 48h in vitro. G, Confocal microscopy 
image of trigeminal sensory neurons labeled with fluorescein-conjugated isolectin B4 (IB4, green). G’, 
Same field as in G, after double immunostaining for IB4 (green) and β-tubIII (red), demonstrating IB4 
colocalization with β-tubIII only in medium/small size neurons. H, Histograms showing the distribution 
of β-tubIII-positive neurons according to the size (diameter) of their soma (indicated as “tot”, light-blue 
columns). The size distribution of IB4-positive neurons was also calculated and expressed as percentage 
of the total neuronal population (“IB4+” blue columns). To rank the diameters of neuronal cells, a 
classification previously proposed by Simonetti and coll. (Simonetti et al., 2006) was used (small 
neurons: diameter < 15 μm; medium neurons: diameter between 15 μm and 25 μm; large neurons: 
diameter > 25 μm). In all pictures, nuclei were labeled with the Hoechst 33258 dye (blue). Scale bars: 15 
μm. 
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4.2. BOTH TRIGEMINAL NEURONS AND SATELLITE GLIAL CELLS BEAR 
FUNCTIONAL P2 RECEPTORS 
Previous studies have highlighted a role for ATP in cell-to-cell signalling in intact 
TG and have indicated the presence of various P2 receptor subtypes on both neurons 
and glia (Weick et al., 2003; Ceruti et al., 2008; Burnstock, 2009a,b). Among the ATP-
responding receptors, the P2X3 receptor subunit represents the most characterized in TG 
sensory neurons (Simonetti et al., 2006; Teixeira et al., 2010; Villa et al., 2010). To 
assess the presence and function of this receptor in our experimental setting, we 
performed double immunostaining experiments with an anti-β-tubIII and an anti-P2X3 
antibody. Most neurons (i.e., 73.6±2.7% of β-tubIII-positive cells, n=440) expressed 
P2X3; Figure 4.2A). Moreover, this receptor was found in almost all (95.3±0.9%, 
n=324) IB4-positive sensory neurons (Figure 4.2B). The presence of P2X3 in our 
cultures was also confirmed by RT-PCR (Figure 4.2C), and by western blot analysis 
(data not shown). Expression of the P2X2 receptor (that can assemble in heterodimers 
with P2X3) was also found, whereas the P2X1 receptor subtype was not expressed 
(Figure 4.2C). Calcium transients induced by the P2X1/P2X3 receptor agonist α,β-
meATP indicated the presence of functional receptor in trigeminal neurons (Figure 
4.2D), with 58.0±4.7% of responding neurons The mean calcium increase (evaluated as 
the change in the 340/380 fluorescence ratio; ΔF340/380) was 0.12±0.01 (n=115). The 
P2X3 receptor was never found in glial cells, as assessed by both immunostaining and 
calcium imaging analysis (data not shown, n=105). 
Trigeminal cells have been demonstrated to express several P2Y receptors (Ruan 
& Burnstock, 2003; Burostock, 2009b; Villa et al., 2010), but a systematic analysis of 
their role in TG cultures has never been performed. Thus, we analyzed the presence of 
all P2Y receptors cloned from rodent tissues in both intact ganglia and mouse trigeminal 
cultures. RT-PCR analysis showed that all known rodent P2Y receptors (i.e., the 
P2Y1,2,4,6,12,13,14 subtypes) were expressed with no appreciable differences in their 
expression profile between the intact tissue and the dissociated cultures (Figure 4.3). 
We next analyzed the responses of TG neurons to the most commonly utilized P2Y 
agonists by single cell calcium imaging. A small percentage of neurons responded to 
either ADP (8.5±3.9% of total, n=142) or UTP (13.0±4.1% of total, n=142; Figure 
4.4C,E) application, with a mean calcium response of 0.44±0.06 ΔF340/380 and 
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0.34±0.09 ΔF340/380, respectively (Figure 4.4D). No neuronal cell showed responses 
to either UDP or UDPglucose (n=83 and n=43, respectively; Figure 4.4C). Response to 
ADP is likely mediated by P2Y1 receptors, as demonstrated by the almost complete 
blockade exerted by the P2Y1 receptor antagonist MRS2179 (Figure 4.4F,G). In some 
experiments, ADP response was also partially antagonized by the P2Y12/P2Y13 
antagonist Cangrelor, suggesting that some neurons may also express these receptor 
subtypes together with P2Y1 (data not shown).  
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Figure 4.2 
P2X3 receptors are expressed and functional in trigeminal ganglion sensory neurons. 
A, Double immunostaining of cultures with anti-β-tubIII (red) and anti-P2X3 receptor antibodies (green), 
showing that most of β-tubIII-positive cells also express P2X3. B, Representative image showing double 
staining of cultures with an anti-P2X3 receptor antibody (red) and FITC-IB4 (green). Scale bars: 15 μm. 
C, RT-PCR analysis showing expression of P2X2 and P2X3, but not of P2X1 receptors, in trigeminal 
cultures. No amplification products were detected in RNA samples that were not subjected to 
retrotranscription (indicated as -RT). β-tubIII was used as an internal control for RT-PCR amplification. 
D, Representative temporal plot of [Ca2+]i increases recorded from two trigeminal neurons upon 
stimulation with the P2X1/P2X3 agonist α,β-meATP (100 μM), followed by application of 50mM KCl. 
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Figure 4.3 
Trigeminal ganglia and cultures express all cloned P2Y receptors.  
Total RNA isolated from either intact trigeminal ganglia (indicated as “tissue”) or from primary 
trigeminal cultures 48 hours after preparation (indicated as “culture”) was subjected to RT and the 
resulting cDNA was amplified with primers specific for each indicated P2Y receptor (see Table 3.1). No 
products were detected in the absence of retrotrascription (indicated as -). Parallel expression of the 
housekeeping gene β-actin (β-act) is shown. No significant differences in P2Y receptor expression were 
detected between freshly isolated tissue and cultures.  
 
 
 
In a similar way, we characterized the functionality of P2Y receptors in TG SGCs. 
Application of P2Y agonists resulted in [Ca2+]i increases in most cells, with 78.0±5.2% 
(n=320) and 83.0±4% (n=331) of SGCs responding to ADP and UTP respectively 
(Figure 4.5A). The mean calcium increases were 0.73±0.03 and 0.8±0.3 ΔF340/380, for 
ADP and UTP respectively (Figure 4.5B). A lower percentage of cells (20±6%, n=237) 
instead responded to UDP, with a mean calcium increase of 0.4±0.06 ΔF340/380 
(Figure 4.5A,B). Examples of agonist-induced calcium transients are reported in Figure 
4.5C; interestingly, 100µM UTP-evoked calcium responses were more sustained and 
prolonged compare to the same concentration of ADP and UDP. Experiments 
performed with MRS2179 and Cangrelor showed that, in glial cells, response to ADP 
mainly involved the P2Y1 receptor with a smaller contribution of P2Y12/P2Y13 receptors 
(Figure 4.5D). Suramin and RB2 (P2Y2/P2Y2 antagonists) inhibited UTP-induced 
[Ca2+]i transients by 76.6% and 76.7%, respectively, thus suggesting the involvement of 
P2Y2/P2Y4 receptors (Figure 4.5E). 
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Figure 4.4 
Trigeminal ganglion sensory neurons bear some functional P2Y receptors. 
A, Series of pseudocolor images of Fura-2 loaded cells before (basal) and at peak [Ca2+]i responses after 
the application of 100 μM ADP, followed by 50mM KCl to indentify neuronal phenotype. B, Identification 
of neurons was confirmed by immunopositivity to β-tubIII (red). Scale bars: 15 μm. C, Histograms 
showing the percentage of neurons responding to the indicated P2Y agonists. D, Histograms showing the 
mean [Ca2+]i increases, evaluated as increase in 340/380 fluorescence ratio (ΔF340/380), induced in 
neuronal cells by the P2Y agonists ADP and UTP. E, Representative temporal plots of [Ca2+]i increases 
recorded from neurons upon stimulation with either ADP or UTP (100µM), as indicated, followed by 50 
mM KCl. In the case of ADP, the neuron is the one marked with a white circle in A and B. F, 
Representative temporal plot of [Ca2+]i changes recorded from two neurons stimulated with 100 μM ADP 
before and after application of the P2Y1 antagonist MRS2179 (100 μM), followed by exposure to 50 mM 
KCl. G, Quantification of data reported in F expressed as mean calcium responses±s.e.m. *p<0.05 with 
respect to ADP alone; one-way ANOVA followed by Scheffe’s analysis. 
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Figure 4.5 
(figure legend in the following page) 
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Figure 4.5 
Trigeminal ganglion SGCs express functional P2Y receptors. 
A, B, Histograms showing the percentage of responding SGCs (A) or the mean [Ca2+]i increases (B) 
induced by the indicated P2Y receptor agonists. C, Examples of [Ca2+]i changes recorded from SGCs 
upon stimulation with various P2Y agonists. D, Left: representative temporal plots of [Ca2+]i changes 
recorded from four SGCs stimulated with 100 μM ADP before and after application of the P2Y1 selective 
antagonist MRS2179 (100 μM), as indicated. Right: Quantification of the mean calcium increases±s.e.m. 
after stimulation with 100 μM ADP before and after exposure to 100 μM MRS2179 (n=25 cells) or 10 
μM Cangrelor (n=20 cells). Values were normalized to results obtained with ADP alone set to 1.00. E, 
Left: representative temporal plots of [Ca2+]i changes recorded from three satellite cells stimulated with 
100 μM UTP before and after application of the relatively P2Y2/P2Y4-selective antagonist Reactive Blue-
2 (RB-2; 100 μM), as indicated. Right: Quantification of mean calcium increases±s.e.m. induced by 100 
μM UTP before and after exposure to 100 μM Suramin (n=24 cells) or 100 μM RB-2 (n=30 cells). 
Values were normalized to results obtained with UTP alone, set to 1.00. *p<0.05 and **p<0.01 with 
respect to corresponding agonist alone, by one-way ANOVA followed by Scheffe’s analysis. 
 
 
 
4.3 CHRONIC APPLICATION OF THE PRO-INFLAMMATORY MEDIATOR 
BRADYKININ DIFFERENTIALLY AFFECTS NEURONAL P2X3 AND GLIAL 
P2Y RECEPTOR FUNCTIONALITY 
The pro-inflammatory mediator bradykinin (BK) is a known activator of sensory 
neurons (Heblich et al., 2001) that was shown to increase the neuronal firing rate in the 
trigeminal subnucleus caudalis of the medulla oblongata and to enhance the release of 
CGRP from cultured dorsal horn and TG neurons (Jenkins et al., 2003). Moreover 
SGCs are also sensitive to BK (England et al., 2001). On this basis, we deemed it 
interesting to study the effect of either an acute (up to 5 min) or a prolonged (24-hour) 
exposure to BK on purinergic signalling in both neurons and SGCs in our culture 
model.  
As a first step, we investigated the expression, functionality, and cellular 
localization of BK receptors (i.e. the B1 and B2 subtypes) in our cultures. RT-PCR 
analysis demonstrated expression of the constitutive B2 receptor subtype in both the 
intact tissue and dissociated cultures (Figure 4.6A). Conversely, the inducible B1 
receptor subtype was barely present in the intact tissue and clearly expressed in primary 
cultures, suggesting its upregulation with time in culture (Figure 4.6A). An acute 
exposure to 100 nM BK evoked changes in the [Ca2+]ì in the 35.11±4.72% (ΔF340/380) 
of neurons (n=188; 11 independent experiments; Figure 4.6B), with respect to the 
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3.76±2.01% of SGCs (n=319; 11 independent experiments) suggesting that, in TG, BK 
receptors are almost exclusively functional on neuronal cells only.  
We then studied the effect of BK treatment on the P2X3 and P2Y receptors 
functionality. An acute application of BK (2-3 min) significantly increased the calcium 
response induced by the P2X3 agonist α,β-meATP (normalized mean calcium increases: 
1.00±0.1 for control cultures, n=24 vs. 1.41±0.3 for BK treated cultures, n=48; Figure 
4.6C). No changes were observed in P2Y receptor-mediated modulation of [Ca2+]ì (not 
shown). This result is in line with previous evidence indicating that acute (50 sec) 
exposure to BK rapidly sensitised P2X3 receptor functionality in Xenopus Laevis 
oocytes (Paukert et al., 2001). 
On the contrary, a 24-hour exposure of trigeminal cultures to 100 nM BK did not 
modify the amplitude of calcium responses induced by 100 µM α,β-meATP (Figure 
4.6D), but resulted in a highly significant reduction of the percentage of responsive 
neurons which was decreased to 28.5±5.7% (n=125) with respect to 62.1±5.8% in 
control untreated cultures (n=118; Figure 4.6E). Interestingly, considerable changes in 
P2Y receptor-mediated responses were recorded in SGCs. In particular, BK-treated 
cultures showed a significant increase of the mean calcium amplitude (expressed as 
ΔF340/380 and normalized to BK-untreated control cells exposed to the same P2 
agonist set to 1.00) of 1.36±0.11 (n=60), 1.39±0.07 (n=119) and 1.44±0.11 (n=75) after 
exposure to 100 µM ATP, 100 µM ADP, and 100 µM UTP, respectively (Figure 4.6F), 
with no changes in the percentage of responding cells (Figure 4.6G). A trend to increase 
in the mean calcium amplitudes, which did not reach the statistical significance, was 
also observed after exposure to 100 µM UDP (Figure 4.6F), whereas the percentage of 
responding SGCs was dramatically increased (% of UDP-responding cells with respect 
to BK-untreated cells set to 100%: 253.9±5.9%, n=265; Figure 4.6G). 
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Figure 4.6 
Acute and chronic exposure to bradykinin (BK) differentially affects the function of 
neuronal P2X3 and glial P2Y receptors.  
A, RT-PCR experiments demonstrating B1 and B2 BK receptor expression (expected PCR product 
lengths: 600 and 508 base pairs, respectively) in intact trigeminal ganglia (T) and primary mixed 
trigeminal cultures (C). The housekeeping gene β-actin (expected PCR product length: 661 bps) was used 
as an internal positive control. B, Representative temporal plots of BK-evoked [Ca2+]i increases in two 
trigeminal neurons (blue lines), and two SGCs (light-blue lines). The depolarizing agent KCl (50 mM) 
was used to discriminate between neuronal (responding) and non-neuronal (non-responding) cells. C, 
Quantification of mean calcium increases±s.e.m. induced by 100 µM α,β-meATP in vehicle (-BK) or 
acutely (2-3 min) BK-treated (100 nM) neurons. D-G, results obtained after a chronic (24 hours) 
exposure of trigeminal cultures to either vehicle (-BK) or 100 nM BK. D: mean calcium responses to α,β-
meATP in neurons. E: mean percentage of neurons responding to α,β-meATP. F: mean calcium 
responses to various nucleotides (normalized to corresponding vehicle-treated control cells, set to 1.00) 
recorded in SGCs. G: mean percentage of glial cells responding to ATP, ADP, UTP and UDP (100 µM; 
normalized to corresponding vehicle-treated control cells, set to 100%). *p<0.05 and **p<0.01 with 
respect to vehicle-treated cells, one-way ANOVA followed by Scheffe’s analysis. 
Results 
82 
 
4.4 FOLLOWING BK APPLICATION, CGRP RELEASED FROM TG NEURONS 
IS RESPONSIBLE FOR P2Y RECEPTORS UPREGULATION IN SGCs 
Our data clearly indicate that exposure of primary mixed neuron-SGCs TG 
cultures to the pro-algogenic mediator BK significantly enhances the responsiveness of 
glial P2Y receptors to ADP and UTP. We also demonstrated that BK receptors are 
almost exclusively functional in TG neurons. For this reason we speculated that the BK-
induced upregulation of P2Y receptors in SGCs could be mediated by the release of a 
neuronal mediator. Since previous studies indicate that stimulation with pro-
inflammatory mediators, like BK, is associated to the release of the calcitonin gene-
related peptide (CGRP; Ebersberger et al., 1999; Meng et al., 2007; Eberhardt et al., 
2008), we chronically (i.e., 24 hours) exposed primary mixed TG cultures to BK alone 
or in the presence of the CGRP receptor antagonist, CGRP8-37, and subsequently 
recorded ADP- and UTP-induced increases in [Ca2+]i in SGCs (Figure 4.7A). As 
expected, BK alone significantly increased the mean peak amplitudes (expressed as 
ΔF340/380, and normalized to values obtained in CTR cells exposed to the same P2 
agonist set to 1.00) exerted by 1 μM ADP (1.52±0.172, n=90 cells), and by 10 μM UTP 
(1.53±0.182, n=71 cells). Pre-treatment with 2 μM CGRP8-37 almost completely 
abolished the BK-induced effect (normalized ΔF340/380: 1.10±0.08, n=172 cells, and 
1.11±0.115, n=95 cells for ADP and UTP, respectively; Figure 4.7A). Similarly to BK, 
a 24-hour exposure to 1 μM CGRP also induced an increase in P2Y receptor-mediated 
responses in SGCs (normalized ΔF340/380: 1.56±0.106, n=146 cells and 1.58±0.119, 
n=121 cells for ADP and UTP, respectively), which is in line with the BK-induced 
effects (normalized ΔF340/380: 1.46±0.157, n=108 cells, and 1.53±0.182, n=71 cells 
for ADP and UTP, respectively; Figure 4.7B). No changes in the percentages of SGCs 
responding cells were observed upon either treatments (data not shown). These results 
clearly suggest a role for CGRP as the key mediator of neuron-to-SGC communication 
upon BK exposure.  
To further demonstrate this hypothesis, we measured extracellular CGRP 
concentrations after application of BK. As shown in Figure 4.7C, a 1-hour treatment of 
primary mixed TG cultures with 100 nM BK almost doubled extracellular CGRP levels, 
from 19.10±2.28 pg/ml (n=22 coverslips) in CTR cultures, to 36.33±4.07 pg/ml (n=23 
coverslips) in BK-treated cultures. The maximal CGRP release was assessed by 
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exposing cultures to the depolarizing agent KCl (50 mM) for 15 min, and corresponded 
to 152.5±27.51 pg/ml (n=21 coverslips).  
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Figure 4.7 
BK-induced enhancement of P2Y receptor function in trigeminal SGCs is mediated by the 
neuronal release of CGRP. 
A, Primary mixed trigeminal cultures were sub-chronically (24 h) treated with vehicle (CTR), or 100 nM 
BK alone or in the presence of the CGRP receptor antagonist CGRP8-37 (2 μM). Cultures were then 
challenged with 1 μM ADP or 10 μM UTP, and the increases in [Ca2+]i recorded from SGCs. B, Primary 
mixed trigeminal cultures were treated for 24 h with vehicle (CTR), 100 nM BK, or 1 μM CGRP, then 
exposed to ADP or UTP, and changes in [Ca2+]i analyzed in SGCs (see above). In both A and B, 
histograms show the mean [Ca2+]i normalized to CTR cells set to 1.0 from at least 3 independent 
experiments. *p<0.05, and **p<0.01 with respect to CTR; §p<0.05, and #p=0.057 with respect to BK 
alone; one-way ANOVA followed by Scheffé’s test. C, Histograms show the mean extracellular CGRP 
concentrations after 1 h application to primary mixed trigeminal cultures of either vehicle (CTR) or 100 
nM BK. A 15-min exposure to 50 mM KCl was utilized as a positive control of maximal neuronal CGRP 
release. **p<0.01 with respect to CTR, one-way ANOVA followed by Scheffé’s test. D, Double 
immunofluorescence staining showing the specific localization of CGRP (red) to vesicle-associated 
membrane protein 2 (VAMP2)-positive axons terminals (green) in primary trigeminal cultures. Nuclei 
were labeled with the Hoechst 33258 dye (blue). Scale bar: 20 μm. 
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Data from literature (Xiao et al., 2008) and our data on maximal CGRP release 
obtained with the depolarizing agent KCl already suggested a neuronal localization and 
release of this neuropeptide. To unequivocally confirm this, we performed a double 
immunofluorescence experiment for CGRP and the vesicle-associated membrane 
protein 2 (VAMP2), demonstrating the selective expression of the neuropeptide in 
VAMP2+ axons terminals (Figure 4.7D), and therefore the exclusive neuronal 
localization of CGRP.  
 
 
4.5 CGRP, BUT NOT BK, RETAINS ITS ABILITY TO INDUCE P2Y RECEPTOR 
POTENTIATION IN PURIFIED SGCs CULTURES 
To get further insights in the molecular pathways linking glial CGRP receptor 
activation to the upregulation of P2Y receptor function, we generated an in vitro model 
of purified SGCs cultures. As described in more details in Paragraph 3.1 and in Figure 
3.1, five days after preparation of primary mixed neuron-SGCs cultures, SGCs 
approached confluence and were replated on uncoated wells. This procedure allowed 
completely removing all neurons, as demonstrated by the lack of staining of the 
neuronal marker NeuN (Fig. 3.1C). We have also previously demonstrated that there 
was no difference in P2Y receptor expression and function between purified SGCs 
cultures and primary mixed neuron-glia cultures (Villa et al., 2010).  
RT-PCR analysis for the two subunits composing the functional CGRP receptor 
(namely, the receptor activity modifying protein 1, RAMP1, and the calcitonin receptor-
like receptor, CLR; Lennerz et al., 2008) showed that the expression of CGRP receptor 
complex was retained in purified SGCs cultures (Figure 4.8A).  
Next, we exposed purified SGCs cultures to 100 nM BK and 1 µM CGRP for 24 
h, and analyzed the mean [Ca2+]i responses after ADP and UTP application. Differently 
from mixed neuron-SGCs cultures (see above), P2Y receptor functionality in purified 
glial cultures was not affected by BK treatment (normalized ΔF340/380: 0.98±0.151, 
n=174 cells, and 0.92±0.180, n=99 cells, after exposure to 1 µM ADP and 100 µM 
UTP, respectively; Figure 4.8B). Conversely, CGRP retained its ability to potentiate 
glial P2Y receptors even in the absence of neurons (normalized ΔF340/380: 1.42±0.112, 
n=366 cells, and 1.48±0.144, n=150, in the case of ADP and UTP, respectively; Figure 
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4.8B-D). Globally, these data further confirm that BK does not directly target SGCs, but 
acts through its neuronal receptors, and that the mediator of this neuronal-to-glial cell 
communication is indeed CGRP. 
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Figure 4.8 
CGRP, but not BK, maintains its ability to potentiate P2Y receptors responsiveness in 
purified SGCs cultures. 
A, RT-PCR analysis from purified SGC cultures (PC), neuron-SGCs mixed cultures (MC), and intact 
trigeminal ganglia (T). Specific primers for the receptor activity modifying protein 1 (RAMP1; expected 
PCR product length: 249 bps), the calcitonin receptor-like receptor (CLR; expected PCR product length: 
483 bps), and the housekeeping gene β-actin (expected PCR product length: 661 bps) were used. B, 
Histograms showing the ADP- and UTP-evoked mean [Ca2+]i increases recorded from purified SGCs 
cultures after a 24-h treatment with either vehicle (CTR), 100 nM BK, or 1 μM CGRP. Mean [Ca2+]i 
values have been normalized to CTR set to 1.0. C, D, Representative plots showing the increased ADP- 
and UTP-induced [Ca2+]i peaks in SGCs after chronic exposure to CGRP compared to CTR. *p<0.05 
with respect to CTR; one-way ANOVA followed by Scheffé’s test. 
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4.6 THE ERK1/2 MAP KINASE PATHWAY HAS A PRIMARY ROLE IN CGRP-
INDUCED POTENTIATION OF GLIAL P2Y RECEPTORS 
Since it is well known that CGRP activates the MAP kinase pathway in trigeminal 
SGCs (Vause and Durham, 2009; 2010), we exposed purified SGCs cultures to 1 μM 
CGRP and analyzed the phosphorylation/activation of the ERK1/2 MAP kinase 
pathway by western blotting. As shown in Figure 4.9A,B, 1 µM CGRP induced a 
biphasic wave of ERK1/2 activation (measured as the ratio between the intensities of 
the phosphorylated vs total ERK1/2 protein bands) peaking at 10 and 40 min of 
incubation, which was completely inhibited by the CGRP receptor antagonist CGRP8-37 
(Figure 4.9C). Noteworthy, the activation of ERK1/2 pathway is directly correlated with 
the potentiation of P2Y receptors function, since the inhibitor PD98059 fully prevented 
the increase in UTP-mediated [Ca2+]i mobilization induced by CGRP (normalized 
ΔF340/380: 1.46±0.078, n=63 cells for CGRP alone, and 0.99±0.158, n=40 for CGRP + 
PD98059; Figure 4.9D).  
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Figure 4.9 
(figure legend in the following page) 
 
 
Results 
87 
 
Figure 4.9 
The ERK1/2 MAP kinase pathway is involved in CGRP-induced P2Y receptor 
upregulation. 
A, Representative western blotting experiment showing the biphasic activation of extracellular signal-
regulated kinase 1/2 (ERK1/2) induced by application of 1 µM CGRP to purified SGCs cultures for 10, 
20 and 40 min. B, Densitometric analysis of western blotting experiments showing the biphasic activation 
of ERK1/2 after exposure of purified SGCs to 1 µM CGRP. For each sample, the ratio between the 
intensities of the phosphorylated and total ERK1/2 (pERK/ERKtot) protein bands has been calculated, 
and normalized to the corresponding mean CTR value (set to 1.0).  C, The CGRP receptor antagonist 
CGRP8-37 (2 μM) inhibits CGRP-induced ERK1/2 activation (10 min). D, The ERK1/2 inhibitor PD98059 
prevents the potentiation of UTP-evoked [Ca2+]i increases induced by CGRP. Histograms show the mean 
calcium increases in SGCs after chronic (24 h) treatment with vehicle (CTR), 1 μM CGRP alone, or 
CGRP + 50 μM PD98059. In A and D data are the mean±s.e.m. of 3 independent experiments. *p<0.05 
with respect to CTR, §p<0.05 with respect to cells treated with CGRP alone; one-way ANOVA followed 
by Scheffé’s test. 
 
 
 
4.7 CGRP RELEASE IS SIGNIFICANTLY ENHANCED IN TG CULTURES 
FROM CaV2.1 α1 R192Q MUTANT KNOCK-IN MICE 
Our data point to a key role of CGRP in neuron-to-glia communication between 
TGs and SGCs and on its contribution to the molecular and signalling network 
controlling the transmission and integration of painful signals. Therefore, we decided to 
evaluate both basal and stimulated CGRP release in primary TG cultures obtained from 
a transgenic mouse model of migraine, the CaV2.1 α1 R192Q mutant knock-in (KI) 
mouse (van den Maagdenberg et al., 2004). Figure 4.10A shows that, under basal 
conditions, a significantly higher CGRP release was detected in primary TG cultures 
from R192Q KI mice (50.49±7.33 pg/ml, n=29 coverslips) with respect to cultures from 
R192Q wild type (WT) animals (33.75±2.80 pg/ml, n=31 coverslips from 3 independent 
experiments). Following exposure to 100nM BK (1h), the increase in CGRP 
extracellular levels was higher in R192Q KI cultures, with CGRP levels being 
61.49±6.73 pg/ml in R192Q WT cultures (n=14 coverslips), and 110.80±19.70 pg/ml 
(n=10 coverslips) in R192Q KI cultures (Figure 4.10B). Moreover, an over twofold 
(238%) higher CGRP release was detected after maximal neuronal depolarization by 50 
mM KCl (15 min) in R192Q KI cultures compared to R192Q WT cultures (from 
194.1±28.25 pg/ml, n=9 coverslips from 3 independent experiments, to 461.1±119.2 
pg/ml, n=8 coverslips in WT and KI cultures, respectively; Figure 4.10B).  
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Figure 4.10 
Both basal and stimulated extracellular CGRP concentrations are higher in trigeminal 
cultures from CaV2.1 α1 R192Q mutant KI mice, compared to WT animals. 
A, B, histograms show the mean extracellular CGRP levels in primary mixed trigeminal cultures from 
R192Q wild type (WT) and CaV2.1 α1 R192Q mutant KI mice, after 48 h in vitro. Basal CGRP 
concentrations were measured after a 15-min incubation with fresh medium alone (A), whereas 
stimulated CGRP levels were measured after a subsequent incubation with vehicle (CTR; 1 h), 100 nM 
BK (1 h), or 50 mM KCl (15 min) (B). #p<0.05 with respect to the basal CGRP levels in WT cultures, 
*p<0.05 with respect to the corresponding stimulated CGRP levels in WT cultures; one-way ANOVA. 
 
 
 
4.8 APPLICATION OF BK INCREASES THE NUMBER OF ADP- AND UTP-
RESPONDING SGCs IN TG CULTURES FROM CaV2.1 R192Q KI MICE 
Having established that the R192Q mutation in CaV2.1 channels is associated to 
increases of both basal and stimulated CGRP release, we next evaluated P2Y receptors 
functionality in TG cultures from KI mice. Since the ability of BK to upregulate ADP 
and UTP mean calcium amplitudes in SGCs is related to the neuronal release of CGRP 
(Figure 4.7), we anticipated the BK dependent P2Y receptor upregulation to be even 
stronger in KI cultures. Surprisingly, no substantial differences in BK-evoked 
upregulation of ADP and UTP mean calcium amplitudes were observed between SGCs 
of R192Q WT and KI cultures. In fact, ADP-elicited ΔF340/380 values were 0.95±0.07 
(n=132) in control- and 1.18±0.08 (n=116) in BK-treated R192Q WT cultures, whereas 
values were 0.98±0.06 (n=136) and 1.28±0.08 (n=165) in control and BK-treated 
R192Q KI cultures, respectively (Figure 4.11A). UTP-elicited ΔF340/380 values were 
0.83±0.08 (n=57) in control- and 1.05±0.11 (n=40) in BK-treated R192Q WT cultures, 
and 0.82±0.07 (n=51) and 1.15±0.08 (n=95) in control- and BK-treated R192Q KI 
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cultures (Figure 4.11B). However, following chronic treatment with BK the percentage 
of UTP-responding SGCs was significantly increased in R192Q KI cultures with respect 
to CTR cultures (Figure 4.11D). A trend to increase was also observed in the case of 
ADP-responding cells (Figure 4.11C). Following BK exposure, the percentage of 
nucleotide-responding SGCs was therefore significantly higher in R192Q cultures when 
compared to BK-treated R192Q WT cultures (% of ADP responding SGCs: 55.6±7.42 
in WT cultures vs. 75.7±3.74 in KI cultures; % of UTP responding SGCs: 20.1±2.71% 
in WT cultures vs. 54.9±5.91%  in KI cultures). No changes in both mean calcium 
increases, and in the percentages of responding cells were observed between R192Q 
WT and KI neurons (not shown). These data suggests that, in the presence of the gain-
of-function R192Q mutation of CaV2.1 channels, application of nociceptive mediators 
(i.e., BK), by stimulating a higher release of neurotransmitters (i.e., CGRP) from 
neurons, can induce an increase in P2Y receptor responsiveness.  
 
 
Figure 4.11 
(figure legend in the following page) 
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Figure 4.11 
The chronic treatment with BK significantly increases the percentage of ADP- and UTP-
responding SGCs in KI cultures. 
A, B, histograms show the 1 μM ADP- (A) or 10 μM UTP-elicited (B) mean [Ca2+]i increases in WT and 
KI cultures, after a 24 hours treatment with vehicle alone (CTR) or with 100nM BK. C, D, mean 
percentage of SGCs responding to ADP (C) and UTP (D) in R192Q WT and KI cultures, after a 24 hours 
treatment with vehicle alone (CTR) or with 100nM BK.  *p<0.05 with respect to the corresponding  WT 
or KI control cultures; §p<0.05 with respect to WT cultures exposed to BK; one-way ANOVA followed by 
Scheffe’s analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS 
Section II: in vivo studies 
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4.9. SET UP OF IN VIVO MODELS OF TRIGEMINAL PAIN FOR STUDYING 
THE ROLE OF THE PURINERGIC SYSTEM IN PAIN TRANSMISSION 
The results obtained during the first part of my PhD experimental work 
demonstrate the presence of functional P2Y receptors in glial cells from TG in vitro, 
and their complex modulation under exposure to pro-inflammatory agents. Taken 
together these data suggest that glial purinergic receptors act as important players in 
nociceptive transmission. For this reason, we deemed interesting to set up in vivo pain 
models of TG sensitization in order to study the involvement of the purinergic system in 
pain transmission, and to validate the role of specific P2Y receptor subtypes through 
their specific knock down in vivo.  
To test the role of selected P2Y receptors in the development of pain behaviour, 
we initially set up a mouse model of acute pain involving trigeminal sensitisation: the 
oro-facial pain model. A solution of formalin was injected into the upper lip of mice, 
and their nociceptive behaviour was monitored with a video camera for 30 min. A 
nociceptive score was then determined by measuring the time (in seconds) that the 
animal spent in grooming the injected area (Luccarini et al., 2006; see Methods). We 
initially focused our attention on the P2Y4 receptor, due to its expression by trigeminal 
SGCs, and to previous data implicating this receptor in pain signalling (Weick et al., 
2003; Vit et al., 2006). The silencing strategy was based on the injection in the TG of 
long double-stranded RNAs (dsRNAs) probes designed to knock down the expression 
of the specific receptors. Sequences directed against the bacterial gene MalE have been 
also designed and injected in parallel as non-specific dsRNA control. Western Blotting 
analysis on explanted trigeminal ganglia showed a strong reduction (about 60%) of 
P2Y4 protein levels in the ipsilateral ganglion of mice injected with P2Y4-dsRNAs, with 
no significant difference after MalE-dsRNA injection (Figure 4.12A). As expected, 
behavioural studies showed that the face rubbing time was significantly higher in 
formalin-injected mice compared to saline-treated animals (Figure 4.12B), but no 
significant differences were detected when comparing formalin-treated mice that also 
received P2Y4-dsRNA with respect to formalin-treated animals receiving MalE-dsRNA 
(Figure 4.12B). These data apparently rule out a role for P2Y4 receptor in acute 
trigeminal pain transmission.  
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Figure 4.12 
P2Y4 receptor knock-down did not produce any change in acute pain behavior following 
orofacial formalin injection. 
A, Western blot autoradiograms showing the P2Y4 protein levels in contralateral (contra) and ipsilateral 
(ipsi) trigeminal ganglia from mice injected with the MalE- (CTR) or the P2Y4-dsRNA (Silenced). The 
housekeeping gene α-Tubulin was used as an internal loading control. B, Time course of the face-rubbing 
activity observed after subcutaneous injection of either saline or 4% formalin into the upper lip of mice 
injected with the MalE- or the P2Y4-dsRNA. The mean time±s.e.m spent rubbing within each 5-min block 
intervals over the 30-min post-injection observation period is shown. At least 4 animals were analyzed in 
each group. 
 
 
We next decided to set up and characterize a model of chronic trigeminal inflammation 
based on the injection of the Complete Freund’s Adjuvant (CFA) into the 
temporomandibular joint (TMJ) of adult rats. This is a well-established model of 
inflammatory pain, which shares several characteristics with migraine-associated TG 
sensitization (Ballegaard et al., 2008; Taub et al., 2008). Since glial cells participate in 
the genesis and maintenance of chronic pain (See Paragraph 1.1.3) and strongly 
express P2Y receptors (See Paragraphs 1.3 and 1.4), but no studies have explored the 
reaction of glial cells following the induction of TMJ inflammation, we have first 
characterized the activation of PNS and CNS glial cells to the injection of CFA into the 
TMJ. The baseline values for the mechanical threshold in non-inflamed rats were 
determined by probing their orofacial regions with von Frey filaments (see Methods). 
Mean head withdrawal thresholds were measured from the left and right orofacial 
regions (16.11±2.06 g for the right side and 15.50±1.73 g for the left side; n=12 
animals; Table 4.1 and Figure 4.13A). Rats were then injected with either saline or CFA 
into the left TMJ and tested for their pain behavior. A significantly lower mechanical 
threshold was measured in the ipsilateral side of CFA injected rats, starting from 24h 
post injection (p.i.), thus demonstrating the development of mechanical allodynia (see 
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Table 4.1 and Figure 4.13A). No significant changes between the ipsi- and the 
contralateral mechanical thresholds were observed in control saline-injected animals 
(see Figure 4.13A and Table 4.1). To further confirm the establishment of inflammation 
following CFA injection, we measured the TMJ extravasation of the Evans’ blue dye 
injected into the tail vein. While there was no difference in the low dye concentration in 
the TMJs of rats injected with saline (0.07±0.07 µg/ml for the ipsilateral side vs. 
0.07±0.06 µg/ml for the contralateral side; n=7 animals; Figure 4.13B), a significantly 
greater amount of dye was extracted from the ipsilateral TMJ of CFA-injected rats, both 
at 24h p.i. (0.76±0.17 µg/ml vs. 0.13±0.05 µg/ml for ipsi- and contralateral tissue, 
respectively, n=6 animals), and, to a lesser extent, at 72h p.i. (0.43±0.07 µg/ml vs. 
0.07±0.03 µg/ml for ipsi- and contralateral tissue, respectively; n=7 animals; (Figure 
4.13B). These results confirm that the injection of CFA into the TMJ induces a 
persistent inflammation associated with the development of mechanical allodynia. 
 
 
 
Table 4.1: Mean head withdrawal threshold values (in grams, g) after saline or CFA 
injection in the TMJ.  Ipsi: ipsilateral side; contra: contralateral side. 
Stimulus Time post injection 
Ipsilateral 
(g) 
Contralateral 
(g) 
n° of 
rats 
p value 
(ipsi vs. 
contra) 
p value 
(ipsi vs. 
baseline) 
baseline - 15.5 ± 1.73 16.1 ± 2.06 12 - - 
saline 4h 15.0 ± 0.00 20.5 ± 5.50 4 0.423 0.813 
24h 12.7 ± 2.33 17.0 ± 4.73 4 0.457 0.395 
48h 17.0 ± 4.73 17.0 ± 4.73 4 1.000 0.845 
72h 16.3 ± 5.24 17.0 ± 4.73 4 0.929 0.962 
CFA 4h 10.1 ± 2.59 15.1 ± 3.07 8 0.231 0.088 
24h 6.94 ± 1.45 14.0 ± 2.47 8 0.05 0.01 
48h 5.33 ± 0.67 10.5 ± 0.96 8 0.01 0.01 
72h 5.67 ± 1.20 12.7 ± 1.48 8 0.01 0.01 
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Figure 4.13 
Injection of CFA into the TMJ produces mechanical allodynia and plasma extravasation. 
A, Rats were tested for the development of mechanical allodynia by probing the contralateral (contra) 
and ipsilateral (ipsi) orofacial regions with von Frey filaments before (pre) and post injection of saline or 
CFA into the TMJ. The head withdrawal threshold force, in grams (g), was measured. Y-axis = log10 
scale. B, The development of inflammation was analyzed by injecting the Evans’ blue dye through the tail 
vein. A significantly higher amount of dye was extracted from the ipsilateral TMJs of CFA-injected rats 
compared to the contralateral side at both 24h and 72h p.i.  ** p<0.01, and * p<0.05 compared to the 
contralateral side of CFA-injected rats, #p<0.01 compared to the contralateral tissue; one-way ANOVA. 
 
 
 
4.10 SGCs AND MACROPHAGES ARE SELECTIVELY ACTIVATED IN TG 
FOLLOWING TMJ INFLAMMATION 
We next evaluated the morphological and biochemical consequences of the 
induction of TMJ inflammation in the TG, with particular focus on SGCs. Previous 
studies have indeed reported that either tooth pulp injury or TG inflammation induces 
SGCs hypertrophy, with increased expression of GFAP (Stephenson et al., 1996; 
Jimenez-Andrade et al., 2006; Takeda et al., 2007), which is considered to be a marker 
of reactivity and activation for this particular type of glia. In the contralateral side of 
CFA injected rats, very low levels of GFAP immunoreactivity were observed, as 
measured by counting the number of TG neurons encircled by GFAP-positive (GFAP+) 
SGCs. A large increase in the number of GFAP-encircled neurons was observed in the 
ipsilateral TG at both 24h (Figure 4.14A’,B) and 72h p.i. (Figure 4.14B), as expected 
(Takeda et al., 2007). From 24h p.i. the number of GFAP-encircled neurons was higher 
in the ipsilateral V3-mandibular division of the trigeminal nerve (29.38±2.20 in the 
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ipsilateral side vs. 5.99±0.94 in the contralateral side; n = 7 animals; Figure 4.14B). 
Similar results were observed in the V2-maxillary division of the trigeminal nerve 
(28.79±2.30 vs. 4.92±1.00; n=7 animals), and in the V1-ophthalmic division, although 
to a lesser extent (12.83±1.24 vs. 3.88±0.69; n=7 animals). At 72h p.i. a reduction in 
GFAP staining compared to the 24 hour values was observed, although it was still 
significantly higher than the contralateral side or controls (n=7 animals; Figure 4.14B). 
No differences in the number of GFAP-encircled neurons were found between the ipsi- 
and contralateral TG in saline-injected rats (n=7 animals; Figure 4.14B). 
Macrophages have been reported to infiltrate the DRG following sciatic nerve 
damage or hindpaw inflammation (Inglis et al., 2005; Hu et al., 2007). We therefore 
evaluated whether a similar effect also takes place in the TG after the development of 
TMJ inflammation. Surprisingly, no changes in the number of Iba1+ resident 
macrophages and no difference in the mean cell size of Iba1+ cells  were observed 
following CFA injection in the ipsilateral TG (n=7 animals; not shown). Nevertheless, 
clear signs of macrophagic activation were detected by using an antibody directed 
against the lysosomal antigen ED1, a marker of activated macrophages (Damoiseaux et 
al., 1994; Mueller et al., 2007; Moxon-Emre et al., 2010). In fact, 24h after CFA 
injection, the densitometric analysis of ED1 immunostaining yielded to a mean value of 
111.39±16.71 pixels for the ipsilateral side vs. 36.44±10.73 pixels for the contralateral 
side (V3 division; n=6 animals; Figure 4.14C-D). This effect persisted at 72h p.i., 
although to a lesser and non-significant extent (82.47±27.86 pixels for the ipsilateral 
side vs. 37.76±15.94 pixels for the contralateral side, V3 division; n=7 animals; Figure 
4.14D). These results suggest that, early after induction of TMJ inflammation, there is 
no recruitment of new inflammatory cells from the bloodstream, but rather a strong 
activation of local resident macrophages. 
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Figure 4.14 
SGCs and resident TG macrophages are activated following induction of TMJ 
inflammation. 
A, Few GFAP+ SGCs (red) encircling NeuN+ neurons (green) were detected in the contralateral 
(CONTRA) TG of CFA-injected rats, or in TGs from saline-injected rats (not shown). A’, A significant 
increase in the number of GFAP-encircled neurons was instead observed in the ipsilateral (IPSI) TG 
starting at 24h post CFA injection. B, Histograms showing the increase in the number of GFAP-encircled 
neurons in the V3-mandibular division of the ipsilateral (ipsi) TG at both 24h and 72h post CFA 
injection. Similar changes were observed in the V1-ophthalmic and V2-maxillary divisions (see text). 
Data are expressed as number of GFAP-encircled neurons per counting field at 40x magnification. C, C’, 
ED1 immunostaining (green) of activated macrophages, showing a significant upregulation 24h after the 
injection of CFA. D, Densitometric analysis, showing that a lower, although not statistically significant, 
effect was also present at 72h p.i. Nuclei were labeled with the Hoechst 33258 dye (blue). Scale bars: 20 
μm. *** p<0.001 and ** p<0.01 compared to the contralateral side; one-way ANOVA. 
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4.11 MICROGLIAL CELLS, BUT NOT ASTROCYTES, ARE ACTIVATED IN THE 
SPINAL TRIGEMINAL NUCLEUS FOLLOWING TMJ INFLAMMATION 
Although previous studies reported that CNS glial cells (astrocyte and microglial 
cells) become activated following CFA-induced sciatic nerve inflammation 
(Raghavendra et al., 2004; Sun et al., 2007; Hernstadt et al., 2009), no studies on the 
reaction of these cells to inflammatory TMJ sensitization are available. 
Immunoreactivity levels for Iba1 (a marker for microglial cells) and GFAP (a marker 
for astrocytes) in the different regions of the spinal trigeminal nucleus (see Paragraph 
1.1.2) were thus evaluated in saline and CFA-injected rats. As shown in Figure 4.15, no 
changes in Iba1 immunoreactivity were observed between the contra- and ipsi-lateral 
sides of saline-injected rats in either the trigeminal subnucleus caudalis of the medulla 
oblongata (n=8 animals; Figure 4.15A) or in the dorsal horn of the cervical spinal cord 
(n=8 animals; Figure 4.15C). However, 72 hours after CFA administration Iba1 
immunoreactivity was significantly up-regulated in the dorsal laminae of the trigeminal 
subnucleus caudalis (normalized values: 1.51±0.13 pixels for the ipsilateral side vs. 
0.90±0.06 pixels for the contralateral side; n=8 animals; Figure 4.15A). In the ipsilateral 
side, microglial cells displayed shorter and thicker ramifications, a typical characteristic 
of activated microglia, when compared to the fine processes of microglia in the 
contralateral side (Figure 4.15B’,B’’). Similar changes were also observed in the dorsal 
horn of the cervical spinal cord (normalized values: 1.80±0.21 pixels for the ipsilateral 
side vs. 1.00±0.12 pixels for the contralateral side; n=7 animals; Figure 4.15C,D). 
Conversely, no reactive astrogliosis was detected in the spinal trigeminal nucleus, 
both in terms of GFAP immunoreactivity (n = 7 animals; Figure 4.16A,C), and of the 
morphology of GFAP+ astrocytes (Figure 4.16B,D). We conclude that, during the sub-
acute phase of CFA-induced TMJ inflammation, microglial cells, but not astrocytes, are 
selectively activated in the CNS regions relaying nociceptive information. 
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Figure 4.15 
TMJ inflammation induces microglial activation in the spinal trigeminal nucleus.  
A, C, Densitometric analysis of Iba1 immunoreactivity (number of immuno-positive pixels, see Methods) 
showing a significant increase in Iba1 immunoreactivity in the ipsilateral side of both the trigeminal 
subnucleus caudalis in the medulla oblongata (delimited by the dotted line; A) and the dorsal horn of the 
cervical spinal cord (C) 72h after CFA injection. The mean values of pixel intensity have been normalized 
to the values obtained from the contralateral side of saline injected rats, set to 1.0. ** p<0.01 compared 
to the contralateral side; one-way ANOVA. B-B’’, D-D’’, Resting microglial cells (i.e., ramified cells 
with fine processes) were detected in the contralateral side of the trigeminal subnucleus caudalis (B’) 
and of the cervical dorsal horn (D’), whereas activated microglial cells (i.e. cells with thicker 
ramifications) were observed ipsilaterally to the site of injection (B’’, D’’). Scale bars: 20 μm.  
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Figure 4.16 
TMJ inflammation does not affect the activation state of GFAP+ astroglial cells in the 
CNS.  
A, C, Densitometric quantification of GFAP immunoreactivity in the trigeminal subnucleus caudalis 
(delimited by the dotted line; A) and the cervical dorsal horn (C) revealed no changes between the 
contralateral (contra) and the ipsilateral (ipsi) sides of CFA inflamed rats. The mean values of pixel 
intensity have been normalized to the contralateral side of saline injected rats, set to 1.0. B-B’’, D-D’’, 
No changes in astroglial cell morphology were detected. Scale bars: 20 μm. 
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4.12 THE PURINERGIC P2Y12 RECEPTOR IS SELECTIVELY EXPRESSED BY 
MICROGLIAL CELLS IN THE CNS, BUT IT IS NOT UPREGULATED BY TMJ 
INFLAMMATION 
In microglial cells, the purinergic P2Y12 receptor subtype was shown to be up-
regulated following nerve injury, and its pharmacological or biotechnological inhibition 
prevented the development of mechanical allodynia (Kobayashi et al., 2008; Tozaki-
Saitoh et al., 2008). On this basis, we analyzed the possible changes of P2Y12 receptor 
expression in our inflammatory model. Using a specific antibody directed against the C-
terminal domain of the rodent P2Y12 receptor (Haynes et al., 2006), we were not able to 
detect any staining within the TG of control animals (Figure 4.17A). This finding is in 
contrast with a previous report indicating the presence of P2Y12 receptor mRNAs in rat 
DRGs (Kobayashi et al., 2006), and to our RT-PCR analysis on both intact ganglia and 
primary TG cultures (Figure 4.3). Interestingly, in the same tissue sections P2Y12 
receptor immunoreactivity was detected at the boundary between the trigeminal nerve 
root (i.e., the PNS) and the CNS (Figure 4.17B), thus indicating that the expression of 
this receptor subtype is probably restricted to cells of the CNS. Furthermore, while 
P2Y12 receptor and Iba1 immunostaining colocalized in CNS microglial cells (Figure 
4.17B, yellow arrows), Iba1+ macrophages resident in the trigeminal nerve root were 
P2Y12-negative (Figure 4.17B). In the brainstem, the P2Y12 receptor was only expressed 
by Iba1+ microglial cells (Figure 4.17C,C’’), confirming previous reports indicating this 
receptor expressed by CNS microglia (Haynes et al., 2006). 
We next evaluated whether or not P2Y12 receptor levels in the spinal trigeminal 
nucleus were affected by CFA injection into the TMJ. Despite the observed 
upregulation of Iba1 immunoreactivity and the morphological changes observed in 
microglial cells (see above), no increase in P2Y12 receptor immunoreactivity in the 
ipsilateral side of CFA-injected rats was observed in either the trigeminal subnucleus 
caudalis (n=7 animals; Figure 4.17D,E) or in the cervical dorsal horn (not shown; n=7 
animals). Taken together, these results suggest that the purinergic P2Y12 receptor, which 
has been implicated in some forms of pain sensations (Kobayashi et al., 2008; Tozaki-
Saitoh et al., 2008), might not be directly involved in the subacute reaction of CNS glial 
cells to TMJ inflammation. 
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Figure 4.17 
P2Y12 receptor is selectively expressed by microglial cells of the brainstem, but its 
expression  levels are not affected by TMJ inflammation. 
A,  In the TG, no staining for the P2Y12 receptor subtype (green) was detected in Iba1-expressing 
macrophages (red). B,  At the trigeminal nerve root (i.e., the PNS/CNS boundary), Iba1+/ P2Y12+ 
microglial cells were observed (yellow arrows). C, C’, In the brainstem, P2Y12 receptor immunoreactivity 
was specifically found on Iba1+ microglial cells (red). Nuclei were labeled with the Hoechst 33258 dye 
(blue). Scale bars: 20 μm. D, Densitometric quantification of P2Y12 receptor immunoreactivity in the 
trigeminal subnucleus caudalis revealed no changes in the receptor expression between the contralateral 
(contra) and the ipsilateral (ipsi) sides of inflamed rats. Similar results were detected in the cervical 
dorsal horn (not shown; see text). The mean values of pixel intensity have been normalized to the 
contralateral side of saline injected rats, set to 1.0. E-E’’, Immunostaining of the P2Y12 receptor subtype 
in the trigeminal subnucleus caudalis 72h after CFA injection. Scale bars: 20 μm.  
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Migraine is a highly disabling neurovascular disorder, affecting about 15% of 
adults in the Western World, with considerable socio-economic implications on both 
productivity and quality of life (Goadsby, 2007). Great progress has been made in 
migraine research during the past few decades: (i) migraine has been better classified 
and defined (Silberstein, 2004); (ii) imaging studies have shown that cortical spreading 
depression is most probably the phenomenon that underlies the migraine aura (see 
Paragraph 1.2.3; Pietrobon, 2007); (iii) the neurobiology of the trigeminal vascular 
system has been better delineated, and several messenger molecules have been strongly 
implicated in the initiation and triggering mechanisms of migraine (see Paragraph 
1.2.2; Pietrobon, 2005); and (iv) and novel classes of selective antimigraine drugs, such 
as triptans and CGRP antagonists, have been developed (see Paragraph 1.2.4; Goadsby 
& Sprenger, 2010). 
Despite these progresses, there is little or no evidence that shows with certainty 
which and how pain fibers are activated during migraine attacks. Most investigators 
currently believe that a migraine attack starts in the brain, as suggested by premonitory 
symptoms. However, a debate about migraine origin is still ongoing: some scientists 
argue for a central origin of the headache pain (Goadsby et al., 2009), whereas others, 
including our research group, believe that the headache is triggered by activation of 
peripheral nociceptors. Indeed, the trigeminal nerve conveys sensory information from 
most extracranial and intracranial structures to the spinal trigeminal nucleus, and it has 
been therefore hypothesized that migraine could arise from a primary dysfunction 
leading to activation and sensitization of the trigemino-vascular system (Olesen et al., 
2009). On this basis, the final aim of my study have been setting up both in vitro and in 
vivo models, as tools for evaluating the molecular and cellular role of the purinergic 
system in trigeminal pain transmission, in order to identify new potential targets for 
migraine pain therapy.  
 
 
5.1 PRIMARY MIXED TG CULTURES AS AN IN VITRO MODEL FOR 
EVALUATING P2 RECEPTOR EXPRESSION AND FUNCTIONALITY  
To characterize calcium signaling via P2 receptors in TG, we have taken 
advantage of in vitro trigeminal cultures that have been previously reported as a reliable 
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experimental model to study purinergic transmission in trigeminal neurons (Fabbretti et 
al., 2008; Simonetti et al., 2006). However, these previous studies were only focused on 
the neuronal P2X3 receptor, and no evidence was provided on the contribution of glial 
cells to purinergic signaling in TG. As a first step, we have characterized the dissociated 
TG cultures in terms of presence and structural organization of the different cell 
populations, demonstrating that primary mixed neuron-glia TG cultures are a reliable in 
vitro model of sensory ganglia. Indeed, cultured neurons survived for several days in 
vitro and displayed a good viability, as indicated by their responsiveness to 
depolarization and by the MTT cytotoxicity assay (data not shown). An analysis of the 
distribution of neurons according to their somatic size showed that small and medium 
nociceptive neurons represent almost the totality of the neuronal population (Figure 
4.1H), in full agreement with data obtained in cell cultures from DRG (Gu et al., 2006) 
and TG (Simonetti et al., 2006). Moreover, most of cultured neurons maintained the 
typical morphological features of sensory neurons with a single axon forming a T-shape 
bifurcation, and retained most of the phenotypical characteristics observed in vivo 
(Figure 4.1D-G’). Finally, cultured neurons retained, at least in part, their physical 
relationships with satellite glial cells (SGCs; Figure 4.1D,E), suggesting that also their 
functional and modulatory activities are preserved.  
We next analyzed single cell calcium changes induced by culture exposure to 
different subtype-selective P2 agonists in both neurons and glial cells 48 hours after TG 
dissociation. As a first step, we focused our attention on the P2X3 receptor subtype, the 
most important purinoceptor involved in pain transmission. Expression levels of P2X3 
receptor, and of the P2X2/P2X3 heterodimer, increases in different inflammatory (Xu & 
Huang, 2002; Shinoda et al., 2005), and neuropathic (Novakovic et al., 1999) models of 
pain, and the pharmacological or biotechnological inhibition of P2X2/P2X3 activation 
reduces or abolished pain sensation (Honore et al., 2002; McGaraughty et al., 2003; 
Dorn et al., 2004). Recent studies reported that P2X3 receptor-mediated responses are 
also increased in trigeminal primary cultures after exposure to pro-algogenic CGRP 
(Fabbretti et al., 2006), suggesting the possible importance of this receptor subtype also 
in migraine pain. Confirming to literature data (Bradbury et al., 1998; Guo et al., 1999), 
we found P2X3 receptors expressed in approximately 70% of neurons (Figure 4.2A), 
and, relevant to pain transmission, in almost the totality of IB4-positive sensory neurons 
(Figure 4.2B). In approximately 60% of neurons, P2X3 was coupled to [Ca2+]i increases 
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as demonstrated by the application of its relatively selective agonist αβ-meATP (Figure 
4.2D). Primary trigeminal cultures also expressed P2X2, which likely dimerizes with 
P2X3 contributing to pain transmission, but not the P2X1 receptor subtype (Figure 
4.2C). Taken together, these results suggest that cultured TG sensory neurons maintain 
their physiological responses to ATP, and express functional algogenic P2X3 and P2X2/3 
receptors, thus confirming the suitability of this in vitro model to study the modulation 
of pain transmission by the purinergic system. 
As mentioned above, the present study has been principally aimed at 
characterising P2Y receptors in both neurons and SGCs in the TG cultures. Regarding 
the presence of these receptors in sensory neurons, immunohistochemical analysis on 
intact DRG, TG, and nodose ganglia has demonstrated that P2Y1 and P2Y4 receptors are 
expressed by two distinct neuronal populations (Ruan & Burnstock, 2003), but so far no 
functional studies have been performed. Interestingly, our RT-PCR analysis showed 
that all cloned murine P2Y receptors (i.e., P2Y1,2,4,6,12,13,14) are expressed in both intact 
TG and in trigeminal cultures 48 hours after plating (Figure 4.3). Results obtained by 
single cell calcium recordings from TG neurons indicated that only some P2Y receptors 
are functional in these cell populations. In particular we showed that TG neurons 
express metabotropic ADP-sensitive P2Y1 and UTP-responding P2Y2/P2Y4 receptors 
(Figure 4.4). We have also evaluated the functionality of calcium-linked P2Y receptors 
on SGCs, for which very few data have been available so far. In fact, in one single study 
on intact TG ganglion, P2Y1 and P2Y2/P2Y4 receptors were demonstrated to couple to 
increases of intracellular calcium concentrations in SGCs (Weick et al., 2003). As 
shown in Figure 4.5, in dissociated TG cultures SGCs expressed functional 
metabotropic P2Y1 and P2Y12/P2Y13 receptors responsive to ADP, as well as 
P2Y2/P2Y4 receptors responsive to UTP, as further indicated by the use of selective 
antagonists. A smaller response to UDP was also found, indicating that P2Y6 receptors 
only marginally contribute to P2-mediated calcium increases in these cells, at least 
under control conditions (see also below). Taken together, our results represent the first 
systematic evaluation of P2Y receptor expression and function in both neuronal and 
non-neuronal TG cells. 
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5.2 EXPOSURE TO ALGOGENS EXERT A COMPLEX MODULATION OF P2 
RECEPTOR FUNCTIONALITY IN NEURONS AND GLIAL CELLS 
Prolonged exposure to algogenic mediators modulates both neuronal and glial cell 
activity, thus contributing to the development of chronic pain (Wang et al., 2007; 
McMahon & Malcangio, 2009). Among known algogens, BK is indeed a known 
activator of sensory neurons and has been demonstrated to increase the neuronal firing 
rate in trigeminal nucleus caudalis and to enhance the release of CGRP from cultured 
dorsal horn and TG neurons (Jenkins et al., 2003). Moreover, literature data indicates 
that an acute (50 sec) exposure to BK rapidly sensitizes the function of the P2X3 
receptor subtype (Paukert et al., 2001). Since subpopulations of SGCs are also sensitive 
to BK (Heblich et al., 2001), we deemed it interesting to study the effect of an acute (up 
to 3 min) or a prolonged (24 h) BK exposure on purinergic signaling in both neurons 
and SGCs. Acute application of BK induced responses in a significant percentage of 
neurons (see also below), and significantly enhanced the amplitude of neuronal P2X3 
receptor-mediated peak calcium response (Figure 4.6C), thus confirming literature data 
in an expression system (Paukert et al., 2001). Instead, chronic treatment with BK 
induced a strong and highly significant reduction of the number of αβ-meATP-
responding neurons (Figure 4.6E). These data represent the first demonstration of a 
P2X3 receptor modulation by BK in a native system. Thus, a biphasic response of P2X3 
receptor to painful situations, with increased or decreased firing depending on the length 
of the exposure to the noxious and pro-inflammatory stimulus, might exist. This 
evidence suggests that different pharmacological manipulations of this receptor subtype 
might be utilized in acute or chronic pain. Interestingly, in TG cultures a 1 hour 
exposure to CGRP also led to the upregulation of neuronal P2X3 receptors (Fabbretti et 
al., 2008). 
Upon chronic exposure to BK, a significant upregulation of P2Y receptors 
responding to either ADP or UTP was also observed in SGCs (Figure 4.6F,G). Of 
interest, very few SGCs (about 3%) responded to BK, compared to the 35% of 
responding neurons (data not shown). This allowed us to hypothesize that the observed 
changes of P2Y receptors functionality in SGCs might be due to a soluble mediator 
released by neurons upon BK stimulation. We identified this mediator as the 
neuropeptide CGRP based on the following evidence: (i) BK-mediated effects on P2Y 
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receptors were inhibited by the CGRP antagonist, CGRP8-37 and mimicked by CGRP 
itself (Figure 4.7A,B); (ii) a significant increase in extracellular CGRP concentrations 
was detected after exposure of cultures to 100 nM BK (Figure 4.7C); (iii) in purified 
SGCs cultures (i.e., in the absence of neurons), BK lost its ability to enhance P2Y 
receptor responses, whereas the effects of CGRP were fully preserved (Figure 4.7B), 
due to direct activation of CGRP receptors on these cells and subsequent activation of 
ERK1/2 MAP kinase signalling pathway. In this scenario, it can be envisaged that BK- 
(and consequently CGRP-) induced upregulation of glial P2Y receptors contributes to 
the long-term maintenance of the TG pro-algogenic state, possibly by promoting the 
synthesis and release of additional glial pro-inflammatory mediators (e.g., chemokines, 
cytokines, or arachidonic acid metabolites), as already demonstrated for the P2Y2 
receptor subtypes in astrocytes (Weisman et al., 2005). Nevertheless, at this stage we 
cannot exclude that the observed plasticity of P2Y receptors represent an attempt to 
counteract the pro-nociceptive effects of BK and CGRP or that the different receptor 
subtypes involved (namely, the P2Y1,12,13 and the P2Y2,4 subtypes for ADP and UTP, 
respectively) might play opposite roles in the modulation of TG sensitivity.  
Our observation that BK-induced effects on SGCs are mediated by the neuronal 
release of CGRP suggests that this whole molecular network could be involved in 
migraine pathology. As discussed in Paragraph 1.2.2, CGRP play a central role in 
migraine. For instance, during the acute migraine attack, CGRP is released by TG 
afferent at the meninges, where it contributes to central neurogenic inflammation and 
induces pain-associated vasodilatation (Tepper & Stillman, 2008). Accordingly, CGRP 
plasma levels are increased during a migraine attack (Goadsby et al., 1990), and return 
to baseline after administration of migraine abortive drugs (Lassen et al., 2002), thus 
demonstrating its causative correlation with headache pain. No wonder if CGRP 
antagonists are now evoked as new effective drugs in untreatable migraine (Tepper & 
Stillman, 2008).  
 
 
5.3 THE GAIN-OF-FUNCTION MUTATION IN CaV2.1 CALCIUM CHANNELS 
AFFECTS P2Y RECEPTORS FUNCTIONALITY IN SGCs  
By using TG cultures derived from CaV2.1 α1 R192Q mutant KI mice we have 
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demonstrated, for the first time, a significantly increased basal and stimulated 
extracellular CGRP release compared to wild type cultures. Transgenic mice carrying 
this mutation were previously shown to exhibit an enhanced Ca2+ influx in cortical 
neurons, which could explain their increased susceptibility to the generation of cortical 
spreading depression (that is also observed in FHM1 patients, see Introduction; van den 
Maagdenberg et al., 2004; van den Maagdenberg et al., 2010). Our results suggest that, 
in R192Q KI cultures, mutated CaV2.1 calcium channels lead to an increased neuronal 
firing, which in turn promotes CGRP release in TG and may augment their sensitivity to 
migraine triggers. More specifically, we hypothesize that the presence of a basal pro-
inflammatory milieu within the TG of these mice might lower the threshold for neuronal 
firing. The fact that the already elevated extracellular CGRP levels can be further 
enhanced by neuronal stimulation stimuli (with BK or KCl) suggests that this pathway 
can contribute to an amplification and worsening of this basal pro-inflammatory state 
under conditions that occur during a migraine attack. Accordingly, in the presence of 
high levels of CGRP, neuronal P2X3 receptors show an enhanced synthesis and a 
reduced desensitization potential (Fabbretti et al., 2006), contributing to the increased 
transmission of pain. Moreover, an increase in basal neuronal P2X3 receptor activity has 
been recently found in TG cultures from CaV2.1 α1 R192Q KI mice, as a consequence 
of calcium-dependent alterations of the receptor phosphorylation state (Nair et al., 
2010).  
We have also evaluated if the augmented CGRP release in R192Q KI cultures was 
associated to modulation of P2Y receptor functionality in SGCs. We observed no 
differences in basal ADP- and UTP-related mean calcium increases between R192Q 
WT or KI SGCs (compare “CTR” histograms in Figure 4.11), thus indicating that the 
higher basal release of CGRP in KI cultures does not affect P2Y receptor functionality 
in glial cells, or that the chronic exposure to CGRP might have triggered some 
compensatory mechanisms. However, following BK application, despite a similar 
upregulation of P2Y receptors in SGCs from R192Q WT and KI animals (Figure 4.11), 
a significant increase in the percentage of ADP and UTP responding SGCs was found in 
R192Q KI cultures (Figure 4.11). This evidence suggests that the larger CGRP release 
induced by BK in R192Q KI cultures might enhance the transcription of specific P2Y 
receptor subtypes or that some yet-to-be identified mechanisms of modulation of P2Y 
receptor function is involved (e.g., receptor phosphorylation or recruitment of scaffold 
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proteins). It should be noted that the percentage of ADP- and UTP-responding SGCs in 
R192Q WT cultures is lower to that reported in our previous experiments, as shown in 
Figure 4.5. This apparent discrepancy could be explained by the use of lower 
concentration of nucleotides in experiments involving R192Q WT and KI cultures 
(1µM for ADP and 10 µM for UTP), compared to our previous experiments (100µM for 
both ADP and UTP). Moreover, the R192Q WT littermates utilized in the last set of 
experiments were selected during the generation of R192Q KI transgenic mice from 
C57black/6 mice (van den Maagdenberg et al., 2004), thus some genetic differences 
with the C57black/6 mice we usually purchase from a commercial source could be 
present. 
In conclusion, we have demonstrated that the gain-of-function R192Q mutation in 
CaV2.1 channels is associated to a basal and stimulated increase of CGRP released from 
TG neurons, which in turn modulates P2Y receptor expression and functionality in 
SGCs. Thus, the complex interplay between TG neurons and SGCs has implications for 
migraine pathophysiology and could become even more important in FHM1 patients. 
To date, the pro- or anti-algogenic role of glial P2Y receptors in pain transmission is 
still unknown; future in vivo studies are therefore needed to clarify this issue. 
 
 
5.4 SET UP OF IN VIVO MODELS OF TRIGEMINAL PAIN AS TOOLS FOR 
EVALUATING THE ROLE OF GLIAL P2Y RECEPTORS IN PAIN 
TRANSMISSION 
The results obtained from our TG cultures in vitro demonstrate that glial P2Y 
receptors act as important players in nociception. For this reason, we deemed interesting 
to set up in vivo pain models of TG sensitization, in order to study the involvement of 
the purinergic system in pain transmission, and to validate the role of specific P2Y 
receptor subtypes. To this aim, we initially set up a mouse model of acute trigeminal 
pain, based on the injection of formalin into the upper lip of mice, and we focused our 
attention on the P2Y4 receptor, due to evidence indicating its expression by trigeminal 
SGCs (Weick et al., 2003; Vit et al., 2006). Although we successfully reduced P2Y4 
protein levels by injecting long double-stranded RNAs (dsRNAs) designed to 
selectively knock-down P2Y4 receptor expression directly in the TG, no significant 
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differences in pain behaviour were detected when comparing formalin-treated mice that 
received P2Y4-dsRNAs to formalin-treated animals receiving control dsRNAs (Figure 
4.12). These data apparently rule out a major role for P2Y4 receptors in acute trigeminal 
pain transmission. Moreover, doubts on the specificity of the anti-P2Y4 commercially 
available antibody, and on the actual expression of this receptor subtype in SGCs have 
been raised (Villa et al., 2010). For this reason, we focused our attention on other P2Y 
receptors subtypes that could be targeted by antibodies whose specificity has been fully 
validated (see below). 
Therefore, we set up and characterized a model of chronic trigeminal 
inflammation based on the injection of the Complete Freund’s Adjuvant (CFA) into the 
temporomandibular joint (TMJ) of adult rat. This paradigm of pain is a well established 
model of chronic trigeminal pain, associated with strong neuronal sensitization both in 
the trigeminal ganglion and in the brainstem (Zhou et al., 1999). Since the trigeminal 
and CNS nociceptive pathways are sensitized in migraneurs as well (Pietrobon, 2005), 
this models can be proposed to mimic the molecular mechanisms at the basis of 
migraine sensitization. It should be also considered that specific in vivo models of 
migraine pain are not available, and even impossible to be achieved. Moreover, relevant 
links between migraine and inflammatory pain can be found in literature. In fact, 
clinical studies have demonstrated a strong correlation between migraine and the 
temporo-mandibular disorders (Taub et al., 2008; Kang et al., 2009), and the 
pharmacological treatment of various temporo-mandibular symptoms significantly 
decreases headache pain (Mitrirattanakul & Merrill, 2006). In addition, it has been 
demonstrated the existence of a prevalence to temporo-mandibular disorders in patients 
with combined migraine and tension-type headache (Ballegaard et al., 2008).  
Due to the limited information on the role glial cells in the spinal-trigeminal 
system following TG sensitization, we have examined the response of TG and CNS 
glial cells in our inflammatory pain model. First of all, we have demonstrated that CFA 
injection into the TMJ produces a significant increase in GFAP expression in SGCs in 
the TG (Figure 4.14), thus confirming the reaction of this glial cell family to the 
administration of a pro-algogenic stimulus (Takeda et al., 2009). The key role of SGCs 
in the development and maintenance of chronic pain has been demonstrated in other 
pain models by their increased expression and release of IL-1β (Takeda et al., 2007), 
TNFα (Zhang et al., 2007), as well as augmented gap junction-mediated cell coupling 
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(Garret et al., 2008; Ledda et al., 2009) following nerve injury. All together, these 
changes are associated with increased excitability of both primary afferents and CNS 
neurons, leading to the development of hyperalgesia and allodynia (Takeda et al., 2009).  
We also provide new evidence on the behavior of TG macrophages under 
inflammatory conditions. In particular, following induction of TMJ inflammation a 
strong upregulation of ED1 (a specific marker for activated macrophages; Hu et al., 
2007) in the ipsilateral side of inflamed rats was found (Figure 4.14). Since no increases 
in either the number or the average cell size of macrophages were detected, we conclude 
that CFA injection does not trigger macrophages infiltration from the bloodstream into 
the trigeminal perineuronal regions, but rather modulates the activation state of resident 
immune cells. These cells can in turn contribute to the development of TG sensitization 
following TMJ inflammation.  
Microglial cells, the resident macrophagic population in the CNS, have been 
crucially implicated in the initiation and modulation of certain chronic pain states 
(Smith, 2010). For instance, in various neuropathic pain models, activated microglia 
was shown to release pro-inflammatory cytokines and other substances that facilitate 
pain transmission (Inoue & Tsuda, 2009; White et al., 2007). Moreover, several drugs 
acting as glial cell inhibitors (e.g., propentofylline, pentoxifylline and minocyclin) 
eventually suppress the development of neuropathic pain by decreasing both microglial 
activation and cytokine release (Mika, 2008; Sweitzer et al., 2001). Here we report for 
the first time that injection of CFA into the TMJ induces a significant ipsilateral 
activation of microglial cells, both in the dorsal laminae of the trigeminal subnucleus 
caudalis in the medulla oblongata and in the dorsal horn of the cervical spinal cord 
(Figure 4.15), which represent the territories innervated by the mandibular fibers of the 
trigeminal nerve (Capra & Dessem, 1992), and represent key stations for the integration 
of temporomandibular painful sensations. Our data are in agreement with previous 
papers indicating an increased expression of microglial cell markers in the lumbar 
spinal cord in CFA-induced ankle or tibio-tarsal joint monoarthritis in rats, associated 
with the appearance of cells having an activated morphology (Sun et al., 2007; 
Hernstadt et al., 2009). This confirms that the induction of deep articular inflammation 
represents a potent trigger for CNS microglial activation.  
We also examined astrocyte activation in the brainstem following TMJ 
inflammation. At variance from previous reports on sciatic nerve inflammation 
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(Raghavendra et al., 2004; Sun et al., 2007), we did not detect any evidence of astroglial 
activation (Figure 4.16). This divergence could be due to the fact that the latter studies 
showed astroglial activation at later time points (11 and 14 days) following the 
inflammatory insult, thus suggesting that astrocytes are not involved in the first sub-
acute phases of tissue sensitization, but might be recruited at later times. 
As discussed in Paragraph 1.4.2, the purinergic P2Y12 receptor is a key player in 
controlling microglia-associated development of neuropathic pain, and thus represents a 
possible therapeutic target for treating chronic pain disorders. For these reasons we 
checked for its possible modulation in our inflammatory pain model. By utilizing a 
custom-made antibody whose specificity was already successfully validated in P2Y12-
deficient mice (Haynes et al., 2006), no P2Y12 immunostaining was detected on TG 
sections, although we have detected its mRNA in mouse TG (Figure 4.3). Interestingly, 
staining for the P2Y12 receptor was observed at the boundary between the trigeminal 
nerve root and the CNS, and in Iba1+ cells of the brainstem (Figure 4.17). This 
observation correlates with previous reports indicating that, unlike other extracellular 
nucleotide receptors, such as the P2X4, P2X7, and P2Y6 receptor subtypes, P2Y12 
receptor expression is restricted to CNS microglia (see Section 1.4; Haynes et al., 2006). 
Quite surprisingly, we detected no changes in microglial P2Y12 receptor levels after the 
injection of CFA in the TMJ, suggesting that this receptor might not participate to the 
first phases of tissue hypersensitivity following an inflammatory stimulus; however, 
only pharmacological studies can endorse this evidence. In a different model of 
inflammatory pain (i.e., the injection of CFA in the hindpaw) the intraperitoneal 
administration of the P2Y12 receptor antagonist 2,2-dimethyl-propionic acid 3-(2-
chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propylester 
(MRS2395) significantly alleviated the mechanical hypersensitivity (Ando et al., 2010), 
but authors did not evaluated the possible changes in P2Y12 receptor expression in their 
experimental model. Thus, it may well be that, despite the lack of detectable receptor 
upregulation, P2Y12 receptor targeting might be beneficial also for treating other 
chronic inflammatory pain states involving the sensitization of the spinal-trigeminal 
system. 
In conclusion, this in vivo model represents an useful tool for evaluating the role 
of specific P2Y receptor subtypes, expressed by glial cells, in the development and 
maintenance of chronic trigeminal pain and migraine-associated pain. We intend now to 
Discussion 
 114
look for possible changes in other P2Y receptors expressed by glial cells, and to 
evaluate the pro- or anti-algogenic effects of their pharmacological or biotechnological 
inhibition. 
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7. ABBREVIATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
 
[Ca2+]i   intracellular calcium concentration 
2MeSADP   2-methylthio adenosine 5'-diphosphate  
a,ß-meATP   a,ß-methylene-ATP  
Ado    adenosine  
ADP    adenosine-5'-diphosphate   
ADPβS  adenosine 5'-[β-thio]-diphosphate   
ASO   antisense oligonucleotides   
ATP    adenosine-5'-triphosphate  
BDNF   brain derived neurotrophic factor  
BK    bradykinin  
CaMKII   calcium/calmodulin kinase II  
CFA    complete Freund's adjuvant   
CGRP    calcitonin-gene related peptide  
CNPase   2',3'-cyclic nucleotide 3'-phosphodiesterase 
CNS   central nervous system 
CSD   cortical spreading depression  
DRG   dorsal root ganglia  
dsRNAs   long double-stranded RNAs   
EIA    enzyme immunometric assay   
FHM1   familial hemiplegic migraine type 1  
FHM2   familial hemiplegic migraine type 2  
FHM3   familial hemiplegic migraine type 3  
GDNF   glial-derived neurotrophic factor  
GFAP    glial fibrillary acidic protein  
GPCR    G protein-coupled receptors  
IASP   international association for the study of pain  
IB4   isolectin B4  
Iba1   ionized calcium-binding adapter molecule 
IL   interleukin  
ISHH    in situ hybridization histochemistry   
KI    knock-in   
MA   migraine with aura  
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MO   migraine without aura 
NA    noradrenaline   
NGF    nerve growth factor 
NO   nitric oxide  
NSAIDs  nonsteroidal anti-inflammatory drugs 
p.i.   post injection  
PET   positron emission tomography  
PNS    peripheral nervous system  
PPADS   pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid   
SCI    spinal cord injury  
SGCs    satellite glial cells  
SP   substance P 
TG   trigeminal ganglia  
TMJ    temporomandibular joint  
TNFα   tumor necrosis factor α 
TNP-ATP   2',3'-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate  
UDP    uridine-5'-diphosphate  
UTP    uridine-5'-triphosphate  
VIP   vasoactive intestinal polypeptide  
VR1   vanilloid receptor subtype 1  
WT   wild type   
 
